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The cytoskeleton plays vital roles in many cell functions and any disorder could 
lead to different diseases such as cancer, which causes uncontrolled cell division, 
cell motility and invasion. Cell migration is important for developmental 
morphogenesis, tissue repair and tumour metastasis. During the migration process, 
microtubule organisation and dynamics play important roles, and are regulated by 
Plus-end Tracking (+TIP) proteins. A better understanding of cell migration 
mechanisms could lead to an efficient treatment for invasive cancer cells such as 
pancreatic cancer. Sulforaphane (SFN) is a potential treatment for different cancer 
types with various possible means of action. Studies have indicated that SFN has 
the potential to slow down the progression of cancer, promote apoptosis and 
suppress cell proliferation. However, how SFN affects microtubule dynamics, 
stability and organisation is poorly understood.  
This project investigated the effect of SFN on microtubule organisation and 
dynamics and the impact on cell migration. Certain pancreatic cancers show up-
regulation of the end-binding protein EB2 and the tubulin deacetylase HDAC6 
which both influence microtubule dynamics and stability and thus also cell 
migration. Other cancers such as breast cancer have reported an up-regulation in 
EB1. This project therefore focused on the effects of SFN on EB1, EB2 and 
HDAC6 expression and localisation and the consequences for cell migration.  
The impact of SFN on normal (ARPE-19) and cancerous (Panc-1) epithelial cell 
migration was assessed by live time-lapse imaging of sparsely seeded cells. 
Microtubule and actin filament organisation was assessed to observe the effects of 
SFN on the treated cells. The impact of SFN on EB and HDAC6 localisation and 
expression was determined by immuno-labelling. Experiments involving SFN 
treatment with or without functional inhibition of HDAC6 (with the HDAC6 
inhibitor tubacin) were carried out and their effect on cell migration was 
investigated. The effect of SFN on microtubule dynamics and stability was assessed 
by analysing live time-lapse GFP-CLIP-170 dynamics. Microtubule post-
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translational modifications were studied by immuno-labelling in SFN treated cells. 
Focal adhesion area and dynamics were also assessed by FRAP and immuno-
labelling in SFN treated cells. 
SFN treatment caused a dramatic decrease in the speed of random migration and 
cell area in ARPE-19 cells. A marked co-alignment between microtubules and actin 
filaments, increased EB1 decoration of the microtubule lattice and an apparent 
increase in cytoplasmic EB2 were also observed upon SFN treatment. However, 
SFN treated Panc-1 cells revealed no significant decrease in the speed of random 
cell migration. Interestingly, a combination of tubacin and SFN caused a significant 
decrease in the speed of cell migration. Analysis of microtubule dynamics in GFP-
CLIP-170 expressing cells revealed that SFN treated cells possessed less dynamic 
microtubules. There was also evidence of SFN inducing microtubule stability. 
The results suggest that SFN or a combination of tubacin and SFN could be 
promising treatments for cancer. Moreover, these results can provide a better 
understanding of the effects of SFN on the organisation of the cell cytoskeleton. 
Treatment with SFN resulted in interesting changes in EB and HDAC6 localisation, 
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1.1 Sulforaphane and the cytoskeleton 
High consumption of cruciferous vegetables, such as broccoli, is associated with a 
lower risk of cancer, in for example, the breast, colon, prostate and pancreas. There 
is preliminary evidence that sulforaphane (SFN) may prevent or slow the 
development of cancer (Fimognari and Hrelia, 2007). SFN has heterogeneous 
biological activities involving cell cycle arrest and apoptosis (Jackson and 
Singletary, 2004, Pledgie-Tracy et al., 2007, Dickinson et al., 2015). It seems that 
SFN is able to prevent, delay or reverse malignant neoplasm, and it thus holds the 
potential to be a therapeutic agent (Fimognari and Hrelia, 2007). However, the 
mechanisms behind its effects are not fully defined and this is especially so with 
regards to its effects on the cytoskeleton. The cytoskeleton plays vital roles in many 
cell functions and it has been linked to different diseases, including cancer. 
Microtubules are one of the main targets for anti-cancer chemotherapy due to their 
vital roles in cell activities including cell division, differentiation and migration. 
The exact effects of SFN on microtubules and their associated functions are not 
fully understood. It is therefore important to provide a better understanding of the 
effect of SFN on microtubules in normal and cancerous cells.  
 
1.2 The Cytoskeleton and Cancer 
This study is focused on the cytoskeleton in disease, and in particular the 
microtubule cytoskeleton and its role in the migration of pancreatic cancer cells. 
Cancer is a major health problem in the world, where the lifestyle and environment 
in the developed world increase the risk of developing the disease. In addition, 
improved healthcare leads to an increased aging population, and it is likely to 
increase the number of people becoming affected. In the UK, it has been reported 
that pancreatic adenocarcinoma is the fifth leading cause of cancer-related 
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mortality and the eighth most common cancer death worldwide (Bond-Smith et al., 
2012, Torre et al., 2015). 
The cytoskeleton is a highly flexible filamentous network composed of three 
components: actin filaments, intermediumte filaments and microtubules. The 
cytoskeleton is vital to cell function, and without it, cells are not viable. 
Additionally, the cytoskeleton has been associated with various diseases, in 
particular with cancer, with cancers causing uncontrolled cell division, cell motility 
and invasion. Microtubules and associated proteins play an important part in these 
cellular processes (Frixione, 2000). The exact mechanisms of these processes are 
not fully understood, so it is therefore vital to provide a better understanding of 
microtubule functions under normal situations, and then examine the effect of 
cancer. 
Microtubules are an important target for anti-cancer chemotherapy; in the 1980s, 
taxol, including its derivatives, became a widely used cancer drug for breast, 
ovarian and lung cancer, as it binds to microtubules and influences microtubule 
dynamics. Taxol causes microtubules to form bundles, and stabilises the 
microtubule lattice and stimulates polymerisation. Consequently, this will block 
cell division and promote apoptosis, and ultimately impede tumour growth – all of 
this is achieved by preventing microtubule dynamics that are required for 
successful mitotic spindle formations and function. Vinca alkaloids are also 
important anti-cancer agents that target microtubule dynamics and thus affect 
spindle microtubules (Jordan et al., 1991, Jordan and Wilson, 2004).  
Recent studies have identified abnormal expression levels and distribution patterns 
of important microtubule plus-end binding proteins in cancer such as EB1 and EB2. 
EB1 overexpression has been reported in some cancers, such as glioblastoma, 
breast, colorectal, esophageal squamous cell carcinoma, hepatocellular carcinoma 
and oral cancer (Dong et al., 2010, Berges et al., 2014, Kumar et al., 2016). It has 
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been reported that EB1 regulates cancer cell sensitivity to the anti-microtubule 
agent (paclitaxel), with EB1 increasing the ability of paclitaxel to bind 
microtubules and promotes tubulin polymerisation and stabilisation in breast 
cancer cells (Luo et al., 2014, Thomas et al., 2015). In addition, EB2 
overexpression has been associated with increased pancreatic cancer invasion 
(Abiatari et al., 2009). EB1 overexpression induces microtubule bundling in human 
breast cancer cells (MCF7), thus, having a role in microtubule assembly and 
reorganisation, which is an important process in cancer (Bu and Su, 2001). These 
findings suggest that further investigations are needed into EBs as potential targets 
for anti-cancer treatments (Bhat and Setaluri, 2007).  
 
1.2.1 Pancreatic cancer 
Pancreatic cancer is a highly aggressive malignancy and is the most complex 
epithelial cancer to treat, where strong resistance to existing treatments are evident 
(Bardeesy and DePinho, 2002, Wang et al., 2011). It remains the fifth leading cause 
of cancer-related deaths in the United Kingdom, fourth in the United States, and 
the eighth globally with only about 5% of pancreatic cancer patients expected to 
survive for five years after diagnosis (Siegel et al., 2016). In general, pancreatic 
cancer seldom occurs before the age of 40, but most cases of pancreatic 
adenocarcinoma occur in those over the age of 70 in both genders (Bardeesy and 
DePinho, 2002). 
The pancreas regulates two major functions, digestion and glucose metabolism. 
The exocrine pancreas comprises acinar and duct cells, where acinar cells are 
organised in a grape-like shape and produce digestive enzymes including 
trypsinogen, chymotrypsinogen, elastase, carboxypeptidase, pancreatic lipase, 
nucleases and amylase. The ducts add mucus and bicarbonate to the enzymes and 
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empty into the duodenum. The acinar cells play a vital role in regulating blood 
sugar by producing insulin  (Figure 1.1) (Bardeesy and DePinho, 2002).  
There are various types of pancreatic cancer, and the most common one, accounting 
for about 85% of cases, is pancreatic ductal adenocarcinoma. This cancer begins in 
the ducts that transport enzymes from acinar cells, and more than 60% of this cancer 
occurs in the ‘head’ of the pancreas near the duodenum (Bardeesy and DePinho, 
2002).  
There are a number of risk factors regarding pancreatic cancer, including cigarette 
smoking. Studies estimate that cigarette smoking doubles the risk of pancreatic 
cancer, and it is believed that about 25% of cases of pancreatic cancer are due to 
smoking. Other identified risk factors include diets high in meat and fat, obesity, 
diabetes mellitus, chronic pancreatitis and inherited predisposition, which accounts 
for about 10% of pancreatic cancer (Bardeesy and DePinho, 2002, Hezel et al., 
2006, Maitra and Hruban, 2008). 
Cancer develops through the accumulation of genetic mutations leading to the 
activation of cancerous genes and inactivation of tumour suppressor genes. 
Multiple combinations of mutations can cause the development of pancreatic 
adenocarcinoma, including KRAS gene (K-ras or Ki-ras), TP53 (tumour protein 
p53) (known as p53 protein), CDKN2A (cyclin dependent kinase inhibitor 2A) 
(encoding p16) and SMAD4 (mother against decapentaplegic homology 4) (also 
known as DPC4, deleted in pancreatic cancer 4). KRAS relates to growth 
increasing signals from the cell surface to the nucleus. It functions as binary 
molecular switches (on/off), where it is a member of the GTP (guanosine 
triphosphate) binding proteins. KRAS proteins interact with signalling molecules 
that regulate cell activities, including proliferation, differentiation, apoptosis, and 
cell migration. Mutations in KRAS decrease GTP hydrolysis and, thus, causes 
KRAS to remain active (Moore et al., 2003, di Magliano and Logsdon, 2013). 
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DPC4 is a tumour suppressor gene that is mutated in pancreatic cancer.  It is 
important in signalling, where it plays a vital role in the transduction of TGF-β 
(transforming growth factor β) signalling from the cell surface to the nucleus 
(Moore et al., 2003, Li et al., 2004, Deer et al., 2010). In addition, p53 is mutated 
in pancreatic cancer cells, where in normal cells it functions as tumour suppressor 
conserving stability by stopping genome mutation. Mutations in p53 could lead to 
abnormal cell proliferation resulting in cancer and more than 50% of human late 
stage cancers, and 26% of  primary stage cancers revealing mutations in p23 gene 
(Moore et al., 2003). Interestingly, most pancreatic cancer cell lines (> 95%) have 
defective p53, including the PANC-1 cell line. Additionally, mutations in p53 and 
p16 play important roles in the cell cycle and the maintenance of the genome after 
DNA damage (Moore et al., 2003, Maitra and Hruban, 2008, Deer et al., 2010).  
The relationship of these mutations to the phenotype of pancreatic cancer is still 
unclear, as a few studies have indicated that there is no correlation with either the 
grade of differentiation, or biological behaviour and mutational status of pancreatic 
cancer cells. However, it has been suggested that genotype and phenotype may be 
correlated, and reported that metastatic activities were linked to p53 mutation in 
vivo (Deer et al., 2010).  
Perineural invasion of tumour cells is one of the characteristic features of human 
pancreatic cancer, which involves growth along pancreatic nerves and this is a 
likely cause of recurrence of the disease. Upregulation in genes including the 
MAPRE (microtubule-associated protein RP/EB) gene family (MAPRE 1, 2 and 
3), which function as microtubule-plus-end associated proteins (EB1, EB2 and 
EB3) have been associated with cancer. It has been demonstrated that MAPRE2 
(EB2) levels are higher in pancreatic cancer cells (PANC-1) compared to normal 
cells; this observation suggests that EB2 might be involved in increased migration 
of pancreatic cancer cells (Abiatari et al., 2009).   
7
Figure 1.1 Anatomy of the pancreas
a) Anatomy of the pancreas: the pancreas is comprised of different
functional parts, which control two main processes, digestion and glucose
metabolism. b) The exocrine pancreas; composes acinar and duct cells.
c) Single acinus: the acinar cells produce insulin and are organised in
grape-like structures. d) Exocrine tissue consists of four cell types, which
are organised into compact islets embedded in acinar tissue, within
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1.3 The Cytoskeleton 
The cytoskeleton is vital for cell survival. The ability of cells to arrange into a 
variety of shapes, organise the many components in their interior, and interact 
mechanically with the environment depends on the cytoskeleton. The cytoskeleton 
also facilitates cell movement, proliferation and differentiation. The advent of the 
electron microscope in the 1930s allowed for the observation of the cytoskeleton, 
and lately fluorescence microscopy allows advanced investigations of cytoskeletal 
fibres. The cytoskeleton has three major networks of filaments: actin filaments, 
intermediumte filaments and, of main interest to this study is the microtubules. 
Each type of filament has distinct mechanical properties and is made from a 
different subunit, and these filaments associate with various accessory proteins and 
give them dynamic structure (Brinkley, 1985, Frixione, 2000).  
 
1.3.1 Actin 
Actin was first noticed as a filament combined with myosin motors in the 
myofibrils responsible for mammalian muscle contraction (Straub, 1943, Szent-
Györgyi, 1953, Frixione, 2000). The actin cytoskeleton has a fundamental role in 
many cell biological processes, including cell migration, morphogenesis, 
cytokinesis and endocytosis, which depend on dynamic actin filaments 
(Lappalainen, 2016). Actin is the smallest in terms of diameters of the cytoskeletal 
filaments with a diameter around 5–9 nm. Each filament is a twisted chain of 
identical globular subunits (G-actin), a 42-kDa protein, arranged in a head tail 
mode. Actin filaments have a distinct polarity, called the plus-ends and the minus 
ends (Figure 1.2). This polarity is important in assembly and disassembly although 
both ends can grow, the plus-end grows faster than the minus end (Dominguez and 
Holmes, 2011). 
Figure 1.2 Actin filament structure
a) Actin filaments consist of two-twisted strands with organisational polarity,
plus and minus ends, and diameter around 7nm. b) Actin Treadmilling, at the
plus-end, actin monomers bound to ATP and added to the growing filament.
Meanwhile, at the minus end, actin–ADP monomers are lost causing
disassembly of actin filaments. c) Actin branching: ARP2/3 binds to the sides
of an actin filament, helping nucleation of a new actin filament and starting a
new actin network. Adapted from Goley and Welch, (2006).
a) Actin filaments 
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Assembly of actin filaments (F-actin) occurs when actin monomers bound to ATP 
(Adenosine Tri-Phosphate) are added to the plus-end – this stage is called 
polymerisation. Shortly after polymerisation, the ATP is hydrolysed to ADP 
(Adenosine Diphosphate); the actin–ADP subunit is unstable in the filament, 
causing actin filament disassembly (Chhabra and Higgs, 2007, Dominguez and 
Holmes, 2011). . 
Actin filaments can assemble into different organisations, such as lamellipodia, 
filopodia and stress fibres, which perform different functions within the cell. 
Lamellipodia are dynamic membrane protrusions, which occur at the leading edge 
of migrating cells and consist of a meshwork of actin filaments that pushes the 
membrane of the cell and drives the cell forward (Dominguez and Holmes, 2011). 
Actin filaments also assemble into stress fibres, consisting of an array of F-actin 
linked to myosin II and their interaction provides tension, where they associate with 
focal adhesions (Pollard and Borisy, 2003, Vinzenz et al., 2012, Blanchoin et al., 
2014). 
Actin filament assembly and disassembly are governed by actin binding proteins 
(ABPs), which can bind to actin filaments in different ways, either at the ends or 
along the filament side. Some proteins form a cap at the end of the filament to 
prevent further addition or loss of actin subunits, such as CapZ. In addition, there 
are some proteins responsible for depolymerisation and turnover of actin filaments, 
including the ADF/cofilin family. Cofilin can bind to actin filaments and increases 
the dissociation rate of actin monomers at the minus ends, where cofilin binds to 
G-actin-ADP and this prevents the filaments from assembling; this effect can be 
reversed by profilin. Profilin induces the exchange of bound ADP for ATP, which 
dissociates cofilin from monomers and then leads to filament assembly. Cofilin and 
profilin with other binding proteins can act together to increase the rapid turnover 
of actin filaments and reorganise the actin cytoskeleton, which is important for cell 
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movements and changes of cell shape (Chhabra and Higgs, 2007, Pollard and 
Cooper, 2009, Dominguez and Holmes, 2011). 
There are several essential nucleation proteins, including the ARP2/3 complex and 
formins, where the actin network within lamellipodia is driven by ARP2/3 
nucleation (Vinzenz et al., 2012). Actin nucleation usually occurs at the cell cortex, 
and it is catalysed by the actin-like ARP2/3 complex. The ARP2/3 proteins act as 
nucleation sites to initiate the assembly of new filaments and regulate the actin 
cytoskeleton by binding to the minus ends of actin. ARP2/3 can also be found at 
the sides of pre-existing actin filaments, causing the formation of a branched actin 
network (Figure 1.2, c) (Goley and Welch, 2006, Pollard and Cooper, 2009, 
Chhabra and Higgs, 2007, Vinzenz et al., 2012). Formins are a group of actin-
binding proteins that play a role in increasing actin filament assembly when needed. 
Formins have essential functions in cytokinesis and cell polarisation, actin 
assembly at the adherent junctions and formation of filopodia. They associate with 
the plus-end and nucleate and promote actin filament elongation and actin bundles. 
These proteins can also control actin assembly at the advancing front of migrating 
cells (Chhabra and Higgs, 2007, Dominguez and Holmes, 2011, Nurnberg et al., 
2011, Blanchoin et al., 2014). 
Generally, actin filaments are assembled into two types of structures, termed ‘actin 
bundles’ and ‘actin networks’. In actin bundles the actin filaments are cross-linked 
into closely packed parallel arrays as found in microvilli, which are found at surface 
projections. In actin networks, the actin filaments are loosely cross-linked 
orthogonal arrays that form three-dimensional meshwork. These structures are 
regulated by a variety of actin binding proteins such as fimbrin and filamin, where 
fimbrin binds actin filaments and holds two parallel filaments close together. 
While, filamin forms cross-links between orthogonal actin filaments, and creates a 
loose three-dimensional meshwork. (Chhabra and Higgs, 2007, Dominguez and 
Holmes, 2011, Blanchoin et al., 2014). 
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The actin network can link to the plasma membrane by binding to spectrins and 
ERM proteins (ezrin, radixin and moesin), that bind membrane associated proteins 
directly to cortex actin filaments (Fehon et al., 2010). Spectrin is related to filamin 
protein, and forms a spectrin–actin network in red blood cells (Louvet‐Vallée, 
2000). The activity of actin can be controlled by the Rho GTPases Cdc42, Rac and 
Rho. These proteins act as molecular switches; when bound to GTP they are 
considered active, and when GTP is hydrolysed to GDP, they are inactive. Active 
Cdc42, Rac and Rho have been linked to filopodia, lamellipodia and focal contact 
formation receptively (Burridge and Wennerberg, 2004).  
1.3.1.2 Intermediumte filaments 
Intermediumte filaments provide mechanical strength and the capability to resist 
external stresses and have a diameter of about 10 nm. In humans, intermediumte 
filaments are diverse with more than 90 genes expressed in a tissue specific manner. 
For example, keratins are expressed in epithelial cells, and vimentins are found in 
mesenchymal cells while lamins are present in the nucleus of all cells (Fuchs and 
Weber, 1994). 
The different types of intermediumte filaments are structurally similar, and are 
assembled to form parallel polymers consisting of two different α-helical 
monomers to form a nonpolar coiled-coil structure. In addition, between two and 
four protofibrils twist into the final lattice of intermediumte filament. 
Intermediumte filaments obtain their strength and flexibility from the large number 
of polypeptides (Fuchs and Weber, 1994, Herrmann and Aebi, 2004). 
The head and tail domains play an important role in the differences between the 
intermediumte filaments. This allows intermediumte filaments to associate with 
different structures, including other cytoskeleton filaments and junctional 
components at the plasma membrane. In addition, this variety of binding proteins 
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associate the intermediumte filament networks with their tissue environment – for 
example, epithelial tissues are linked to each other, and to the basal lamina, by the 
intermediumte filament networks through specialist junctions, and this gives more 
strength across the tissue via integrity. However, mutations in intermediumte 
filaments and in associated proteins cause disruption of intermediumte filaments 
and many diseases, which lead to the loss of mechanical functions, and skin 
blistering (Lane et al., 1992, Fuchs and Cleveland, 1998, Haines and Lane, 2012). 
 
1.4 Microtubules 
Microtubules have many vital functions in biological processes, including: cell 
division, cell morphology by providing internal structure and support, cell polarity, 
and cell motility, which is of particular interest to this project (Vasiliev et al., 1970, 
Drubin and Nelson, 1996, Mitchison and Salmon, 2001, Hawkins et al., 2010). 
Moreover, microtubules provide tracks for the transport for of organelles, vesicles, 
and signalling molecules (Cole and Lippincott-Schwartz, 1995). 
 
1.4.1 Microtubule structure 
Microtubules are tubular structures that exist in all eukaryotic cells. As shown in 
figure 1.3, a microtubule is assembled from polymers, which are made of α-tubulin 
and β-tubulin heterodimers assembled into polarised protofilaments. A microtubule 
is usually arranged in thirteen parallel protofilaments, which form a hollow rigid 
tube approximately 25 nm in diameter. However, the number of protofilaments may 
vary in certain differentiated cells, such as the pillar cells in the inner ear, where 
many of the microtubules have15 protofilaments. Protofilaments can assemble into 
B-type lattice, by which subunits of protofilaments associate in α-α and β-β manner. 
The polymerisation in microtubules is a head-to-tail process, starting with initial 
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nucleation and then elongation, thus dictating the polarity of the microtubule. As a 
result, the two ends of the microtubule are termed the ‘plus-end’ or ‘fast-growing 
end’, which is terminated by β-tubulin, and the ‘minus end’ or ‘slow-growing end’, 
which is terminated by α-tubulin (Desai and Mitchison, 1997, Howard and Hyman, 
2003, Conde and Caceres, 2009).  
Microtubules can be assembled and disassembled. However, the minus-end is often 
stabilised and anchored at the centrosome, whereas the plus-ends elongate towards 
the cell periphery. This elongation requires energy from the adding of GTP-tubulin 
(Akhmanova and Hoogenraad, 2005). The disassembly of microtubules is known 
as depolymerisation, and causes the shortening of microtubules (Desai and 
Mitchison, 1997, Nogales, 2000, Nogales and Wang, 2006). Both α and β tubulins 
are able to bind GTP, but GTP can only be hydrolysed on β-tubulin. Therefore, 
heterodimer addition occurs specifically at the β-tubulin exposed growing 
microtubule plus-ends. The nucleotide status of tubulin heterodimers in the 
microtubule lattice determines the level of curvature in the protofilament. GTP-
tubulin subunits are bound as a cap at the growing end of a microtubule, which 
gives longitudinal strength and encourages straight protofilaments. Thereby, this 
GTP-cap provides enough energy in the lattice to enable further tubulins to be 
added to the growing microtubule. The hydrolysis of GTP to GDP on β-tubulin 
causes a conformational change, where the protofilaments curve outwards, 
generating a lateral pulling that enhances depolymerisation of the microtubule 
(Nogales and Wang, 2006, Howard and Hyman, 2007, Rice et al., 2008) 
(Figure1.4). Two models have been suggested which depend on the relationship 
between GTP and conformational change in αβ-tubulin, the allosteric model and 
the lattice model. The allosteric model proposes that, α/β tubulin heterodimers are 
curved when GDP is bound, and when GTP binds the dimer straightens out and 
allows lateral incorporation onto microtubule. This model relies on observations 
that straighter microtubules elongate from GTP bound αβ-tubulin, and curve from 
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GDP αβ-tubulin (Müller-Reichert et al., 1998, Wang and Nogales, 2005). The 
lattice model indicates that conformational alterations with straightening are a 
consequence of   microtubule assemble. It also suggest that the GTP acts to increase 
recruitment and that straightening is due to lateral associations. A study that 
supports the lattice model shows that γ and αβ-tubulin rearrangements did not occur 
in response to GTP binding (Wang and Nogales, 2005, Nogales and Wang, 2006, 
Rice et al., 2008). 
  
Figure 1.3 Microtubule Structure
Microtubules consist of α- and β-tubulin heterodimers, which form
protofilaments. 13-protofilaments assemble laterally in a non-
symmetrical helix to form a hollow tube 25 nm in width, which rises by
three monomers every turn. Note the seam in the microtubule wall, and













Figure 1.4 Microtubule assembly and disassembly
Microtubules can switch rapidly between phases of growth and
shrinkage. Growing microtubules possess a GTP-tubulin cap.
Protofilaments are straight and the lattice stable, allowing incorporation
of GTP-tubulin heterodimers at the plus end. Hydrolysis of GTP in β-
tubulin in the cap causes protofilaments to curve and peel away, and the
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1.4.2 Microtubule nucleation 
The process in which various αβ-tubulins interact to form a microtubule seed, 
termed ‘microtubule nucleation’, controls the number of microtubules formed and 
enables microtubules to extend in the cytoplasm (Kellogg et al., 1994, Job et al., 
2003). Microtubule nucleation is organised by the microtubule organisation centre 
(MTOC). In eukaryotic cells, it is often the centrosome while the fungal spindle 
pole body (SPB) is a MTOC in fungae. Despite morphological differences between 
MOTCs they share functional nucleating complexes, which contain γ-tubulin and 
several γ-tubulin complex proteins (GCPs). In the centrosome, the nucleating 
complex consist of the small γ-tubulin complex (γTuSC), associated with one 
molecule each of GCP2 and GCP3 (Figure 1.5, a). Several copies of γ-TuSC and 
linked by additional accessory proteins (GCP2, GCP3, GCP4, GCP5 and CGP6) 
are arranged into the more potent γ-tubulin ring complex (γTuRu) (Figure 1.5, b) 
(Raynaud-Messina and Merdes, 2007, Kollman et al., 2011). 
Two models for γ-TuRC-based microtubule nucleation have been proposed: the 
protofilament model and the template model. The protofilament model proposes 
that γ-TuRCs interact with each other longitudinally and encourage the lateral 
addition of αβ-tubulin heterodimers. The template model suggests that γ-TuRCs 
form a cap that surrounds the minus ends of the microtubule, where γ-tubulin 
subunits are laterally organised and longitudinally contact with α-tubulin (Figure 
1.5, c and d). Most of the evidences support the template model (Wiese and Zheng, 
2006, Kollman et al., 2011). It is still unclear how the template model could 
nucleate the thirteen protofilaments of microtubules, as an even number of γ-
tubulins (12 or 14) would have to be combined into the γTuRC through six or seven 
of γ-TuSC complexes. A study showed that thirteen γ-tubulin are present in the 
γTuRC, where the first and seventh γTuSC overlap. This may be controlled by 
lateral interactions between GCP proteins, as GCP4, 5 and 6 are directly combined 
into the ring without acting as a scaffold for γTuSC subunits. This allows the half 
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Figure 1.5 Microtubule nucleation by γ-tubulin complexes
a) γ-Tubulin small complex (γ-TuSC) consists of two molecules of γ-
tubulin associated with one molecule each of GCP2 and GCP3. b) γ-
TuRC, large complex or γ-tubulin ring complex, consists of multiple
γTuSCs assembled with GCP4, GCP5, and GCP6 into the γ-tubulin ring
complex (γTuRC). c) The template model: the γTuRC acts as a template,
creating a ring of γ-tubulins that make longitudinal contact with αβ-tubulin.
d) The protofilament model: the γTuRC attaches to present a γ-tubulin
protofilament, which nucleates through lateral contacts with αβ-tubulin.
Adapted from Kollman et al. (2011).
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1.4.3 Microtubule minus-end associated proteins and 
microtubule anchorage   
A centrosome-focused radial array facilitates cytoplasm organisation keeping 
organelles in position and providing tracks for vesicular traffic (Cole and 
Lippincott-Schwartz, 1995). Centrosomes consist of many ring structures formed 
from γ-tubulin and several γ-tubulin complex proteins (GCPs), which are the 
nucleation site for the assembly of one microtubule (Mogensen et al., 1997). The 
αβ-tubulin dimers are added to the nucleation site in a specific orientation with the 
minus end of each microtubule embedded in the centrosome and the plus-end 
growing outwards into the cytoplasm. In addition, the centrosome in most animal 
cells contains a pair of centrioles made of a cylindrical array of short microtubules 
and pericentriolar material (PCM) (Kaverina et al., 2002). The centrioles have no 
direct role in the nucleation of microtubules in the centrosome; however, they aid 
in organising the PCM around them (Bobinnec et al., 1998, Mogensen, 1999) 
Many differentiated epithelial cells can assemble a non-centrosomal microtubule 
array, such as the skin, gastrointestinal tract, kidney, retina and cochlea (Furness et 
al., 1990, Mogensen et al., 1997, Mogensen, 1999). The mechanism that controls 
the organisation and behaviour of microtubule minus-ends remain unclear. 
However, there are several minus-end proteins that play vital roles in stabilising the 
apico-basal non-centrosomal microtubule array, such as ninein and CAMSAPs (1, 
2 and 3). It has been indicated that, in the inner ear CAMSAP3, which is a minus 
end-binding protein, may help to establish and protect the non-centrosomal site 
(Zheng et al., 2013). Ninein has been referred to as responsible for microtubules 
anchorage at both the centrosome and at non-centrosomal sites (Moss et al., 2007, 
Goldspink et al., 2017). It accumulates at the mother centrosome and associates 
with minus-ends of microtubules. Importantly, in cochlea pillar cells, ninein is 
located at the apical non-centrosomal sites, where minus-ends of microtubules 
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array are located. Ninein is released and travels along microtubules to these apical 
sites, and it stabilises the minus-ends of the microtubules. Therefore, ninein is vital 
for the successful anchorage and apical-basal array (Moss et al., 2007, Goldspink 
et al., 2017). 
 
1.4.4 Post-translational modifications 
Different subtypes of microtubules exist through the expression of different tubulin 
isotypes (7α and 8β tubulin present in the human genome) and post-translational 
modification, such as detyrosination and acetylation. Together this is referred to as 
the ‘tubulin code’, which result in unique microtubule interaction with associated 
proteins which has functional implications (Sirajuddin et al., 2014, Yu et al., 2015). 
For example, detyrosinated microtubules enhance the traveling of some motor 
proteins along them, such as kinesin motors (kinesin 1 family). Moreover, CLIP-
170 and p150Glued could recognise and bind to tysosinated microtubules, and affect 
their dynamics (Hammond et al., 2008, Garnham and Roll‐Mecak, 2012, Sirajuddin 
et al., 2014). 
Post-translational modifications generally occur on the C-terminal tail domains of 
α and β-tubulin, which are exposed on the outer face of the polymer. This location 
provides a ‘code’ for suitable MAP recruitment, hence affecting the microtubule 
properties, in particular stability. This allows specific microtubules with dissimilar 
properties to perform particular roles within the microtubule networks. 
Alternatively different modifications can occur along the length of the microtubules 
(Verhey and Gaertig, 2007, Garnham and Roll‐Mecak, 2012, Yu et al., 2015). The 
post-translational modifications include detyrosination, acetylation, 
phosphorylation, glutamylation and glycylation. Additionally, further post-
translational modifications, such as polyamination, β-tubulin acetylation and 
succination have recently been discussed (Li and Yang, 2015). 
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1.4.4.1 The detyrosination/tyrosination cycle  
Tyrosination was the first modification identified in the early 70s, and it consists of 
the removal of a C-terminal tyrosine to expose a glutamine (Barra et al., 1973, 
Hallak et al., 1977). The C-terminal of α-tubulin undergoes a cycle of loss and re-
addition of tyrosine, known as the tyrosination–detyrosination cycle. The removal 
of the tyrosine exposes a glutamic acid residue at the C-terminus, termed ‘Glu-
tubulin’, and modifies tubulin to detyrosintion, which accumulates only in stable 
microtubules. Whereas the specific carboxypeptidase enzymes responsible for 
detyrosination have yet to be recognised (Janke and Bulinski, 2011, Garnham and 
Roll‐Mecak, 2012, Yu et al., 2015), the re-addition of tyrosine involves tubulin-
tyrosine ligase (TTL). This enzyme requires ATP to function and works to re-
tyrosinate soluble heterodimers. The tyrosination–detyrosination cycle is 
reversible. Detyrosinated tubulin at the C-terminus can be further modified by 
removing the last glutamic acid residue and ends with irreversible Δ2-tubulin 
(Janke and Bulinski, 2011, Yu et al., 2015). 
In undifferentiated cells, there are two distinct populations of tubulin at interphase 
and most are tyrosinated; however, there is a small  subgroup of detyrosinated 
microtubules (Gundersen et al., 1984). This subgroup has been linked with stable, 
long-lived microtubules, while most of the microtubules are dynamic (Webster et 
al., 1987). Detyrosinated tubulin (Glu-tubulin) is used as a marker for microtubule 
stability (Peris et al., 2009). 
On the other hand, it has been reported that detyrosination of the lattice inhibits the 
binding of depolymerising motors for microtubules (MCAK and KIF2A) (Peris et 
al., 2009). Moreover, these associations of motor proteins and detyrosinated 
microtubules have been shown to cross-link microtubules with vimentin 
intermediumte filaments. Meanwhile tyrosinated tubulin has been shown to 
enhance microtubule dynamics by binding +TIP, such as CLIP-170 and p150Glued 
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which contain a CAP-Gly domain. However, EB1 binds plus-ends of microtubules 
independent of tubulin tyrosnation. Consequently, defective tyrosination and 
detyrosination have been involved in diseases that link to the reduction of TTL and 
decreased tubulin tyrosination, such as disorganisation of neuronal networks, and 
cancer tumorigenesis and invasion (Hammond et al., 2008, Garnham and Roll‐
Mecak, 2012). 
1.4.4.2 Acetylation 
Tubulin is a major target for acetylation at the N-terminus of α-tubulin on lysine 40 
(Lys-40). Acetylation was first discovered in the late 1960s on histones, and in the 
1970s and 1980s was noticed on different non-histone proteins such as α-tubulin. 
In the last decade, acetylation was identified in post-translational modifications 
with about 2000 acetylation proteins. Acetylation is reversible and requires several 
acetyltransferase enzymes to be activated, including Mec-17 (mechanosensory 
abnormality protein 17) and αTAT1 (α-tubulin acetyltransferase 1). The effect of 
tubulin acetylation on microtubule dynamics is still not fully understood; however, 
it is known to be linked to stable microtubules (long-lived microtubules) but does 
not significantly influence polymerisation or depolymerisation. In mice lucking 
αTAT1 and acetylated microtubules, the microtubules were sensitive to 
nocodazole, thus, suggesting decreased stability (Kalebic et al., 2013). Acetylation 
affects protein interaction with microtubules. Some studies showed that acetylated 
tubulin increases kinesin-1 binding to microtubules (Reed et al., 2006, Dompierre 
et al., 2007, Rymut and Kelley, 2015, Yu et al., 2015), it has also been shown that 
acetylated tubulin interacts with membranes and provides tracks for movement 
(Janke and Bulinski, 2011, Garnham and Roll‐Mecak, 2012). Two tubulin 
deacetylases have been identified: histone deacetylase 6 (HDAC6), which co-
localises with the microtubule network (Hubbert et al., 2002), and Sirtuin 2 
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(SIRT2). Deacetylation occurs on tubulin dimers (North et al., 2003, Rymut and 
Kelley, 2015).  
HDACs associate with different non-histone substrates to regulate various cellular 
activities such as cell division, cell movement and angiogenesis. There are two 
different phylogenetic classes for HDAC: class I and class II, where class I 
comprises HDAC 1, 2, 3 and 8, and they are generally close to yeast, and class II 
consists of HDAC 4, 5, 6, 7, 9 and 10. Most HDACs are located in the nucleus, 
including class I; however, HDAC3 can also localise to the cytoplasm. Class II can 
be found in the nucleus and cytoplasm due to their ability to shuttle in and out of 
the nucleus (Figure 1.6, a) (De Ruijter et al., 2003)  
Studies have shown that histone deacetylase 6 (HDAC6) is a unique enzyme in 
HDACs due to the fact that it has a minimal effect on cell cycle-related gene 
expression and cell proliferation. HDAC6 can be found in the cytoplasm, although 
in the nucleus it associates with HDAC11, and functions as α-tubulin deacetylase, 
regulating microtubule-dependent cell motility. HDAC6 has been noted to be a 
microtubule-associated protein, which deacetylates α-tubulin and regulates 
microtubule dynamics (Huo et al., 2011). It was observed, in vivo, that HDAC6 
plays an important role in regulating stability and dynamics of microtubules, where 
depolymerised tubulin is quickly deacetylated, whereas acetylated tubulin occurs 
in polymerised microtubules (Hubbert et al., 2002, Matsuyama et al., 2002, Zhang 
et al., 2003). Furthermore, HDAC6 can participate in a varied range of cellular 
processes, and interacts with microtubule-associated proteins at the microtubule 
plus-end (De Ruijter et al., 2003, Clarke et al., 2011, Ding et al., 2014, Li et al., 
2014). HDAC6 consists of two deacetylation domains and binds tubulin via these 
domains (Zhang et al., 2003), while the N- and C-terminals are responsible for 
HDAC6 associating with EB1 (the end binding protein 1), Arp1 (actin related 
protein 1) and CLIP-170, with no overlapping with domains involved in tubulin 
binding (Zilberman et al., 2009, Li et al., 2011, Li et al., 2014) (Figure 1.6, b). 
Figure 1.6 HDACs, Phylogenetic tree and HDAC6 domain
a) Phylogenetic tree of HADCs have two classes, I and II. Class I contains
HDAC 1, 2, 3 and 8. Class II contains HDAC 4, 5, 6, 7, 9 and 10.
b) HDAC6 domains comprise two deacetylation domains and bind tubulin
through these domains, whereas C-terminals are responsible for HDAC6
associated with EB1 (the end binding protein 1), Arp1 (actin-related protein 1)
and CLIP-170 without overlapping with domains involved in tubulin binding.
Moreover, tubacin inhibiter binds HDAC6 via C-terminal. Adapted from Zhang
et al. (2003).
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Overexpression of HDAC6 causes complete deacetylation of microtubules and 
promotes cell migration of many cancer cells, including pancreatic cancer, ovarian 
cancer and prostate cancer cell (Hubbert et al., 2002, Yang and Seto, 2008, Huo et 
al., 2011, Li et al., 2014, Rymut and Kelley, 2015). It has been indicated that 
HDAC6 activity can be inhibited by several HDAC6 inhibitors, such as trichostatin 
A (TSA, a non-specific inhibitor of HDAC6), tubacin (tubulin acetylation inducer) 
and tubastatin A (a specific inhibitor of HDAC6). Tubacin is a specific inhibitor of 
the deacetylation of α-tubulin with no effect on the level of histone acetylation and 
gene expression of cell cycle processing, where it interacts with one of deacetylate 
domains of HDAC6 at the C-terminal (Haggarty et al., 2003). It has been reported 
that treating cells with tubastatin A, TSA or tubacin dramatically increases α-
tubulin acetylation, efficiently increasing the amount acetylation microtubules 
(Zilberman et al., 2009, Asthana et al., 2013). Inhibition of HDAC6 with TSA and 
tubacin or tubastatin A leads to an increase in microtubule acetylation and this 
decreases microtubule dynamics, meanwhile genetic knockout and RNAi-
mediumted knockdown increases acetylated tubulin but does not affect microtubule 
dynamics (Zilberman et al., 2009, Asthana et al., 2013) . In addition, TSA and 
tubastatin A increase the co-alignment between HDAC6 and microtubule lattice in 
MCF7 treated cells with 240nM of TAS or 30µM tubastatin A for 24 hour (Asthana 
et al., 2013). So HDAC6 has been used as a target for cancer drugs (Hubbert et al., 
2002, Haggarty et al., 2003, Zilberman et al., 2009, Li et al., 2014). Ziberman et al. 
(2009) suggested that HDAC6 makes a cap at the plus-end of microtubules, and 
under normal conditions the HDAC6 cap quickly deacetylates α-tubulin and is 
removed from the microtubule end. Thus, the capping activity has a very quick 
effect on microtubules and should not impede microtubule dynamics, while the 
overexpression of HDAC6 influences microtubule dynamics and increases cell 
movement. Moreover, the HDAC6 cap tracks EB1 and Arp1, and this facilitates 
the interaction of HDAC6 with the microtubule plus-ends. While inhibition of 
HDAC6 activity decreases microtubule dynamics by affecting the microtubule 
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plus-end proteins. For example, it has been found that inhibition of HDAC6 activity 
leads to a reduction in the length of EB1 comet tail, and decreases microtubule 
dynamics. However, HDAC6 knockdown has no effect on EB1 comet length, 
which suggests that HDAC6 is associated with EB1 and Arp1 and affects their 
localisation at microtubule ends (Zilberman et al., 2009). 
Inhibition of HDAC6 activity by tubacin and TSA impairs cell migration, and TSA 
(but not with tubacin) increases CLIP-170 acetylation in pancreatic cells (Li et al., 
2014). At the same time, inhibition of HDAC6 activity by tubacin in mouse 
embryonic fibroblast cells increases the total area of adhesion and decreased 
adhesion turnover, which then rapidly suppressed cell motility (Tran et al., 2007).  
1.4.4.3 Other post-translational modification 
 Polyglutamylation and polyglycylation are types of translational modifications 
found in the axonemes of cilia and flagella. They consist of adding one or more 
glutamate and glycine to side chains on one or more of the glutamates in the C-
terminal domains of both α and β tubulins by tubulin tyrosine ligase-like (TTLL) 
family enzymes. Polyglutamylation has vital roles in control of transport within 
cilia and flagella, which allow fine-tuning of motor activity (Janke et al., 2005, 
Janke and Bulinski, 2011, Yu et al., 2015). 
Phosphorylation can also occur on microtubules at serine and tyrosine residues near 
the C-terminal. α-Tubulin is phosphorylated on tyrosine residue by kinases, such 
as Cdk1, CK2 and CamkII and Scr, while β-tubulin is phosphorylated on serine 
residues, which inhibits polymerisation. In general, phosphorylation of tubulin has 
been poorly studied and little is known about the process (Janke and Bulinski, 2012, 
Yu et al., 2015). 
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1.5 Microtubule Dynamics and Microtubule-
associated Proteins 
1.5.1 Dynamic instability 
A fundamental characteristic of microtubules is their ability to be highly dynamic. 
Microtubules can switch rapidly between phases of growth, pause and shrinkage at 
the microtubule plus-end; this behaviour is called dynamic instability. Dynamic 
instability allows the microtubules to explore the cytoplasm and make contact with 
cellular structures such as kinetochores or the cell cortex (Galjart and Perez, 2003, 
Galjart, 2010). This helps microtubule networks to rapidly rearrange in response to 
cellular function. The alteration from growth to shrinkage is termed ‘catastrophe’, 
and the conversion from shrinkage to growth is termed ‘rescue’ (Mitchison and 
Kirschner, 1984, Howard and Hyman, 2003, Akhmanova and Steinmetz, 2015).  
The dynamic property of microtubules is based on the GTP-cap model; in the 
presence of this cap a microtubule continues to grow and becomes elongated. On 
the other hand, loss of the GTP-cap by hydrolysing to GDP causes rapid 
microtubule shrinkage, where the hydrolysis of GTP to GDP on β-tubulin  
depolymerised microtubules (Howard and Hyman, 2007, Akhmanova and 
Steinmetz, 2015). A tight lattice is generally organised by growing microtubules 
that are bound to GTP, and this affects microtubule structure and stability. 
However, unstable microtubules bound to GDP undergo disassembly at the end of 
the filament, and the microtubule begins to depolymerise. In this phase, unstable 
microtubules experience catastrophe and begin to shrink. Rescue can occur in the 
shrinking microtubules, enabling them to start growing again (Desai and Mitchison, 
1997, Akhmanova and Steinmetz, 2015). The actual growth rate of an individual 
microtubule can differ over time and relies on the length of the GTP-cap at the 
microtubule plus-end. Dynamic instability is influenced by a variety of 
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microtubule-associated proteins (MAPs) that tightly control the changes between 
phases of growth and shrinkage. Post-translation modification of tubulin also 
affects dynamics. However, regulation of microtubule dynamics remains unclear 
(Howard and Hyman, 2009, Akhmanova and Steinmetz, 2015). 
 
1.5.2 Polymerases and depolymerases 
Polymerases and depolymerases facilitate and regulate microtubule plus-end 
switching between growth and shrinkage. Microtubule depolymerisation factors 
are kinesin families, kinesin-8, kinesin-13 or kinesin-14. Kinesin-13 family 
proteins such as MCAK have been identified as regulating microtubule 
disassembly. MCAK requires ATP hydrolysis to function, in order to remove 
terminal subunits from microtubule ends. Kinesin-8 can destabilise the GTP cap on 
microtubules by using their ability to walk along the microtubule to plus-ends and 
remove the subunits. Furthermore, they accumulate at the end of longer 
microtubules and depolymerise them. Additionally, these kinesin families can 
disassemble stabilised microtubules (Howard and Hyman, 2007, Howard and 
Hyman, 2009, Akhmanova and Steinmetz, 2015).  
The polymerase XMAP215 (human homologue chTOG, gene CKAP5) has been 
well studied and identified as a polymerase, where it promotes the growth rate of 
microtubules up to ten times, thus, accelerating the regrowth of microtubules. TOG 
domains are important for increasing regulating microtubule growth. It has been 
suggested that there are two ways in which XMAP215 might catalyse 
polymerisation. XMAP215 could act as an adaptor and bring multiple tubulin 
monomers to growing microtubule ends, or modify the structure of growing 
microtubule ends to facilitate tubulin binding (Howard and Hyman, 2007, 
Akhmanova and Steinmetz, 2015). 
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1.5.3 Microtubule plus-end tracking proteins (+TIP) 
Microtubule plus-end tracking proteins (+TIPs) are a varied group of microtubule-
associated proteins that track the plus-end of growing microtubules. They are 
highly diverse proteins that include microtubule-dependent motors and non-motor 
proteins. Microtubule +TIPs can be distinguished from other microtubule-
associated proteins by their specific accumulation at the plus-ends of growing 
microtubules. However, investigating +TIPs is complex, due to their interactions 
with each other and binding to the plus-end of microtubules (Galjart and Perez, 
2003, Galjart, 2010). +TIPs have an important function, by which they contribute 
to regulating the dynamic behaviour of microtubules, which affects the shape of the 
microtubule network, and thus cell functions such as cell division and motility. 
They also have a role in cargo capture through interactions with motors and 
facilitate interactions of microtubule ends with various cellular components, such 
as the cell cortex and kinetochores (Akhmanova and Hoogenraad, 2005, Galjart, 
2005, Galjart, 2010, Akhmanova and Hoogenraad, 2015). 
It has been demonstrated that there are three mechanisms by which +TIPs associate 
with microtubule plus-ends, including treadmilling, hitchhiking and motor 
transport. Treadmilling is the most studied mechanism and was described using live 
imaging of GFP-CLIP-170. The +TIPs lasts only for a short time and dissociates at 
the microtubule plus-ends, and this +TIP does not move along the microtubule 
lattice. The addition and loss of +TIP molecules from the microtubule ends is not 
fully understood; however, some +TIPs, such as CLIP-170 and p150Glued, may co-
assemble with tubulin heterodimers, and when phosphorylated increase the release 
from the microtubule. Other treadmilling +TIPs such as the end binding proteins 
(EBs) may use different mechanisms, by recognising the structural features or 
affinity for the GTP-cap at tubulin, EB1 binds to a stabilised microtubule in the 
presence of the GTP-cap. Hitchhiking is similar to treadmilling, as it involves 
transient binding to the microtubule via other +TIPs (Carvalho et al., 2003, Galjart 
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and Perez, 2003, Galjart, 2010, Akhmanova and Steinmetz, 2015). The budding 
yeast protein Kar9p is a well-studied example, where a relative homologue of the 
mammalian tumour suppressor protein, adenomatous polyposis coli (APC), 
depends on EB1 homology Bim1p for recruitment to the microtubule plus-end. The 
final mechanism depends on motor transport; some +TIPs, including APC, are 
transported to the plus-ends of the microtubule by kinesin family motor proteins 
(Carvalho et al., 2003, Akhmanova and Steinmetz, 2015). So the +TIPs can use a 
single mechanism or combinations of mechanisms, as demonstrated for APC 
(Carvalho et al., 2003). APC can associate with microtubules by three different 
methods: direct binding to microtubules through their microtubule binding domain 
by hitchhiking through EB1 or by transport via a kinesin motor (Carvalho et al., 
2003). 
1.5.3.1 The end binding proteins  
The most prominent group of +TIPs are the end binding (EB) proteins. Mammalian 
cells have three highly conserved proteins: EB1, EB2 and EB3, encoded by three 
separate genes MAPRE 1, 2 and 3. EB1 is considered to be the master controller of 
+TIPs, due to its ability to independently recognise and bind to the plus-ends of 
growing microtubules. EB1 was first discovered as an APC (adenomatous 
polyposis coli) binding partner in a yeast two-hybrid screen, and its gene located to  
human chromosome 20q11.2, which is called MAPRE 1 (Su et al., 1995). It was 
later shown that the EB1 organisation revealed an association with microtubules in 
both interphase and mitosis, independently from its interaction with APC 
(Morrison et al., 1998). In humans two more genes were identified: MAPRE 2 on 
chromosome 18q12.1 (encoding EB2) and MAPRE 3 on chromosome 2q23.3-
p23.1 (encoding EB3) (Su and Qi, 2001). 
EBs are small proteins with a molecular weight of around 30–39 kDa, and consist 
of an N-terminal calponin homology (CH domain), which is followed by a 
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changeable linker region, and a coiled-coil domain followed by the C-terminal 
acidic tail region. The CH domain in the linker region is necessary to specifically 
recognise and track growing microtubule ends. The linker region is composed of 
Ser, Thr and Tyr residues, which contribute to the phosphorylation of EB function 
during the cell cycle (Akhmanova and Steinmetz, 2015). The coiled-coil domain 
extends into an end-binding homology (EBH) domain and a C-terminal EEY/F 
acidic tail region. It has been suggested that the coiled-coil domain has a role in 
controlling the direct binding to GTP-tubulin, while the C-terminal domain tail 
region interacts with various +TIPs (Akhmanova and Steinmetz, 2008, Akhmanova 
and Steinmetz, 2015). It has been revealed that the capability of the EB proteins to 
dimerise through the EBH domain is crucial for their plus-end tracking ability (Slep 
and Vale, 2007). The C-terminal acidic tail has also shown to be important as a 
self-inhibitor of EB activity, beside its main function as a location for protein 
binding (Figure 1.7, a) (Hayashi et al., 2005, Akhmanova and Steinmetz, 2008, 








































a)  EB Proteins
b)  CLIP-170
c)  CLASP1/2
Figure 1.7 Domain structures of +TIP proteins
a) The EBs bind microtubules through their N-terminal CH domain. They
bind CAP-Gly+TIPs via the C-terminal acidic tail domain and recognise
serine/basic regions through the EBH region. They dimerise via a central
coiled-coil region. b) CLIP-170 recognises the C-terminal tail of EB1 and
microtubules through N-terminal CAP-Gly domains. CLIP-170 can also bind
further +TIPS through additional sites, and can self-inhibit via its own C-
terminal tail region. c) CLASP1/2 recognise EB1, microtubules and CLIP-
170 through serine/basic. Adapted from Akhmanova and Steinmetz (2008).
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Several models have been proposed to explain how the CH domain of EBs 
recognises the growing ends of the microtubules. EBs may distinguish extended 
sheets of tubulin at the growing ends, or may bind an A-lattice conformation similar 
to that found in a microtubule seam. The most well-studied model is its recognition 
of the GTP tubulin cap, a model proposed in which the EBs may recognise the GTP 
and GDP nucleotide status of the microtubule (Akhmanova and Steinmetz, 2011). 
It has been demonstrated that EBs (EB1 and EB3) recognise the end of growing 
microtubules due to their high affinity for the specific structural conformation 
exhibited by the GTP tubulin cap, or probably by the GTP hydrolysis processing at 
this end site. This was shown by using microtubules incorporating GTPγS (a slowly 
hydrolysable analogue of GTP) (Maurer et al., 2011, Maurer et al., 2012). 
Interestingly, it has been discovered that remnants of GTP tubulin along the mature 
microtubule lattice may act as switch points for rescuing depolymerising 
microtubules (Cassimeris, 2009). Despite the binding to the plus-end of 
microtubules, all three EB members can also associate along the entire microtubule 
lattice, as a result of their transient overexpression, they switch to distribution along 
the lattice (Bu and Su, 2001). 
EB1 has been described as the ‘master controller’ of +TIPs (Vaughan, 2005), 
because of its ability to track the plus-end of growing microtubules, and interact 
with most other +TIPs including CLIPs (Lansbergen et al., 2006, Dixit et al., 2009), 
CLASPs and APC (Mimori-Kiyosue et al., 2005). EB1 and EB3, but not EB2, have 
an essential role in the regulation of interactions at the plus-end of the microtubule, 
by facilitating microtubule connections with internal cell structures, such as the 
cortex, organelles and kinetochores, and also with the actin cytoskeleton (Vaughan, 
2005, Lansbergen and Akhmanova, 2006). Furthermore, EB1 is also an active 
component in the centrosome (Louie et al., 2004), where it has been implicated in 
spindle formation (Rehberg and Gräf, 2002). It has also been reported to play a role 
in a microtubule minus end anchoring complex (Yan et al., 2006). EBs affect the 
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dynamic instability of microtubules, which is an important process for microtubule 
apico-basal reorganisation during epithelial differentiation. EB1 has been shown to 
modify microtubule dynamics in vitro and in vivo, and it is also involved in the 
accurate chromosome separation during mitosis and in polarisation of the 
microtubule cytoskeleton in migrating cells (Bu and Su, 2001). 
The importance of the role of EBs lies in the regulation of microtubule dynamics, 
but the exact mechanisms by which they directly perform this function are not fully 
understood. It has been suggested that EB1 catalyses the rescue phases of 
microtubule dynamics (Bieling et al., 2007, Vitre et al., 2008), or by suppressing 
the catastrophe phase (Manna et al., 2008). However, some studies showed no 
effect at all on both phases; it seems that the EB1 role is to stimulate microtubule 
growth by impeding catastrophe, which was reported in vivo in Xenopus and the 
fission yeast homologue Mal3 (Busch and Brunner, 2004). Structural studies 
showed EB1 binding between protofilaments and suggest that EB1 discourages the 
peeling away of protofilaments from the microtubule, which occurs in the 
catastrophe phase and thus promotes growth (Sandblad et al., 2006, des Georges et 
al., 2008, Maurer et al., 2012). Additionally, recent studies have shown that the 
length of the EB1 comet reflects the area of the GTP tubulin cap (Seetapun et al., 
2012, Duellberg et al., 2016). 
It has also been shown how the domains of the EB family members influence their 
ability to govern microtubule growth. It was found that EB1 and EB3, but less so 
EB2, were needed for enhancing microtubule growth, and also suppressing 
catastrophe, instead of directly promoting growth rate or rescue. From the structural 
point, the C-terminal acidic tail is not required for the growth, but the EBH domain 
has the ability to dimerise. EB2 was found to have less ability to compete with other 
family members for contact with microtubule ends. Phosphorylation of EB2 leads 
to dispersal in the cytoplasm instead of localisation along the microtubule lattices, 
which causes a delay in cell mitosis (Iimori et al., 2016). Consequently, EB1 and 
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EB3 comets appeares as classic +TIP firework shapes, while EB2 is more 
associated along the microtubule lattice with little accumulation at the plus-ends in 
interphase cells. This is due to the difference between EB2, EB1 and EB3 amino 
acids, which are clustered at important CH domain residues (Komarova et al., 
2009). Recently, Goldspink et al. suggested that EB2 is expressed during the early 
stages of differentiation, thus keeping a dynamic microtubule population, which is 
vital for cell-to-cell junction formation and initial microtubule reorganisation 
(Goldspink et al., 2013). A recent study showed that overexpression of EB2 is 
involved in the invasion of pancreatic cancer (Abiatari et al., 2009). Moreover, it 
has been suggested that EB2 associates with HAX1  (HCLS1-asociated protein X-
1) and plays a vital role in focal adhesion turnover and cell migration, where 
interaction between EB2 and HAX1 in skin epidermal cells promotes focal 
adhesion turnover while their knockdown results in focal adhesion stability and 
impair cell migration (Liu et al., 2015). It has also been reported that EB2 associates 
with MAP4K4 and increases focal adhesion turnover and cell migration (Yue et al., 
2014). In addition, CK2 (casein kinase II) has been shown to decrease cell adhesion 
under shear stress in endothelial cells by phosphorylating EB2 at residue serine 236 
(Stenner et al., 2013).  
1.5.3.2 Cytoskeleton-associated protein Gly-rich (CAP-Gly) 
proteins 
This group of proteins includes two major +TIPs; the cytoskeletal linker protein 
(CLIP-170 and CLIP-115), and p150Glued, a subunit of dynactin. They can bind to 
the C-terminal of EBs via their CAP-Gly domains at the N-terminal regions. CAP-
Gly domains are globular components that specifically distinguish the acidic C-
terminal EEY/F tail motif that is found in EBs, microtubules and CLIP-170 itself 
(Akhmanova and Steinmetz, 2008, Manna et al., 2008, Honnappa et al., 2009, 
Komarova et al., 2009, Akhmanova and Steinmetz, 2015).  
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CLIPs and p150Glued are structurally similar, containing two microtubule-binding 
domains in the N-terminus, CAP-Gly domains, followed by coiled-coil regions that 
allow them to form parallel dimers, and Zinc metal motif in the C-terminus that 
associates with other +TIPs. CLIP-170 can fold back on itself due to the existence 
of CAP-Gly (Figure 1.7, b) (Akhmanova and Steinmetz, 2008, Akhmanova and 
Steinmetz, 2015). 
CLIP-170 was the first +TIP to be identified, as comets at the plus-end of 
microtubules in living cells (Perez et al., 1999). It has also been observed that there 
are two CLIP proteins in mammals, although lower eukaryotes only have one CLIP 
(Dzhindzhev et al., 2005). Studies have shown that CLIP-170 moves with the 
growth end of microtubules in living cells. Therefore, it has been suggested that 
CLIP-170 and CLIP-115 may act as rescue factors, as they were observed in the 
rescue phase of microtubules, but not in the catastrophe. CLIP proteins are 
dependent on EBs, in particular EB1 and EB3; depletion of both EB1 and EB3 
decreases the level of associated CLIPs with microtubule plus-ends, and can be 
rescued by transfection of an EB1 construct (Komarova et al., 2005). Moreover, 
CLIP-170 can interact with HDAC6 via coiled coil domain and Zinc finger, and 
this interaction functions to stimulate the cell migration of pancreatic cancer (Li et 
al., 2014). 
1.5.3.3 Other +TIPs 
Many other +TIPs found on microtubules can be characterised by their unique 
structures. For instance, cytoplasmic linker-associated proteins (CLASPs) are an 
important class of microtubule-associated proteins (MAPs) and +TIPs. Two 
members of the CLASP family, CLASP1 and CLASP2, are associated with 
multiple cellular functions. They contribute to the organisation of subcellular 
structures by linking microtubules to organelles, and are required for proper spindle 
assembly during mitosis (Lansbergen et al., 2006, Mimori-Kiyosue et al., 2006, 
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Wilbur and Heald, 2013). In the interphase cell, CLASPs are involved in forming 
polarised microtubule arrays and can bind directly to distal microtubule ends and 
stabilise microtubules by increasing pause and suppress shrinkage in association 
with EB1 (Mimori-Kiyosue et al., 2005). In particular, CLASP2 links microtubules 
to the cell cortex via its COOH-terminal domain, and is involved in stabilising 
microtubules (Mimori-Kiyosue et al., 2005). CLASPs can promote interactions 
between the microtubule plus-end and the cell cortex via two CLASP partners, 
LL5β and ELKS, which form a microtubule-independent membrane bond complex, 
and can bind to EB1 and EB3, and recognise the growing plus-end of microtubules 
(Mimori-Kiyosue et al., 2005, Lansbergen et al., 2006).  
CLASP proteins structurally consist of conserved TOG-like (TOGL) domains and 
SR-rich domains, which are regions with stretches of sequences rich in serine, 
proline and arginine. S. cerevisiae Stu1, S. pombe Cls1, and C. elegans Cls2 have 
two TOGL domains, and D. melanogaster MAST/orbit and human CLASP1 and 
CLASP2 have three TOGL domains in their C-terminals (Al-Bassam et al., 2010, 
Al-Bassam and Chang, 2011). Studies have shown that CLASP proteins enhance 
microtubule rescue and suppress microtubule catastrophe. These functions are 
related to the structure of the CLASPs, wherein conserved TOG domains are used 
to attract tubulin dimers to microtubules by binding a single αβ-tubulin dimer 
through two sets of TOG domains, and binding to the microtubule lattice through 
two S/R-rich domains without releasing its bound tubulin dimer (Figure 1.7, c) (Al-
Bassam and Chang, 2011). 
The polymerase XMAP15 is characterised as a +TIP that binds microtubules via 
several N-terminal TOG domains (Slep and Vale, 2007). There are different 
microtubule motors that can accumulate at microtubule ends, and thus can be 
defined as +TIPs, which bind through multiple tubulin-binding TOG domains. 
These include dynein and kinesin MCAK, the depolymerised protein, containing 
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basic/serine SxlP regions, which can bind to EB1 (Akhmanova and Steinmetz, 
2015). 
 
1.6 Cell Migration 
Migration of single and sheets of cells is vital during embryonic development, and 
remains essential in the mature organism. Cell migration is required for 
developmental morphogenesis, tissue repair, regeneration and tumour metastasis. 
Generally, migration consist of a repetition of four basic steps: a) protrusion, (b) 
adhesion, (c) contraction, and (d) retraction ( Figure 1.8) (Vicente-Manzanares et 
al., 2005, Tschumperlin, 2013). These different steps have to occur without any 
disorder, and need to be coordinated in time and space. The four migration steps 
consist firstly of membrane protrusion at the leading edge leading to the formation 
of lamellipodia and filopodia. These extensions at the leading edge then attach to 
the extracellular matrix (ECM) by focal adhesions and via integrins. This 
attachment to the ECM of the internal cytoskeleton allows movement by myosin II 
activity to pull the cell over the matrix. In the final step, retraction occurs at the cell 
rear with disassembly of focal adhesions to allow a new cycle to start again (Figure 
1.8) (Etienne-Manneville, 2013, Tschumperlin, 2013).  
The migration steps are controlled by many different proteins and especially the 
Rho family of GTPases (RhoA, Rac1 and Cdc42), which interact with actin 
filaments, microtubules and focal adhesions during cell movement. Generally, 
RhoA is considered to influence actin contraction and retraction, and Rac to 
encourage lamellipodium extension and actin polymerisation while Cdc42 is 
assumed to enhance filopodia elongation and inhibit actin depolymerisation. The 
active GTP-bound forms of Rac and Cdc42 accumulate at the front edge of the cells 
and promote protrusion and initiate adhesion. Meanwhile, at the back of the cell 
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body Rho activity is important of the maturation of focal adhesions and for cell 
contraction. 
Serious consequences may occur during disorganised migration processes, 
including intellectual disability, vascular disease, tumour and metastasis. 
Moreover, a better understanding of cell migration mechanisms could lead to 
effective treatment for diseases such as invasive cancer cells (Lauffenburger and 























Figure 1.8 Cell migration mechanism
Schematic representation of the steps in cell migration. 1. Extension of a
protrusion at the leading edge forming the lamellipodium. 2. Formation of new
adhesions that attach the cell to the ECM, which allows the cell to crawl over
the matrix. 3. Contraction at the rear area and 4. De-adhesion at the trailing
edge to start a new cycle again. Adapted from (Tschumperlin 2013)
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1.6.1 Cytoskeletal organisation in migrating cells 
The cytoskeleton consist of actin filaments, intermediate filaments and 
microtubules that play an essential role in cell migration. The cytoskeleton needs 
rearrangements in order to produce the force to perform the required movement. 
Generally, the leading edge of a migrating cell extends to form a lamellipodium 
that is characterised by an extensive actin network. This actin network pushes 
forward the membrane with myosin II and actin stress fibres contracting at the back 
of the cell. At the same time, the centrosome and Golgi apparatus relocate to a 
location in front of the nucleus. Meanwhile, microtubules are required for the 
direction of migration. Microtubules act to suppress regional remodelling of cell 
morphology and thus specify the direction of migration. In migrating cells, 
lamellipodia extend at the front area with some stable microtubules, resulting in 
inhibition of lamellipodium retraction in that region. Microtubules aid in the 
delivery of vesicles that help to maintain the growth of the leading edge, and 
therefore prioritise the lamellipodium to establish the leading edge. At the same 
time, the rear area of the cell is rich in dynamic microtubules, which cause high 
turnover of focal adhesions at the back of the cell but little turnover at the front 
(Pollard and Borisy, 2003, Goley and Welch, 2006, Ganguly et al., 2012, Vinzenz 
et al., 2012, Etienne-Manneville, 2013).  
Actin filaments play essential roles in cell migration, where they are involved in all 
processes of migration, protrusion, adhesion, contraction, and retraction. At the 
leading edge of migrating cells, an actin network provides forces through the 
formation of lamellipodium, which derives from retrograde actin flow and myosin 
generated tension. Actin filaments are nucleated by ARP2/3 complex at the front 
of the cells with most of their plus-ends close to the plasma membrane. Filopodia 
consist of actin filaments, which are finger-like structures found at the advance 
front of the leading edge where the plus-ends of the actin bundle point outward. 
The actin bundle within filopodia are nucleated by formins that associate with the 
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plus-end of actin filaments to promote assembly. Moreover, filopodia are vital for 
the directional response of the migrating cell. Actin filaments also create contractile 
stress fibres (actin and myosin II), which are responsible for contraction of the cell 
body and retraction of the trailing edge, and also for contacting focal adhesions 
(Figure 1.9, a) (Pollard and Borisy, 2003, Blanchoin et al., 2014). There are 
different types of stress fibre, ventral stress fibres, which are anchored at each end 
by focal adhesions, and dorsal stress fibres, which are anchored at one end by a 
small focal adhesion behind the leading edge. Dorsal stress fibres extend towards 
the nucleus and link with transverse arcs. Arcs consist of a bundle of actin filaments 
and little or no myosin II that form behind the front of migrating cell or spreading 
cells and are generated by the ARP2/3 complex. They act as connectors for the the 
ventral adhesion with the dorsal contractile actin network (Figure 1.10) (Burridge 











Figure 1.9 Cytoskeletal organisation in cell migration
a) A migrating cell undergoes different actin related processes. During
migration, polymerised actin filaments in Lamellipodia push forwards the
plasma membrane at the leading edge. Focal adhesions are attached to the
ECM, allowing tension exerted by actomyosin contraction in stress fibres to
pull the cell forward. Finally, focal adhesions turnover and the rear of the cell
retracts. b) Microtubules reorganise during cell migration. The centrosome
and Golgi apparatus relocates to the front of the nucleus facing the leading
edge, where stable microtubules extend to the leading edge. Dynamic
microtubules also extend to the rear of the cell. Adapted from (Lauffenburger























Figure 1.10 Schematic representation of stress fibres types
Four different types of stress fibre in migrating cells, dorsal stress fibres that are
anchored at one end by focal adhesion close to the cell front edge. Ventral
stress fibres anchored at the both ends by focal adhesion. Arcs are formed
behind the leading edge of spreading cells of migrating cells, and they are not
directly linked by focal adhesion. Fourth type is the perinuclear actin cap, which
is consisted of ventral stress fibres that wrap over the nucleus and anchor to
elongated focal adhesions, which associate focal adhesion from at each end.
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Migrating cells are controlled by the Rho GTPase family of proteins, including 
RhoA, Rac and Cdc42. They play important roles in cell migration by regulating 
the changes in the cytoskeleton and in adhesions to establish movement. In general, 
Rho family protein activity is important for regulating adhesions sites and have 
major roles in modulating microtubule stability (Wojnacki et al., 2014). The 
activity of Rho family proteins is regulated by GTP-binding, exchanging GDP to 
GTP by GEFs (guanine nucleotide exchange factors) that activate Rho family. 
GAPs (GTPase-activating proteins) are inactivators that prevent the activity of Rho 
family proteins and hydrolyse GTP to GDP. Rac can also be activated by tyrosine 
receptors or G-protein couple receptors, and also by integrin (Raftopoulou and Hall, 
2004, Etienne-Manneville, 2013). 
Actin filaments are the main target for Rho family proteins. Rho family proteins 
play different important roles in actin filament regulation during cell migration. 
RhoA has a critical role in regulating the formation of stress fibres and regulates 
cell body contraction by controlling myosin II. Meanwhile, the formation of the 
lamellipodium can be promoted by Rac1 via stimulation of actin polymerisation, 
where it has been found that inhibition of Rac can suppress cell migration. Rac can 
also stimulate actin polymerisation by interaction with WASp and N-WASp that 
leads to activation of the ARP2/3 complex (Raftopoulou and Hall, 2004). Cdc42 is 
another Rho family protein that induces filopodia formation and acts at the 
advancing front of migrating cells to control the direction (Ridley, 2001, Burridge 
and Wennerberg, 2004, Raftopoulou and Hall, 2004, Etienne-Manneville, 2013). 
Adhesion formation is an important step toward cells migration. It occurs during 
the binding of adhesion receptors to ECM via integrins along the cell periphery. 
The attachment between cell and ECM generates the required force for crawling 
over the matrix, which relies on the ability of the cells to dynamically remodel 
adhesion sites. Small focal adhesions can be located in the lamellipodium, and they 
are referred to as focal complexes, and allow the cell to generate traction and then 
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rapidly turnover. In contrast, focal complexes can mature into focal adhesions, 
which are stable large complexes, and associate the ends of stress fibres (Wolfenson 
et al., 2009, Danen, 2013). Several large proteins have been defined at focal 
adhesions, due to different interaction partners that allow the cell to construct many 
signalling complexes with different behaviours. These proteins include paxillin, 
vinculin, FAK (focal adhesion kinase) and ILK (integrin-linked kinase), along with 
ingegrin subunits, such as α-V and β-3 (Figure 1.11) (Wozniak et al., 2004). 
Integrins mediate cell adhesion with the extracellular matrix (ECM) and have vital 
roles in cell survival, differentiation and migration. Integrins are heterodimers 
consisting of α and β subunits, with different types determining the receptor 
specificity for the different ECM molecules. For example, human retinal pigment 
epithelial cells (ARPE-19) expresses integrin α5 that interact with fibronectin 
(Hynes, 1992, Elner and Elner, 1996, Proulx et al., 2004). There is little information 
of integrins in PANC1 cells but one study seems to indicate that α2 β1 which 
interacts with collagen1 is expressed in these pancreatic cells (Arao et al., 2000). 
In migrating cells, a dissociation occurs to the small adhesions near the cell leading 
edge that allows the cell to detach from ECM and then re-attach again at different 
spots. While the mature focal adhesion anchors stress fibres to generate contraction 
forces and also to stop the cell movement (Parsons et al., 2010). The connection 
between focal adhesions and actin filaments is obtained by adaptor proteins, such 
as talin and tensin. This allows new focal adhesions to grow and mature and then 
provide forward traction forces with actin filaments and myosin II. These processes 
are governed by Rac1 that is vital for actin filament growth in lamellipodium that 
lead to promote adhesions growth, with Cdc42 contribution to Rac activation or 
localisation at the leading edge (Ridley, 2001). Focal adhesions have to disassemble 
in the cell body and in the rear of the cell in order to allow the cell to move forward, 
and this requires dynamic microtubules. To complete the migration cycle integrin 
mediumted focal adhesions connect the actin filaments and allow cells to crawl on 
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the extracellular matrix during migration. However, focal adhesions can increase 
cell adhesion with ECM, and thus decrease cell migration, where RhoA controls 
focal adhesion turnover (Wozniak et al., 2004, Parsons et al., 2010, Etienne-

















Figure 1.11 Cell adhesion composition
Mature stable focal complexes termed focal adhesions. Focal adhesions
are large and consists of a large number of proteins, including paxillin,
vinculin and two integrins α-V and β-3. Adhesion complexes link with actin
filaments via different proteins, such talin and tensin. Adapted from
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Microtubule dynamics have critical roles in cell migration, where the microtubules 
act differently at the front and the rear of migrating cells. During cell migration, 
stabilised microtubules enable the centrosome to reorient towards the leading edge, 
which causes a polarised microtubule array that facilitates cell movement. 
Basically, migrating cells relay on both actin filaments and microtubules to 
generate required forces in protrusions. Stable microtubules contribute to the 
generation of pushing forces needed for the lamellipodium  with a few microtubules 
interacting with actin filaments near the leading edge. These microtubules are 
referred as pioneer microtubules and are found in the lamellipodium . Stable 
microtubules also target and interact with young adhesions to deliver additional 
components or to dissolve adhesions at the front to maintain the cycle. Meanwhile, 
more dynamic microtubules found at the cell rear influence focal adhesion turnover 
to start the contraction at the cell rear (figure 1.9, b) (Kaverina and Straube, 2011, 
Etienne-Manneville, 2013, Akhshi et al., 2014, Charafeddine et al., 2016). 
Microtubules also play an indirect role in cell protrusion by regulating signalling 
proteins and impact on the activity of RhoGTPases and locally increasing actin 
polymerisation. Rac is mainly active at the cell front, thus induces actin filament 
assembly, and RhoA is mainly active at the cell rear to induce myosin II contraction 
and focal adhesion turnover. Both proteins are regulated by dynamic microtubules, 
with stable microtubules at the cell front regulating Rho activity by sequestering 
the Rho effector GEF-H1 from microtubules but dynamic microtubules at the rear 
area release Rho GEF-H1 to activate Rho and cause focal adhesion turnover and 
influence myosin II contraction (Stehbens and Wittmann, 2012, Akhshi et al., 
2014). It has been shown that, nocodazole treatment activates RhoA signalling 
through ROCK (Rho-associated kinase) to trigger the release of Rho effector GEF-
H1 from microtubules and activate Rho (Chang et al., 2008). Rac  is inactive at the 
cell rear and  binds cytoplasmic tubulin, however, it is active at the cell front and 
causes an increase in focal adhesion growth and polymerises actin filaments 
(Akhshi et al., 2014, Charafeddine et al., 2016). 
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Dynamic microtubules promote focal adhesion turnover by delivering important 
proteins for disassembly with +TIPs contribution. Recently, it has been reported 
that EB2 increases focal adhesion turnover via association with essential protein  
kinase kinase kinase 4 (MAP4K4, disassembly protein) (Yue et al., 2014). 
Furthermore, EB2 associates with HAX1 to increase focal adhesion turnover and 
promotes migration, while knockout will impair cell migration (Liu et al., 2015). 
Moreover, depleting EB2 can inhibit microtubule dynamics and result in co-
alignment between microtubules and actin filaments with EB1 and ACF7 
associated along the lattice, which leads to impair migration (form unpublished data 
from our lab) (Goldspink et al., 2013). APC can increase protrusions in migrating 
cells by promoting the growth of microtubules and decreasing shrinkage (Carvalho 
et al., 2003, Kroboth et al., 2007, Komarova et al., 2009). It has been shown that 
microtubule associated protein CLIP-170 binds closely to formins to increase actin 
filament elongation. Thus, dynamic microtubules are required for rapid actin 
filament assembly (Stehbens et al., 2014, Henty-Ridilla et al., 2016). ACF7, CLIP-
170 and ACP are localised at the growing microtubule ends via an interaction with 
EB1 and this contributes to microtubule organisation and stabilisation near the 
leading edge and also localise focal adhesion sites in migrating cells (Stehbens and 
Wittmann, 2012, Akhmanova and Hoogenraad, 2015). Moreover, microtubule 
associated motors can deliver β-actin and ARP2/3 complexes to influence actin 
polymerisation (Vinzenz et al., 2012, Etienne-Manneville, 2013). Many +TIPs 
(including APC, CLIPs and CLASPs) can also interact with Rac and Cdc42 via 
IQGAP1. In addition, ACF7 has been linked to the disassembly of focal adhesions, 
where it associates with EB1 at the plus-end of microtubules and help to guide 
along actin filaments (Wu et al., 2008, Kaverina and Straube, 2011).  
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1.7 Sulforaphane (SFN) 
Several natural components in our diet have been found to have an inhibitory 
influence on tumorigenesis. Isothiocyanates (ITCs) are produced in plants and 
specifically in cruciferous vegetables, and the most characterised component is 
sulforaphane (SFN). It has been documented that SFN has various possible 
mechanisms to prevent cancerous activity and slow progression of the disease 
(Fimognari and Hrelia, 2007). However, the molecular mechanisms of the effects 
of SFN in many cancer diseases has not been fully clarified and especially its effect 
on microtubules.  
Cruciferous vegetables, for instance broccoli, cauliflower, cabbage and kale, have 
been associated with cancer protection. Studies showed that 67% of investigations 
on the consumption of these vegetables and cancer risk reported an inverse relation 
between consumption and risk of cancer. Furthermore, the studies found the 
greatest inverse associations between the consumption of broccoli/brassica and risk 
of different cancers, such as lung, stomach, prostate and pancreatic cancer 
(Verhoeven et al., 1996, Cohen et al., 2000). 
Crucifers contain various bioactive components, including flavonoids, minerals 
(selenium) and vitamins (vitamin C); however, the bioactive compounds connected 
with cancer protection are glucosinolates (GLS). GLS is a chemical compound that 
consists of a β-D-thioglucose group (a sulfonated oxime group and a side chain 
comes from methionine, phenylalanine), tryptophan or branched-chain amino 
acids. Glucosinolates have to be hydrolysed to become bioactive and are then called 
isothiocyanate (ITC). Isothiocyanate is released when the cell wall is ruptured 
during chewing, producing an enzymatic reaction between the myrosinase enzyme 
and glucosinolates (Figure 1.12) (Fimognari and Hrelia, 2007, Houghton et al., 




Figure 1.12 Sulforaphane (SFN)
Isothiocyanate (ITC) released when the cell wall is ruptured during chewing,
produces an enzymatic reaction between the myrosinase enzyme and
glucoraphanin. The most characterized broccoli-derived isothiocyanate is
sulforaphane (SFN). SFN comprises [1-isothiocyanato-4-(methylsulfiny) butane],
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In humans, high concentrations of isothiocyanate can be established in the diet by 
ingesting crucifers, where the highest SFN concentrations of ~2-3 µM in plasma, 
serum and erythrocytes are achieved one hour after ingestion of broccoli or sprouts 
containing 200 µM equivalents of isothiocyanates (Gasper et al., 2005). It has been 
reported that super broccoli has approximately 2.5 μmol of glucoraphanin per gram 
(Traka et al., 2013). This will equate to 2.5 μmol of SFN/gram if fully converted, 
so it can suggest that to get a concentration of 23 μmol/L we would need to eat 
1Kg/ broccoli.  
Studies have shown that there are several different possible mechanisms of SFN in 
preventing cancer, including the inhibition of carcinogen-activating enzymes, such 
as the cytochrome P450 isoenzyme 2E1, the induction of conjugating enzymes, 
such as glutathione S-transferases, the reduction of the DNA binding ability of 
nucleus and the inhibition of histone deacetylase (HDAC) activity in vitro and in 
vivo. SFN can also induce apoptotic cell death by significantly reducing the 
viability, as found in breast cancer cells. It seems that SFN induces apoptosis 
through the mitochondrial pathway, where cytochrome c is released and activates 
caspases (degrades proteins) (Pledgie-Tracy et al., 2007, Dickinson et al., 2015). In 
addition, SFN is known to affect microtubule polymerisation in cancerous cells, 
inhibiting cell proliferation and initiating apoptosis, thus retarding or eliminating 
neoplastic cells and inhibiting the progression of benign tumours into malignant 
tumours, and metastasis formation. Therefore, it seems SFN is capable of 
preventing, delaying or reversing the formation of a malignant neoplasm, as well 
as having the ability to act on cancerous cells, and thus holds the potential to be a 
therapeutic agent (Fimognari and Hrelia, 2007). 
Studies suggest that SFN plays a significant role as an anti-proliferative agent in 
cancer. Jackson and Singletary (2004) showed that 15 µM SFN for 48 h induces 
mitotic arrest in the breast cancer cells (MCF7 cell line). They also showed that 
SFN simulated cell death in vitro and in vivo, and disrupted microtubule dynamics 
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at the mitotic stage. However, high concentrations of SFN inhibit tubulin 
polymerisation in vitro (Jackson and Singletary, 2004). Similarly, in bovine aortic 
endothelial cells (BAE cell line), SFN disturbed microtubule polymerisation and 
inhibited the mitotic cell cycle when treated with 15 µM for 48 hour (Jackson et 
al., 2007).  
Gamet-Payrastre et al. (2000) investigated the effect of SFN in growth and viability 
in a human colon cancer (HT29 cell line), where SFN induced cell cycle arrest, 
followed by cell death via an apoptotic process. The effect of 96 hours of SFN on 
cell viability was studied by using an MTT assay and SFN at 15 µM was shown to 
significantly decrease cell viability with inhibition in growth rate and increase in 
apoptosis. It also notice that after 48 incubation SFN with ≤ 20 µM dramatically 
inhibits cell viability (Gamet-Payrastre et al., 2000). 
A critical property of microtubules is their dynamic instability, and the central 
mechanism of anti-cancer treatments is to suppress this dynamic activity, such as 
the chemotherapy agents, taxanes (for prostate cancer) and the vinca alkaloids. It 
has been found that a concentration of SFN of 15 µM for 20 hours inhibits 
microtubule dynamic instability and reduces microtubule turnover in human breast 
cancer adenocarcinoma cells (MCF7 cells). Specifically, this concentration 
decreased the shortening rate by 50% and the shortening length by 57%. It also 
suppressed the growth rate and the length of growth to around 30 and 49%, 
respectively, and reduced the total dynamics by 53%. Additionally, the durations 
of individual growth and shortage events were decreased. However, only four 
microtubules were used to analyse dynamic instability (Azarenko et al., 2008).  
SFN also causes an increase in acetylation of microtubules in human breast cancer 
with 15 and 25 µM SFN, compared with untreated cells. At high concentrations of 
up to 50 µM, microtubules were mostly depolymerised and remaining microtubules 
became completely stable and highly acetylated. (Azarenko et al., 2008). Therefore, 
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from these observations, SFN causes changes in microtubule post-translational 
modifications, where it increases tubulin acetylation, which is known to be linked 
with stable microtubules. Similarly, it has been noticed that tubulin acetylation was 
increased in prostate cancer cells treated with 15 µM SFN (Gibbs et al., 2009, 
Clarke et al., 2011).  
Interestingly, recent studies reported that SFN decreased the level of acetylated 
tubulin; this was observed in vitro in skin human keratinocytes (HaCaT) after 
treatment with 15 µM SFN for a 48 hour incubation. A reduction was only observed 
in the level of HDAC6 (Dickinson et al., 2015). 
HDAC6 activity functions as α-tubulin deacetylase and regulates microtubule-
dependent cell motility. Inhibitors of HDAC have become interesting as novel 
chemoprotective agents, as they target genetic events that can occur at different 
stages of cancer development. The effect of SFN on HDAC activity was 
investigated in a variety of human breast cancer cell lines, such as MDA-MB-231, 
MDA-MB-468, MCF-7 and T47D. These cell lines were treated with a range of 
SFN concentrations (5, 15 and 25 µM) and incubated for 48 hours, then the activity 
of HDAC was measured using an HDAC activity assay, in vitro. It was found that 
SFN significantly inhibited HDAC activity in breast cancer cell lines. Moreover, 
no significant changes were observed in the acetylation global histone H3 or H4 in 
cells treated with SFN up to 25 µM. HDAC6 inhibitor trichostantin A (TSA) was 
used as a positive control for 48 hours; results showed that the inhibition of HDAC6 
leads to the accumulation of acetylated tubulin in breast cancer cells (Pledgie-Tracy 
et al., 2007). Recent studies showed that SFN for 48-hour incubation decreases 
HDAC6 level but not the nuclear HDACs. It has been suggested that this difference 
in SFN effect on HDACs may be due to the serum in the culture medium, where 
serum has a different effect on signalling that may impact on SFN function 
(Dickinson et al., 2015). 
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In human prostate cancer cells the effect of SFN on HDAC activity was 
investigated. Two prostate cancer cell lines were used, LnCaP and PC-3. Treating 
prostate cancer cells with 15 µM SFN for 48 hours inhibited HDAC6 activity. 
Whereas immunoblotting confirmed that SFN increased the amount of acetylated 
histone H3 and H4 in prostate cancer cells, with reduction on HDAC activity 
(Myzak et al., 2006, Clarke et al., 2011). The reduction in HDAC6 level was also 
observed in prostate cancer cells after long incubation with SFN (Gibbs et al., 
2009).  
The expression of HDAC6 in human pancreatic cancer (PANC-1) was examined, 
and it has been found that HDAC6 is overexpressed, which may induce cell 
migration (invasion and growth). The inhibition of HDAC6 activity decreases its 
expression and thus impairs the movement of cancerous pancreatic cells, where 
overexpression of HDAC6 showed enhancement of cell motility (Li et al., 2014). 
It seems that overexpression of HDAC6 in pancreatic cancer cells may rescue the 
HDAC6 level from SFN treatment, which deacetylates microtubules (Gibbs et al., 
2009). 
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1.8 Summary 
The microtubule cytoskeleton plays essential roles and it has the ability to 
reorganise with a variety of cellular functions. Microtubules are highly dynamic 
and this is very important for their ability to reorganise and perform different roles, 
such as cell division, trafficking, polarisation and migration. These functions 
require association with multiple proteins, in particular +TIPs such as the end-
binding proteins, which influence their dynamics and stability. The end binding 
proteins influence microtubule dynamics at the growing end, and their expression 
level and localisation cause changes in microtubule states. Furthermore, HDAC6 
has a role in tubulin deacetylation and that influences cell migration. 
In many animal cells, microtubules are arranged in a radial array with the minus-
ends anchored at the centrosome and the plus-ends directed towards the cell 
periphery. In general, microtubules contribute to cell migration by regulating actin 
polymerisation, transporting membrane vesicles to the leading edge, and 
facilitating the turnover of focal adhesions. Most anti-cancer treatments target 
microtubule dynamics to suppress their roles in different cellular functions. 
SFN is a natural product present in, for example, broccoli and it is particularly 
interesting as a chemo-preventive agent. SFN has various possible mechanisms to 
prevent cancerous activity and slow progression of the disease. SFN is known to 
affect microtubule polymerisation, inhibit cell proliferation and initiate apoptosis, 
thus retarding or eliminating neoplastic cells and inhibiting the progression of 
benign tumours into malignant tumours and metastasis formation. It has been 
suggested to affect microtubule dynamics by increasing their stability, and to 
inhibit HDAC6 activity. 
This study aims to examine whether the migration of epithelial cells and in 
particular pancreatic cancer cells, can be affected by SFN.  The investigation is 
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focused on the effects that may occur on microtubules and actin filament 
organisation. In addition, analysis of whether SFN may affect the expression and 
localisation of EBs and HDAC6. 
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1.9 Hypothesis and Aims 
We hypothesise that relatively high concentrations (≥10µM) of SFN will increase 
microtubule stability while also decreasing dynamic activity and cause a reduction 
in the speed of migration. 
SFN has been reported to affect microtubule behaviour, cell migration and mitosis. 
Understanding these actions will lead to more effective drug use. The aim of this 
study is to investigate the effects of SFN on microtubule organisation, dynamics 
and stability, and particularly with regard to cell migration in normal and cancerous 
cells. The impact on end-binding proteins (EBs) and HDAC6 will also be studied.  
Objectives: 
To achieve these aims the cell models (ARPE-19 and PANC-1) to be used in this 
project first will need to be characterised. This will involve characterising the 
organisation of microtubules and actin filaments in ARPE-19 and PANC-1 cells 
and determined the expression and localisation of EBs and HDAC6. The next 
objective is to study the effects of SFN on cell migration using different SFN 
concentrations for 48 hour. In addition, immuno-labelling will be perform to 
determine microtubule modifications and to observe microtubule and actin filament 
organisation and EBs and HDAC6 localisation in SFN treated cells compare with 
untreated and DMSO treated cells. HDAC6 is highly expressed in PANC1 cells, a 
further objective is therefore to use a specific inhibiter of HDAC6 (tubacin) to 
examine the effect of its inhibition on cell migration and microtubule and actin 
filament organisation. In addition, the effects of combinations of tubacin and SFN 
will also be investigated. A further objective is to study the direct effect of SFN on 
microtubules dynamics and stability and the consequences for focal adhesion 
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2.1 Cell culture 
2.1.1 Maintenance of cell lines  
All work in tissue culture for this project were performed under sterile conditions 
in a Class II laminar flow tissue culture hood. Cells were grown in 75cm2 culture 
flasks (Nunc) with a vented cap and membrane to allow sterile gas exchange. Cell 
lines were maintained at 37ºC in a humid atmosphere containing 5% CO2. Cell lines 
were grown in appropriate medium containing the indicated supplements (Table 1). 
 
Table 1: List of cell lines and medium. 
Cell Line Medium Supplements Antibiotics 
ARPE-19 
DMEM/F:12 (1:1) 
(High Glucose, +NEAA) 
10% FBS 
1% L-Glutamine 
2% Sodium bicarbonate 
0.1µg/ml gentamicin 








0.1 mg/ml streptomycin 
ATCC 
DMEM, DMEM/F: 12 (Invitrogen, Paisley, Scotland). Penicillin, streptomycin, L-Glutamine 
(Sigma, Poole, Dorset). FBS (PAA Laboratories, Yeovil, Somerset). 
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2.1.1.1 Passaging of cell lines 
Cells were passaged twice a week to maintain an exponential growth phase until 
they reached 80% confluency. All reagents were warmed to 37ºC using a water 
bath prior to use. For subculture of a flask, the medium was removed and the cells 
were washed with 0.25% trypsin/1mM ethylenediaminetetraacetic acid (EDTA) 
(Sigma, Poole, Dorset) to remove any traces of medium that could interfere with 
cell detachment from the plastic. After removal of this wash, cells were incubated 
in 5ml of 0.25% trypsin/EDTA at 37ºC, 5% CO2 for five minutes until the cells had 
detached from the tissue culture plastic. Afterwards, the trypsin was neutralised by 
adding 5ml of medium containing 10% foetal bovine serum (FBS) (Invitrogen). 
The suspended cells were then pelleted in sterile tubes by centrifugation at 1000rcf 
for five-minutes at room temperature. After the supernatant was removed, the cell 
pellet was resuspended in relevant fresh medium. Finally, resuspended cells were 
diluted into new 75cm2 culture flasks (T75) in a total volume of 10ml medium. 
2.1.1.2 Freezing and thawing cells 
Cell lines in low passage were stocked in a liquid nitrogen dewar to avoid potential 
phenotypic changes associated with high passage numbers. To freeze cells, firstly, 
a flask was passaged until the cell pellet was ready for resuspension, with the pellet 
resuspended in appropriate medium with 10% dimethylsulphoxide (DMSO) to act 
as a cryopreservant. This was aliquoted into several cryovials (Corning, 
Amsterdam, Netherlands) and immediumtely transferred to a freezing box 
containing isopropanol (Mr Frosty™) before being gradually frozen at -80°C. For 
long-term storage, cryovials were placed in liquid nitrogen dewars. 
To thaw cell lines from frozen the cryovials were quickly heated in a 37°C water 
bath, after which the cells were immediumtely transferred to a sterile tube 
containing pre-warmed 10ml of medium and centrifuged for five-minutes at 800rcf 
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to remove the DMSO. The cell pellet was resuspended in 5ml of medium and 
transferred into a 25cm2 culture flask. The medium in these flasks was changed 
every other day until the cells reached 80% confluency. Once the cells reached this 
level, they were passaged as per standard maintenance procedures, which helped 
the cells to settle before use in any experiments. 
2.1.1.3 Cell counting 
The cells were counted during cell passaging with a haemocytometer before the 
centrifugation stage. The haemocytometer chamber was mounted with a coverslip, 
allowing the medium containing the cells to enter the chamber by capillary action. 
In the chamber there was a large 4x4 square grid, and the number of cells within a 
single square was used to determine the cell concentration by multiplying this 
number by 1x104, which provided a final cell concentration per ml. To ensure a 
correct cell count, the number of cells in four squares was counted and the mean 
was used to estimate the concentration of cells. 
 
2.1.2 Seeding cells 
Cells were seeded onto appropriate surfaces for experiments as needed, including 
multiwell plate plastic surfaces (Nunc, Penfield, New York, USA), 13mm diameter 
glass coverslips (No. 0 thickness) (VWR International, Lutterworth, Leicestershire) 
and glass-bottomed dishes (MatTek, Ashland, Massachusetts, USA) for live 
fluorescence microscopy. Oven baking was used to sterilise glass coverslips at 
180°C overnight. For seeding, cells were trypsinised as described above and 
resuspended in fresh medium. Cell counting was used to determine cell 
concentration, followed by appropriate dilution of seeds to a specified density. This 
variety in density depends on different cell types and experimental purposes. 
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2.2 Drug treatments 
2.2.1 Sulforaphane (SFN) 
Sulforaphane (SFN) (LKT LABS) was dissolved in DMSO and stock solutions 
stored at -20C with a total concentration of 100mM. When required, it is freshly 
prepared and added to the cell cultures to achieve the indicated final concentrations. 
The DMSO concentration was 0.005% in the final solutions of the SFN treatment 
range (0.5, 1, 2, 5, 10, 15, 20, 30 and 40µM), where DMSO alone at 0.01% 
concentration was found to have no significant effect on cellular function. In our 
experiments, cells were treated with normal medium containing SFN and DMSO, 
diluted to a final concentration range to examine appropriate concentration, and 
incubated for 48 hours at 37C and 5% CO2. Different experiments were applied to 
investigate the effect of SFN on cancerous and normal epithelial cells, including 
live imaging, immunolabelling, Western blotting and MTT assay (these methods 
are described later in this chapter). 
 
2.2.2 Tubacin 
Tubacin (Sigma, Poole, Dorset) was dissolved in DMSO with a final concentration 
of 10mM, with stock solutions freshly prepared each time and added to the cell 
medium to obtain the indicated final concentrations (2, 5 and 10 µM). The 
concentration of DMSO was 0.01% and the tubacin concentration was 10µM in the 
final solution. Cell lines were treated with different concentrations of tubacin (2, 5 
and 10 µM) and incubated for various timepoints throughout the treatment in a 
37C, 5% CO2 incubator. MTT assay was applied to determine the effects of 
tubacin on cell viability, followed by investigation of effects on cell migration, 
microtubules and associated proteins by immunolabelling. 
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Combinations treatment of 10 and 15µM SFN and 10µM tubacin were used in our 
experiments. Cells were treated with a combination of SFN and tubacin and 
incubated in, then used in a variety of experiments, including live imaging, 
immunolabelling, Western blotting and MTT assay. 
 
2.3 Cell viability assay (MTT assay) 
Cytotoxicity has been assessed by using an MTT assay (Sigma, UK) to determine 
the effect of a drug on cellular viability. The MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5 diphenyl tetrazolium bromide) assay is based on the conversion of the 
tetrazolium salt MTT, a yellow solution, into purple formazan crystals in living 
cells. The principle of the MTT assay is that the activity of mitochondria in most 
viable cells is stable, thus an increase or decrease in the number of living cells is 
related to mitochondrial activity. These changes in living cell numbers can be 
detected by measuring formazan concentration using a plate reader at 750nm (van 
Meerloo et al., 2011). The MTT assay is largely utilised to measure the cytotoxic 
effects of drugs on cell lines in vitro, then compare the treated cells to DMSO 
control cells. 
Cells were seeded in 96-well microplates in triplicate to minimise the variability of 
the results, and then incubated for 24 hours at 37°C with 5% CO2. After incubation, 
the medium was removed and replaced in quadruplicate with fresh medium 
containing the drugs, SFN, tubacin, or a combination of them, and incubated again 
for 48 hours. Following this, 10µl MTT agent was added to each well and the plate 
was agitated for one minute on a plate-shaker in slow mode, and then incubated for 
four-hours. Afterwards, 100µl crystal dissolving solution was added to each well 
and then the plate was left to rest for ten-minutes before measuring. The cellular 
homogenate was measured at 570nm using the plate reader. Cell viability results 
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were compared to DMSO treated cells and expressed as the mean of three 
independent experiments using GraphPad Prism 5.0 software. 
 
2.4 Transfection of plasmids 
Transformation of all used plasmids in experiments was in the DH5α Escherichia 
coli cells. The DH5α cells were defrosted on ice for about 20 minutes, and then 1µl 
of plasmid (20µg/ml) was added to 50µl of DH5α cells and left on ice for another 
15 minutes. The cells were heat shocked at 42ºC for two-minutes and placed back 
on ice for one-minute. Sterile Lysogeny broth (500µls) was added to the cells and 
incubated for one-hour at 37ºC under gentle agitation. Cells were then spread onto 
agar and sealed with a lid, then incubated overnight at 37ºC. The following day, a 
medium aread colony was picked from the agar plates and placed into 10 ml of LB 
starter culture containing the appropriate selective antibiotics and incubated for 6-
8 hours at 37°C under gentle agitation. One ml of the cells was placed into 250 mls 
of LB plus antiobiotics and placed at 37°C under gentle agitation overnight. Cells 
were harvested by centrifugation at 6000g for 15 minutes at 4°C. The constructs 
were then isolated and purified from the E.coli cells using a high-speed midi kit 
(Qiagen), according to manufacturer’s instructions and stored in TE buffer. The 
concentration of the cDNA was measured using nano-drop (LabTech, Ringmer 
East Sussex, UK) and stored at -20ºC. The constructs were amplified in bacteria 
and purified before use in cell transfection. Table 2 shows a list of constructs used 
in this study.  
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Table 2: Constructs details 





Cells grown on coverslips were all fixed in methanol at -20C, however, an 
alternative methanol-formaldehyde fix has been used where the protocol has been 
modified from the Rogers protocol (Rogers et al., 2002). The method in this 
protocol gave a better quality of labelling for proteins localised along microtubules 
such as EB2. A formaldehyde solution was prepared by diluting a 37.5% 
formaldehyde stock solution on ice-cold methanol. 
 
2.6 Immunolabelling 
The fixation techniques used in these experiments were dependent on the antibody 
being labelled. Cells were seeded on coverslips at 5x103 cells in a 3cm Petri dish 
and incubated for 24 hours. Methanol was used as the standard fixative for five-
minutes at -20ºC. Samples were also fixed by methanol-formaldehyde. After 
fixation, the cells were washed three times in 1% goat serum (Sigma-Aldrich) in 
PBS (Oxoid, Basingstoke, Hampshire) and placed in a PBS blocking buffer with 
10% goat serum for 30 minutes to prevent non-specific binding of antibodies. For 
the methanol-formaldehyde fixed samples the blocking solution contained 0.1% 
Triton X-100. 
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All primary antibodies used in this study are listed in Table 3. The antibodies were 
diluted in PBS with 1% goat serum then added to the cells. A 50µl spot of primary 
antibody was used for each coverslip. Coverslips were gently inverted onto the 
antibody spot, cell side down, and incubated at room temperature for one hour. 
Excess primary antibodies were removed by washing the cells in PBS with 1% goat 
serum six times every five-minutes. All secondary antibodies were diluted in PBS 
with 1% goat serum.  
The secondary antibodies used are listed in Table 4. Coverslips were again inverted 
onto secondary antibody spots and incubated for 30 minutes in the dark at room 
temperature. The cells were then placed in PBS with 1% goat serum for three 
washes of ten minutes to remove any excess secondary antibodies. If a nuclear stain 
was required, the cells were stained using DAPI (Sigma, Poole, Dorset) diluted in 
PBS (1:2000) for ten-minutes, followed by three washes in PBS for ten-minutes. 
Coverslips were mounted cell side up onto glass slides using hydro-mount 
(National Diagnostics), DABCO was added to reduce photobleaching of 
fluorophores, and a long glass coverslip (0.13-0.17mm thickness) was then gently 
lowered to cover the coverslips. Finally, the samples were incubated overnight at 
4°C to set before imaging. 
Combinations of primary antibodies were used depending on the species it was 
raised in (mouse, rat and rabbit). Basically, rat and rabbit or mouse and rabbit 
antibody combinations were mixed when diluting the primary, and convenient 
secondary antibodies were used. Importantly, all primary antibodies have been 
previously validated to check specificity.   
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Table 3: Details of primary antibodies. 
 
Primary antibody Raised in Source Dilution* 
Acetylated tubulin Mouse Sigma (T6793) IF: 1:100, WB: 1:500 
α-tubulin Rabbit Abcam (ab15246) IF: 1:100, WB: 1:1000 
Tyrosinated tubulin 
(YL1/2) 
Rat AbD Serotec (Kidlington, 
Oxfordshire) (MCA77G) 
IF: 1:200, WB: 1:200 
Detyrosinated tubulin Rabbit Abcam (ab48389) IF: 1:200, WB: 1:500 
Vinculin Mouse Abcam (ab18058) 1:200 
β-actin Rabbit Abcam (ab8227) IF: 1:1000, WB: 
1:10000 
EB1 Mouse BD Biosciences (610535) 1:500 
EB1 Rabbit Abcam (ab50188) 1:200 
EB2 (KT52) Rat Abcam (ab45767) 1:200 
EB3 Mouse Abcam (ab45855) 1:200 
γ-tubulin Rabbit Abcam (ab16504) 1:1000 
γ-tubulin Mouse Abcam (ab11316) 1:1000 
HDAC6 Rabbit Abcam (ab1440) 1:200 
FAK Rabbit Cell Signalling (9330) IF: 1:100, WB: 1:1000 
Paxillin Rabbit Sigma-Aldrich 1:200 
*IF= Immunofluorescence, WB= Western Blot 
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Cy5 Anti-MOUSE IgG 1:500 Jackson (Stratech, 
Newmarket, Suffolk) 
 
Goat anti-MOUSE IgG 1:3000 
Goat anti-RABBIT IgG 1:1000 







Note: all secondary antibodies were raised in goat. 
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2.7 Western blotting 
2.7.1 Cell lysis 
Cells grown in multiwell plates (of 6-wells) or tissue culture flasks were washed 
with ice cold PBS, then lysed for 30 minutes with 100x Halt Protease/Phosphatase 
inhibitor (Pierce, Cramlington, Northumberland), diluted into cell lysis buffer 
(Appendix A). A tissue culture flask, T75, needs 500µl lysis buffer, where 100µl 
is enough for a six-well plate. Cells were scraped every 15 minutes during lysis and 
the lysates transferred to an Eppendorf tube. Samples were centrifuged at 
13000rpm at 4C for ten minutes and the pellet was discarded, then stored in a fresh 
Eppendorf at -20C.   
 
2.7.2 Protein quantification 
Protein quantification was carried out using a BCA (Bicinchoninic Acid) protein 
assay kit (Pierce, Cramlington, Northumberland). This is based on preparing 
several bovine serum albumin (BSA) standards ranging from 0-2000µg/ml in 
concentration, diluted in ddH2O. A 96-well plate was used to quantify proteins, 
with 40µl water added to each well followed by 10µl of each standard and each 
sample to be analysed in triplicate. Next, 200μl of the protein assay reagent (reagent 
A: reagent B, 50:1) was added to each well and the plate incubated for one hour at 
37ºC. Absorbance readings at 550nm were measured using a spectrophotometer 
and the BSA values were used to generate a standard curve, from which the protein 
concentrations of the cell lysates were estimated. 
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2.7.3 SDS-PAGE electrophoresis 
Using the standard curve from the concentrations calculated in the BCA assay, 
20µg of protein content (diluted in ddH2O) for each sample and 10μl of 5X sample 
buffer (Appendix A) containing 12.5% β-mercaptoethanol were added, and the 
tubes heated at 95ºC in a heat block for two-minutes. 
Gels were made between spaced glass plates by adding a 8-10% lower resolving 
gel (Appendix A) and left to set for about 30 minutes. Upper gel was added using 
a spacing comb, which was removed once the upper gel had set. These gels were 
transferred to a Mini Protean II tank (BioRad, Hemel Hempstead, Hertfordshire), 
which was filled with 1X SDS running buffer, diluted in ddH2O from a 10X stock 
(Appendix A). The prepared samples and protein ladder (BioRad, Hemel 
Hempstead, Hertfordshire) were loaded into separate wells of the gel. The 
electrophoresis was performed using 30mA per gel until the sample buffer had 
migrated towards the bottom of the gel, taking approximately 35-45 minutes. 
2.7.3.1 Protein transfer 
Once electrophoresis was complete, the gel was placed into transfer buffer 
(Appendix A), along with a nitrocellulose membrane (BioRad, Hemel Hempstead, 
Hertfordshire) and two sheets of extra thick blot paper (BioRad, Hemel Hempstead, 
Hertfordshire), which was left for 15 minutes to equilibrate. Proteins were 
transferred using the semi-dry transfer system (BioRad, Hemel Hempstead, 
Hertfordshire). In the transfer stage the sheets, gel and membrane were assembled 
as follows: thick blot paper at the bottom, the nitrocellulose membrane, the gel, and 
thick blot paper on the top. Proteins from the gel were transferred to the 
nitrocellulose membrane at 15V for 35 minutes. 
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2.7.4 Protein detection 
After protein transfer, the nitrocellulose membrane was processed for 
immunoblotting. The membrane had a quick wash in 0.5% (w/v) dried milk powder 
(Oxoid, Basingstoke, Hampshire) in PBS-0.05%Tween-20 (Appendix A), followed 
by incubation in 5% (w/v) milk PBS-T (blocking) on a rocker for either two hours 
at room temperature, or overnight in the cold room. 
2.7.4.1 Antibody probing 
Primary antibodies were diluted in 1ml of 0.5% milk PBS-T (Table 3), and added 
to the membrane (after blocking) in a plastic bag and incubated overnight on a cold 
room rocker. The next day, the membrane was placed on the rocker at room 
temperature and washed for ten minutes, three times, with 0.5% milk PBS-T. 
Secondary antibodies (HRP conjugated) were used and diluted in 10ml of 0.5% 
milk PBS-T, then added to the membrane for one hour on the rocker at room 
temperature. Excess secondary antibodies were removed from the membrane then 
washed with 0.5% milk PBS-T for 30 minutes, with regular changes in the wash 
over ten-minutes on the rocker at room temperature. 
2.7.4.2 Immuno-detection 
The membrane was incubated with a custom-made in the laboratory 
electrochemical luminescence solution (ECL), consisting of ECL reagent A and B, 
for one-minute. Excess solution was removed and the membrane placed into a 
cassette lined with cling-film. In the dark room, Hyperfilm ECL photographic film 
(Amersham, Little Chalfont, Buckinghamshire) was placed side up in prepared 
cling-film for an appropriate exposure time and developed in a Xenograph. 
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2.7.4.3 Re-probing 
Membranes were stripped and re-probed to examine levels of an additional protein, 
β-actin, most commonly used as a loading control. To strip, 10X re-blot solution 
(Chemicon, Watford, Hertfordshire) was diluted in ddH2O and added to the 
membranes for 10-15 minutes on a rocker. Following this, the solution was 
removed then membrane washed by adding 0.5% milk PBS-T three times for five-
minutes. Finally, primary antibodies were added and then the protocol followed as 
per the first probing. 
 
2.7.5 Fluorescence Western Blot - Odyssey 
This method depends on fluorescent detection using secondary antibodies labelled 
with infrared fluorescent dyes instead of enzymes, and on multiplex detection of 
multiple protein targets without stripping and re-probing. The protocol for this 
technique is similar to the Western blot that has been previously described, with 
several differences at particular stages.  
After transfer, the membrane was processed for immunoblotting and washed in 
PBS-T (T20, 0.05%) (Appendix A), followed by incubation in PBS-T (T20, 0.05%) 
and 5% goat serum (blocking) on the rocker overnight in the cold room. Primary 
antibodies were diluted in 1ml of 0.5% PBS-T and 2% goat serum, and added to 
the membrane and incubated for one hour at room temperature. 
After the primary antibodies were incubated, the membrane was washed three times 
for five minutes with 0.5% PBS-T. Secondary antibodies (IRDye 800 or IRDye 
680) were used and diluted in 10ml of 0.1% SDS, 2% goat serum and 0.05% PBS-
T, then added to the membrane for one-hour on the rocker at room temperature. 
The membrane washed with 0.05% PBS-T for five minutes, where a final wash 
with PBS alone. Finally, digital imaging was obtained by using an Odyssey 
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scanner, with the membrane placed face-down and on the bottom left-hand side of 
the grid. The scanner revealed target protein signals with high sensitivity.   
 
2.8 Microscopy 
2.8.1 Widefield fluorescence 
Fixed cells were imaged on a widefield upright Zeiss Axiovert 200M microscope 
using a monochrome CCD camera (immunofluorescence) to capture the images. 
The fluorescence of immunolabelled cells was detected using a 100W mercury 
lamp and dichroic mirror filter set. Axiovision software (Zeiss) was used to create 
multi-channel images, with Photoshop CS2/7.0 (Adobe) used for further image 
improvement. 
 
2.8.2 Live imaging of migrating cells 
A Zeiss Axiovert inverted microscope was used for performing live time-lapse 
imaging, with samples maintained in a sealed chamber containing 5% CO2 at 37°C 
on a heated stage. Axiovision (Zeiss) software was used to set up time-course 
experiments and images were captured using a monochrome CCD camera. 
For migration experiments cells were seeded in multiwell plates (24 well), with 
different conditions of treatment and phase images captured every ten-minutes over 
the experimental time-period of 16 hours from different positions. The objective 
used was x10. For each condition, an individual cell position was tracked at each 
time-point in Image J, which was also used to combine tracking traces representing 
all paths tracked for each condition analysed. The average velocity was also 
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calculated for each cell. Graph and data analysis preparation was completed in 
Prism GraphPad software. 
 
2.8.3 Live imaging of CLIP-170 dynamics 
For live imaging of microtubule dynamics (GFP-CLIP-170 expressing), ARPE-19 
and PANC-1 cells treated with different conditions were grown in glass-bottomed 
3cm dishes (MatTek, Ashland, Massachusetts, USA), using a x63 objective lens, a 
100W mercury lamp and dichroic mirror filter sets for fluorescence. DMEM/F12 
medium without phenol red (Invitrogen, Paisley, Scotland) was used to image cells. 
Cell images were captured at set exposure levels every three-seconds over a three-
minute period, with different areas imaged for each condition. A high-powered 
LED light was used to excite the GFP, with the ability to switch on and off with no 
need to open and close the light shutter. 
 
2.8.4 Confocal microscopy and FRAP of focal adhesion 
Immunolabelled cells were imaged using an inverted Zeiss LSM510 META 
scanning confocal microscope. An appropriate laser was required to excite the 
samples: Enterprise UV (364nm) for DAPI, Argon (488nm) for Alexa 488 
fluorophores, Helium/Neon (HeNe1, 543nm) for Alexa 568 fluorophores, and 
HeNe2 (633nm) for Alexa 647/Cy5 fluorophores. The Argon laser (488) was 
utilised at 4% intensity for image acquisitions, where focal adhesion was selected 
and photobleached at 30-40 iterations at 100% intensity. 
Analysis of focal adhesion recovery was performed by fluorescence recovery after 
photobleaching (FRAP). This method relies on powerful and focused light to 
bleach florescence in selected areas of a living cell. Following observation and 
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analysis of the fluorescence time needed to return to the first state. In our 
experiment, GFP-paxillin-expressing ARPE-19 and PANC-1 cells treated with 
different conditions were grown in glass-bottomed 3cm dishes (MatTek, Ashland, 
Massachusetts, USA), using a x63 objective lens, a powerful and focused 
fluorescence light (for bleaching) and a100W mercury lamp and dichroic mirror 
filter sets for fluorescence. DMEM/F12 medium without phenol red (Invitrogen, 
Paisley, Scotland) was used to image the cells. Focal adhesion images were 
captured at set exposure levels, every three-seconds over three-minutes period in 
selected regions. A high-powered LED light was used to excite the GFP. 
 
2.9 Random cell migration 
Cells were seeded sparsely in six-well plates, at 10,000 cells per well, for different 
treatment conditions. Each condition was imaged by live time-lapse microscopy, 
where each condition was set for several regions. Images were acquired every ten-
minutes over a 16-hour period. 
ImageJ software was used to track the position of individual cells across several 
regions at each time-point. Moreover, it was used to prepare combined tracking 
traces representing all paths tracked for each condition analysed, and to calculate 
the average velocity for individual cells. Finally, Prism (Graphpad) software was 
used to analyse the data and present graphs. 
 
2.10 Cold treatment 
Cells were treated with cold medium after seeding and addition of SFN for 48 
hours. They were incubated on ice for 15 minutes, 30 minutes and one-hour. Cells 
were fixed by removing medium and adding methanol at -20°C for five-minutes, 
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followed by three quick washes in 1% goat serum in PBS. Cells underwent the 
immunolabelling procedure as described previously with primary antibody α-
tubulin. 
 
2.11 Analysis of microtubule acetylation 
To analyse the degree of microtubule acetylation in this project, cells were treated 
and fixed. The microtubules were visualised with rabbit anti-α-tubulin primary 
(1:100, Abcam) and secondary goat anti-rabbit, Alexa 647 (1:1000, Invitrogen 
Molecular, Paisley, Scotland). Acetylated microtubules were visualised with 
mouse anti-α-acetylated tubulin primary antibody (1:100, Sigma) and a secondary 
goat anti-mouse, Alexa 488 (1:1000, Invitrogen Molecular, Paisley, Scotland). The 
extent of microtubule acetylation in the absence and presence of SFN treatment 
was analysed with ImageJ software. Specifically, the fluorescence intensity of 
acetylated microtubules (green channel) in at least ten interphase cells (PANC-1 
and ARPE-19) per condition was analysed. To obtain the percentage of acetylated 
microtubules area the total area of acetylated tubulin was dividing by the total areas 
of tubulin. Mitotic cells were not analysed because they were too small and round, 
with the stain concentrated in a small area. 
ImageJ software was used to analyse the area of acetylated tubulin. Firstly, images 
were exported in two different channels and saved, one for α-tubulin and the other 
for acetylated tubulin with grey scale (not merged image). During this stage ten 
cells were used for analysis. Channel properties were changed with length unit 
micron and pixel width and height to 0.102 micron when a x63 obj lens was used. 
To prepare for analysis the image background was subtracted and pixels in radius 
unit adjusted until a satisfactory image was obtained; approximately 80% met the 
defined criteria. Data were saved to an Excel file, where the total area of acetylated 
tubulin and α-tubulin was illustrated. Finally, to determine the area of acetylated 
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tubulin as a proportion of the total tubulin, the total area of acetylated tubulin was 
divided by the total area of tubulin and multiplied by 100 to get a percentage value. 
 
2.12 Analysis of area and shape of EB1 and lattice 
intensity 
The EB1 comet shape was analysed by measuring the circularity of EB1 at the 
microtubules plus-end. Macron for comet analysis was applied in ImageJ. 
Axiovision images (14-bit; i.e., intensity values range from 0 to 16,383) were 
opened and analysed with ImageJ (Rasband, 1997). Background subtraction 
(Castle and Keller, 2007) was carried out using a rolling-ball of radius 10 pixels 
and the images thresholded using the algorithm of Otsu (Otsu, 1979). After 
background subtraction and thresholding, the intensity (arbitrary Fluorescence 
Units) and circularity of objects was measured. Objects smaller than 0.12 μm2 (i.e., 
<12 pixels2) and larger than 3 μm2 (i.e., >300 pixels2) were ignored. This comet 
analysis code was written by Paul Thomas (Henry Wellcome Laboratory for Cell 
Imaging, UEA). 
For intensity analysis of EB1 along the microtubule lattice, average fluorescence 
intensity along 2 µm segments at randomly selected regions along the lattice 
located away from the plus-end (using tubulin channel) was measured from set 
exposure images (from the same experiment) using ImageJ software, where code 
was written Paul Thomas (Henry Wellcome Laboratory for Cell Imaging, UEA). 
Statistical significance was determined using a two-tailed unpaired t-test or one-
way ANOVA was performed using Tukey’s multiple comparison post-hoc test.  
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2.13 Analysis of CLIP-170 comet dynamics 
To assess the effect of SFN treatment on microtubule dynamics, GFP-CLIP-170 
comets were analysed in DMSO and SFN treated cells. Cells were grown in glass-
bottomed dishes and incubated overnight. Cells were then treated with 10 and 15 
µM SFN and incubated for 48 hours. Thirty-hours after adding the SFN, the cells 
were transiently transfected with 2µg GFP-CLIP-170 construct for four-hours, 
where it was delivered using jetPRIME (plasmid kit) (Polyplus) (Akhmanova et al., 
2005), then washed with fresh medium and incubated for a total of 48 hours. For 
each concentration, cells demonstrating GFP-CLIP-170 in microtubules were 
imaged using live time-lapse fluorescence microscopy for three-minutes, and 
frames taken every three-seconds, yielding 60 frames in total. The live time-lapse 
recordings were analysed using the automated tracking software U-Track, 
originally packaged as PLUSTIPTRACKER (Applegate et al., 2011). This enabled GFP-
CLIP-170 comet paths to be obtained. MATLAB was used to conduct all post-
tracking analysis and the microtubule plus-tip tracking package code was written 
in this program. A series of TIFF files, one for each frame of the recordings were 
used for the plus-tip tracking to analyse dynamics of the microtubules as described 
by Applegate et al. (Applegate et al., 2011). Importantly, it must be noted that stable 
microtubules cannot be identified via this method and GFP-CLIP-170 may cause 
an increase in microtubule rescue. 
 
2.14 FRAP analysis 
Cells were transfected with GFP-paxillin, incubated for four hours, given fresh 
medium and then incubated for a total of 48 hours. To measure the adhesion 
dynamics in live cells, after the cells expressing GFP-paxillin, individual focal 
adhesions were subjected to FRAP (fluorescence recovery after photo-bleaching). 
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Confocal microscopy was used for the live imaging of GFP-paxillin-expressing 
cells. FRAP data obtain using the Zeiss LSM 510 META confocal. Images of focal 
adhesion were collected prior to photobleaching as a measure of the original 
intensity. The Argon/Ion LASER (488) was utilised at 4% intensity for image 
acquisitions. The focal adhesion in GFP-paxillin transfected ARPE-19 and PANC-
1 cells was selected using the LSM imaging software and photobleached utilising 
the Argo/Iron laser at 30-40 iterations at 100% intensity. Focal adhesion images 
were recorded post-bleaching over recovery. GFP-paxillin recovery was 
determined by measuring the signal intensity of the photobleached over three-
minute period (Sprague et al., 2004). 
 
2.15 Statistical analysis 
Illustration and preparation of graphs and statistical analysis was performed in 
GraphPad Prism software. For experiments with multiple groups, one-way 
ANOVA was performed using Tukey’s multiple comparison post-hoc test to assess 
the significance of any differences between two separate groups within the data set. 
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3.1 Overview 
This chapter characterises the model cell lines utilised in this project. The results 
illustrate the characteristics of the cell models focussing on the four following 
aspects: microtubule organisation and tubulin modification, actin organisation, 
end-binding (EB) protein expression and localisation and microtubule-associated 
deacetylase 6 (HDAC6) expression and localisation. 
 
3.2 Introduction 
The main aim of this project is to investigate whether sulforaphane (SFN) treatment 
could inhibit cell migration, especially in pancreatic cancer cells. To achieve this 
target, it is essential to characterise the cell line models, with both normal epithelial 
cells and pancreatic cancer cell lines being required for this investigation. Normal 
epithelial cells are required for comparison with the cancerous cells when studying 
the effect of SFN. 
A human retinal pigmented epithelial cell line (ARPE-19) was used as the normal 
epithelial model. Unfortunately, we were unable to obtain a normal pancreatic cell 
line for these studies. However, ARPE-19 cells are widely used as a model for 
undifferentiated epithelial cells. An important feature in this cell line is the 
organisation of the microtubules, which show a classic radial array with the minus 
ends anchored at the centrosome and the plus-ends elongating toward the cell 
periphery. EB proteins, such as EB1, associate at the plus-ends of microtubules and 
appear as comet-like shapes (Bellett et al., 2009). In addition, ARPE-19 cells are 
relatively flat, which is ideal for microscopy and analysis of the effects of SFN.  
Pancreatic cancer is an aggressive malignancy and it is one of the most difficult 
types of cancers to treat, as it exhibits resistance to existing treatments. It can also 
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attack other unaffected parts of the body (Bardeesy and DePinho, 2002, Wang et 
al., 2011). There are many different types of pancreatic cancers, but the most 
common is pancreatic ductal adenocarcinoma, and the PANC-1 cell line represents 
this type of cancer. Gene mutations in PANC-1 cells include p53, which is linked 
to metastatic activity (Bardeesy and DePinho, 2002, Hezel et al., 2006). In general, 
the PANC-1 cell line represents undifferentiated epithelial cells that mainly migrate 
as single cells, which is an interesting feature for studying migration. Cell adhesion 
is mediumted by contact with the extracellular matrix, and collagen type I is known 
to stimulate migration. Importantly, the EB2 gene (MAPRE2) is highly 
overexpressed in PANC-1, and it has been suggested to promote cell migration 
(Abiatari et al., 2009). EB2 associates along the microtubule lattice and influences 
microtubule dynamics (Goldspink et al., 2013). HDAC6 is another overexpressed 
protein in PANC-1 cells. This deacetylates α-tubulin and regulates microtubule 
dynamics (Huo et al., 2011, Li et al., 2011), and thus, it also promotes cell migration 
(Li et al., 2014). 
The organisation of microtubules is vital for fulfilling their roles in cells. The main 
functions of microtubules are cell division, cell shape maintenance, intercellular 
transport, cell polarity and cell migration. This project focus on the effects of SFN 
on microtubule organisation, modification and dynamics. Many animal cells show 
microtubules arranged in a radial array, where the minus-ends are anchored at the 
centrosome, and the plus-ends are elongate toward the cell edge (Cole and 
Lippincott-Schwartz, 1995, Mogensen, 1999). Disruption in the normal 
microtubule array formation is likely to contribute to a migration phenotype. 
Microtubules undergo post-translational modifications, such as acetylation and 
detyrosination, which affect their properties and may increase stability (Verhey and 
Gaertig, 2007, Garnham and Roll‐Mecak, 2012, Yu et al., 2015). A critical property 
of microtubules is their dynamic instability, which allows the microtubules to 
explore the cytoplasm and make contact with other cellular structures, including 
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the cell cortex (Galjart and Perez, 2003). This dynamics requires a variety of 
associated proteins to control the alternations between phases of growth and 
shrinkage, as well as interactions with tubulin modifications that affect the 
microtubules’ stability (Howard and Hyman, 2009). To fully understand the 
possible effects of any potential disorganisation of microtubules and actin filaments 
or the redistribution of +TIP in SFN treated normal and pancreatic cancer cells, it 
must be first understanding of the characterisation of the cell models to be used in 
this study. 
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3.3 Results 
3.3.1 Characterisation of ARPE-19 and PANC-1 cells 
For initial characterisation, ARPE-19 and PANC-1 cell lines were seeded onto 
glass coverslips and immunolabelled with various antibodies to characterise the cell 
lines in this project. Cells were stained for microtubules, actin filaments, 
centrosomal components, EBs and HDAC6 to analyse subsequently the subsequent 
effect of SFN. 
 
3.3.2 Microtubule organisation and tubulin modifications 
The PANC-1 model cell line to be used is a sub-clone of the parental line obtained 
from ATCC, and it was specifically selected for high EB2 expression. ARPE-19 
and PANC-1 cell lines were seeded on glass coverslips and grown overnight to 
reach about 60% confluence. The cells were fixed for immunolabelling and 
fluorescence microscopy. Live imaging was used to observe the different 
morphologies of ARPE-19 and PANC-1 cells, during migration. Live imaging 
showed that the morphology of ARPE-19 cells were mainly elongated, with thin 
protrusions around the periphery. The PANC-1 cells appeared rounded with some 
elongated protrusions (Figure 3.1). 
ARPE-19 and PANC-1 cells were fixed and immunolabelled for α-tubulin, γ-
tubulin and stained with DAPI for the nucleus. Microscopic images of ARPE-19 
cells revealed a classic radial array of microtubules emanating from a centrosome 
located near the nucleus, with plus-ends elongating out to the cell periphery (Figure 
3.2). Although most the microtubules appeared to focus at the centrosome (marked 
by γ-tubulin), a more disorganised network of microtubules was evident in PANC-
1 cells (Figure 3.3). Some microtubules also appeared to be oriented parallel to the 
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cortex. Interestingly, in some cells, which appeared to display a migratory 
phenotype, distinct bundles of microtubules were directed towards the leading 
edge, while other microtubules appeared to form a criss-cross network (Figure 3.7).  
ARPE-19 and PANC-1 cells were labelled for tubulin modifications, such as 
acetylated tubulin, tyrosinated tubulin and detyrosinated tubulin. This was done to 
determine the extent of these tubulin modifications in the two cell lines. In ARPE-
19 cells, most microtubules were tyrosinated, with some acetylated tubulin evident 
in the central cell area; this formed a bundle, sometimes revealing a curly nature. 
Detyrosinated tubulin was mainly observed around the centrosomal region, with a 
few microtubules extending towards the cortex (Figure 3.4). PANC-1 cells showed 
minimal expression of detyrosinated tubulin. However, most microtubules 
expressed tyrosinated but also a substantial amount of acetylated tubulin in the 
central cell areas and near the cell periphery (Figure 3.5). 
Overall, ARPE-19 cells presented a classic radial array of microtubules, and most 
tubulin is tyrosinated, with little detyrosination and acetylation of tubulin. In 
PANC-1 cells, the microtubule network was more disorganised. Similarly, most of 
the tubulin was tyrosinated tubulin but extensive acetylated microtubules in the 
centre and minimal or no expression of detyrosinated tubulin. 
 
3.3.3 Actin organisation 
Actin is an essential element of the cell cytoskeleton, and it plays an important role 
in cell movement and shape; therefore, actin organisation was investigated in this 
study. An antibody against β-actin was used to investigate the localisation of all 
actin, whereas phalloidin was used to stain only F-actin (actin filaments).  
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The results illustrated that, in ARPE-19 cells, actin filaments formed an actin 
network at the cell periphery, with parallel, thick actin stress fibres in the cell body 
(Figure 3.6). In PANC-1 cells, peripheral bands of actin filaments were evident in 
most cells. Distinct dorsal actin filaments were observed in some cells protruding 
at the front edge (Figure 3.7), while filopodia and microspikes were seen at the very 
front of the leading edge (Figure 3.8).  
 
3.3.4 End-binding protein expression and localisation  
EBs play an important role in the regulation of microtubule dynamics. It is therefore 
critical to understand the complex molecular processes behind their regulation, with 
the aim of investigating their regulation in cancer diseases. The localisation and 
expression of EBs in our cell models were studied, and cells were stained for EBs 
and microtubules. ARPE-19 and PANC-1 were immunolabelled for EB1 and α-
tubulin. In ARPE-19 cells, EB1 was expressed as classic comets at the growing 
microtubule plus-ends, as is typical (Figure 3.9). In PANC-1 cells, EB1 tended to 
have a slightly extended tail associated at the plus-ends of microtubule compared 
to ARPE-19 cells (Figure 3.10).  
Interestingly, the level of EB3 expression varied considerably within both ARPE-
19 and PANC-1 cells populations. In most ARPE-19 cells EB3 expression was low 
and tended to be concentrated around the nucleus. EB3 could also be seen along 
the microtubule lattice and apparently free in the cytoplasm (Figure 3.11). 
However, sporadic high EB3 expression has previously observed in ARPE-19 cells 
(Mogensen lab unpublished observations). Varying levels of EB3 expression were 
also evident in PANC-1 cells (not reported before). Here some cells shared distinct 
plus-end comets throughout the cell while in others a few comets of EB3 were 
evident (Figure 3.12).  
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For localisation of EB2 in ARPE-19 and PANC-1 cells were immunolabelled for 
EB2 and α-tubulin. In ARPE-19 cells EB2 was found to localise mainly along the 
microtubule lattice, with some association at the plus-ends (Figure 3.13). EB2 was 
overexpressed in PANC-1 cells, and it was observed to be punctate in the cytoplasm 
and along the microtubule lattices (Figure 3.14). 
 
3.3.5 HDAC6 localisation and expression 
HDAC6 is a tubulin deacetylase that regulates microtubule dynamics and promotes 
cell motility. It has been reported that overexpression of HDAC6 leads to 
significantly increased cell migration in cancerous cells, such as in breast and 
pancreatic cancer (Li et al., 2014). Due to its important role in microtubule 
acetylation and cell migration, HDAC6 expression and localisation were studied in 
our cell line models using immunolabelling. Unfortunately, the antibody did not 
work in western blotting. So the expression level could not be assessed. 
ARPE-19 and PANC-1 cells were immunolabelled for HDAC6 and microtubules. 
The results illustrated that ARPE-19 cells expressed HDAC6, which was mainly 
localised in the cytoplasm, but with distinct concentrations around the nucleus and 
at the leading edge. Staining for acetylated and tyrosinated tubulin did not show an 
obvious association between HDAC6 and microtubule plus-ends or along the 
lattice (Figure 3.15). PANC-1 cells were also immunolabelled for HDAC6. The 
images showed that HDAC6 was mainly free in the cytoplasm, with some 
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3.4 Discussion 
The microtubule cytoskeleton is important for several cell functions, and the 
precise behaviours and organisation of the microtubules in a cell needs to reflect 
these functions. Microtubules anchored at the centrosome by minus-ends and the 
plus-ends elongated and exploring the cellular space to provide support and 
transport, not least in migration (Cole and Lippincott-Schwartz, 1995, Mogensen 
et al., 1997, Hawkins et al., 2010). Therefore, disruptions in the microtubule 
organisation or post-translational modifications may affect their dynamics and 
stability, as well as their association with +TIPs, and this may lead to loss of 
function. The results of this study showed that the microtubules in ARPE-19 cells 
were organised in a classic radial array, with the minus ends anchored at the 
centrosome and the plus-ends elongating toward the cell periphery. This is an 
expected result that has been shown previously (Bellett et al., 2009). This makes 
the ARPE-19 cell line an ideal model, as changes in microtubule organisation can 
easily be detected following treatment with various compounds, such as SFN.  
PANC-1 cells showed a different microtubule organisation. Here microtubules 
appeared disorganised, although there were still many focussed on the centrosome. 
Interestingly, bundles of microtubules anchoring at the centrosome and extending 
to the leading edge were evident on some cells. This would provide a stable system 
for vesicle transport during migration.  
Generally, in undifferentiated cells, in interphase there are two main populations of 
α-tubulin, a tyrosinated and a small subgroup exhibiting detyrosination (Gundersen 
et al., 1984). Immunolabelling for tyrosination (YL1/2) and detyrosination (Glu-
tubulin) in ARPE-19 and PANC-1 cells showed that most of the microtubules were 
tyrosinated, suggesting more dynamic microtubules. Tyrosinated tubulin has been 
showed to recruit some +TIP proteins that are known to influence microtubule 
dynamics, such as CLIP-19 and p150Glued (Janke and Bulinski, 2011, Garnham and 
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Roll‐Mecak, 2012, Yu et al., 2015). A few detyrosinated microtubules were evident 
at the cell centre and small segments along the microtubules in ARPE-19 cells, 
suggesting more stable microtubules; these have been found to prevent the 
depolymerisation of microtubules with +TIPs, such as MCAK and KIF2A (Peris et 
al., 2009, Janke and Bulinski, 2011, Yu et al., 2015). However, PANC-1 cells 
showed very low expression of detyrosinated tubulin. 
The effect of tubulin acetylation on the dynamics of microtubules is still not fully 
clear. However, acetylated tubulin has been used as marker for stable microtubules, 
and it may affect the microtubule dynamics and increase stability (Palazzo et al., 
2003, Dompierre et al., 2007). Moreover acetylated microtubules provide tracks for 
some motor proteins, including dynein and kinesin-1 (Garnham and Roll‐Mecak, 
2012, Janke and Bulinski, 2012). Immunolabelling for acetylated tubulin was 
carried out, and the images illustrated that acetylation occurred along segments of 
microtubules found in cell body, with some concentrated near the cell centre. These 
localisations were observed in both cell models. 
Actin filaments have a vital role in cell functions, such as cell movement, cell 
division and structural support. The precise organisation of the actin filaments is 
important for performing these functions (Lappalainen, 2016). In ARPE-19 and 
PANC-1 cells, actin filaments were observed around the cell periphery, with some 
stress fibres mainly running parallel to the cell body near the centre. Dorsal actin 
arcs were also observed protruding at the front edge in PANC-1 cells and some 
filopodia and microspikes at the very front edge. 
+TIP proteins regulate microtubule dynamics, and this includes the EB proteins 
(EB1, 2 and 3). EB1 and EB3 have the ability to recognise growing microtubule 
plus-ends, which are associated with GTP-tubulin and interact with most other 
+TIPs (Morrison et al., 1998, Lansbergen and Akhmanova, 2006). This ability is 
important in helping to determine the state of microtubules. EB1 binds to 
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elongating microtubule plus-ends and it binds between microtubule protofilaments 
and promotes growth (Sandblad et al., 2006, des Georges et al., 2008, Maurer et 
al., 2012). Moreover, the length of EB1 comets is an indication of the GTP-tubulin 
growing tip, which promotes further microtubule polymerisation (Duellberg et al., 
2016). A classic EB1 comet-like association at the plus-ends was evident in ARPE-
19 cells, while an apparent slightly longer comet tail was present in PANC-1 cells. 
No EB1 or EB3 microtubule lattice association was observed. Interestingly, 
sporadic EB3 expression was observed in both ARPE-19 and PANC-1 cells. 
Further studies of EB3 were therefore not carried out. 
EB2 had a different localisation from EB1 and EB3, as it is associated along 
microtubule lattices and exhibits only a slight accumulation at the microtubule plus-
ends. This association along the lattice could possibly prevent EB1 association 
along the microtubules and thus maintain microtubule dynamics (Goldspink et al., 
2013). It has been shown that depletion of EB2 inhibits the dynamics leading to 
bundles of microtubules co-aligned with actin filaments with EB1 and ACF7 lattice 
association (Goldspink et al., 2013). However, some EB2 was observed to be free 
in the cytoplasm of PANC-1 cells, although EB2 is overexpressed in this cell line. 
Overexpression of EB2 has also been suggested to result in alternating actin 
filament distribution, as well as the promotion of microtubule dynamics and 
invasion (Abiatari et al., 2009). Dispersion of EB2 in the cytoplasm may be due to 
the phosphorylation of EB2 by Aurora B as observed during mitosis (Iimori et al., 
2016). 
HDAC6 is another protein that is expressed in PANC-1 cells (Li et al., 2014). The 
results observed here were similar to those of other studies. HDAC6 is mainly 
found in the cytoplasm of ARPE-19 and PANC-1 cells, with no obvious association 
with the microtubule lattice or at the plus-ends. Some accumulation at the cell 
periphery was observed in both cell lines. Previous studies have indicated that 
HDAC6 is a microtubule-associated protein, functioning as an α-tubulin 
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deacetylase that regulates microtubule dynamics and influences cell migration 
(Huo et al., 2011). However, it is mainly found in the cell cytoplasm but can interact 
with different +TIP proteins, including CLIP-170 and EB1 (Zilberman et al., 2009, 
Li et al., 2011, Li et al., 2014). Moreover, overexpression of HDAC6 leads to total 
deacetylation of the microtubules, stimulation of actin polymerisation and 
promotion of cell migration in many cancer cells (Huo et al., 2011, Li et al., 2014, 
Ran et al., 2015). 
In summary, the results showed that ARPE-19 cells (used here as a normal 
epithelial cell model) have a classic radial microtubule array, with actin filaments 
found at the cell periphery and some as central stress fibres. In PANC-1 cells some 
microtubules were focussed on the centrosome, but a more disorganised network 
was evident in most cells. Some cells revealed distinct microtubule bundles that 
targeted the leading edge. Relatively narrow lamellipodia were evident, with 
microspikes and filopodia, while stress fibres were distinct. The EBs showed a 
typical plus-end association with microtubules in both cell models. However, 
HDAC6 did not show any noticeable association with microtubule plus-ends or 
along the lattice (Huo et al., 2011), rather, it was mainly found in the cytoplasm, 
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Figure 3.1 ARPE-19 and PANC-1 cell morphology
Frames from live time-lapse imaging of subconfluent ARPE-19 and PANC-1
cells showing different cell morphologies.
ARPE-19 cells appear mainly elongated with thin membrane protrusion
around some migrated cells.
The PANC-1 cells look rounded but with relatively large lamellipodia evident
in some cells (arrow) with some pointed protrusions. Scale bars = 100µm.
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Figure 3.2 Microtubule organisation in ARPE-19 cells
Widefield fluorescent images of cells immuno-labelled for α-tubulin
(green) and stained with DAPI (blue). a) A field illustrating
subconfluent cells with microtubules arranged in radial arrays. b) A
cell highlighting radial organisation with microtubules focused at a
point (centrosome) near the nucleus (arrow) and extending towards
the cell periphery. Scale bars = 10µm.
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Figure 3.3 Microtubule organisation in PANC-1 cells
Widefield fluorescent images of cells immunolabelled for microtubules
(α-tubulin; green/single channel) and γ-tubulin (red/single channel). a
and b) Some of the microtubules are focused at the centrosome with the
plus ends directed towards the cell periphery but some are arranged
parallel to the cortex (arrow). c) High concentration of γ-tubulin is evident
at the centrosome (arrow) which is located close to the nucleus. d)
Western blot showing EB2 expression in high and low PANC1 sub-
clones with the EB2Hi sub-cloned selected as a model cell line for this
study. Scale bars = 10µm.
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Figure 3.4 Tubulin modifications in ARPE-19 cells
a) Cells were immunolabelled for α-tubulin (red, invert) and acetylated
tubulin (green, invert), illustrating a classic microtubule array with some
acetylated tubulin at the centre of the cell and few radiating out to the cell
edge. b) Immuolabelling for tyrosinated tubulin (YL1/2, red) and
detyrosinated tubulin (glu-tubulin, green, invert) showing that most of the
microtubules are tyrosinated with some detyrosinated microtubules
observed at the central area of the cell, and with small segments along
the microtubules. Scale bars = 10µm.
100
Chapter III: Characterisation of Model cell lines
Figure 3.5 Tubulin modifications in PANC-1 cells
a) Cells immunolabelled for acetylated tubulin (red, invert) and α-tubulin
(green, invert). The microtubules appear in disorganised network and
most of the acetylated microtubules are present in the centre of the cell
body and a few close to the cell edges. b) Immuolabelling for
tyrosinated tubulin (red, invert), illustrating that many microtubules are
tyrosinated with very few detyrosinated microtubules (green,











Figure 3.6 Actin organisation in ARPE-19 cells
Cells were immunolabelled for (a) α-tubulin (red) and actin (β-actin;
green, invert) illustrating actin organisation and (b) microtubules (red)
and actin (Phalloidin; green, invert) showing actin filaments. The actin
filament organisation shows a cortical networks and stress fibres in the
centre mainly running parallel to the long axis of the cell (enlarged
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Figure 3.7 Actin organisation in PANC-1 cells
Widefield fluorescent images of cells immunolabelled for α-tubulin (red,
invert) and actin (β-actin; green, invert) illustrating parallel actin
filaments at the cell edge with dorsal actin filament bundles evident at
the front edge (arrows and enlarged boxed). Scale bars = 10µm.
Figure 3.8 Actin organisation in PANC-1 cells
Cells were immune-labedlled α-tubulin (red, invert) and actin
(Phalloidin; green, invert). The actin filament organisation shows
stress fibres in the cell body (arrow) with filopodia and microspikes at
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Figure 3.9 EB1 localisation in ARPE-19 cells
Widefield fluorescent images of cells labelled for α-tubulin (red) and
EB1 (green, invert). The microtubule network extends forward to the
leading edge and EB1 appear as classic comets at the plus-ends.
Enlarged region boxed, note EB1 comets at the plus-ends of
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Figure 3.10 EB1 localisation in PANC-1 cells
Widefield fluorescent image of cell immunolabelled for EB1 (purple,
invert) and α-tubulin (green) showing the microtubule network
extending from the centrosome towards the leading edge with EB1
comets at the plus ends. Enlarged region boxed, showing EB1 comets
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Figure 3.11 EB3 localisation in ARPE-19 cells
Widefield fluorescent image of cell immunolabelled for α-tubulin (purple)
and EB3 (green, invert) showing EB3 mainly as punctate in the
cytoplasm and concentrate around the nucleus (arrow), but also at plus-
end and with some associated along microtubule lattice. Enlarged region
boxed showing EB3 along the microtubule lattice and at the plus-ends
(arrows). Scale bar = 10µm.
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Figure 3.12 EB3 localisation in PANC-1 cells
Cells were immunolabelled for EB3 (green, invert) and microtubules
(purple), a) showing EB3 expression is different with some cells appeared
highly expressed (arrow) and others with low expression of EB3. b) Cells
show microtubules and EB3 with low expression. EB3 localises mainly at
the plus-ends of microtubules (enlarged boxed, arrow). Scale bar = 10µm.
Figure 3.13 EB2 localisation in ARPE-19 cells
Cells were immunolabelled for EB2 (green, invert) and α-tubulin (purple).
EB2 is clearly visible along the microtubule lattice as well as some at
plus-ends (arrows). Scale bars = 10µm.
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Figure 3.14 EB2 localisation in PANC-1 cells
Widefield fluorescent image of cell immunolabelled for EB2 (green,
invert) and α-tubulin (purple). EB2 is mainly punctate in the cytoplasm
(arrow) but can also be seen along the microtubule lattice. Enlarged
region boxed showing EB2 along the microtubule lattice and the
cytoplasm (arrows). Scale bar = 10µm.
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Figure 3.15 HDAC6 localisation in ARPE-19 cells
Widefield fluorescent images of cells immunolabelled for: (a)
tyrosinated tubulin (YL1/2, green) and HDAC6 (red, invert). b)
Acetylated tubulin (green) and HDAC6 (red, invert). It can be seen that
HDAC6 is mainly in the cytoplasm and concentrated around the
nucleus, but also accumulating in some areas at the periphery
(arrows).Scale bar = 10µm.
Figure 3.16 HDAC6 localisation in PANC-1 cells
Cells were immunolabelled for: (a) tyrosinated tubulin (YL1/2, green)
and HDAC6 (red, invert). b) Acetylated tubulin (green) and HDAC6 (red,
invert). HDAC6 is mainly in the cytoplasm, but with some accumulated
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4.1 Overview 
This chapter presents the study of the effect of sulforaphane (SFN) on cell 
migration in pancreatic cancer and normal epithelial cells. The main questions of 
this study are: Does sulforaphane have an effect on cell migration velocity in 
normal epithelial and pancreatic cancer cells, and does it influence microtubule and 
actin organisation? The study also investigates whether SFN affects EB and 
HDAC6 localisation and expression. In addition, does inhibition of HDAC6 by 
tubacin, or a combination with SFN and tubacin, affect cell motility and 
microtubule organisation and EBs localisation? 
 
4.2 Introduction 
Cell migration and invasion of tumour cells through tissues to distant sites is a key 
mechanism in the cancer disease process, known to be responsible for the majority 
of cancer deaths (Chambers et al., 2002). Pancreatic cancer is one of the most 
aggressive epithelial cancers. It is the fifth leading cause of death in the United 
Kingdom, where only 5% patients are expected to survive for only five years after 
diagnosis. Pancreatic cancer is strongly resistant to current cancer treatment 
(Bardeesy and DePinho, 2002, Wang et al., 2011). 
The cytoskeleton plays an essential role in cell movement by rearranging and 
producing force in order to initiate this movement. A critical property of 
microtubules is their dynamic instability; the central mechanism of anticancer 
treatments is to suppress this instability. It has been reported that SFN suppresses 
microtubule dynamics in human breast cancer (Azarenko et al., 2008); moreover, 
excessive microtubule stabilisation has been shown to impede disassembly of focal 
adhesions which then affect cell migration (Li et al., 2011).  
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SFN has cancer chemopreventive and therapeutic potential through several 
possible mechanisms. Accordingly, SFN has been shown to have preventive and 
therapeutic effects on different cancer types both in vitro and in vivo. SFN has been 
reported to affect microtubule polymerisation, inhibit cell proliferation and initiate 
apoptosis in cancerous cells (Gamet-Payrastre et al., 2000, Jackson and Singletary, 
2004). Therefore, SFN may be capable of retarding or eliminating neoplastic cells 
and inhibiting the progression of tumours into metastasis. It has been reported that 
SFN reduces cell migration in ovarian cancer cells, but only with cytotoxic 
concentration (Bryant et al., 2010). 
Overexpression of HDAC6, which is evident in a number of cancers, completely 
deacetylates microtubules (Aldana-Masangkay and Sakamoto, 2010, Li et al., 
2014). HDAC6 promotes and regulates cell motility with overexpression of 
HDAC6 showing enhancement of cell motility, while inhibition impairs cell 
movement. It has been reported that SFN affects HDAC6 by inhibiting its activity 
(Pledgie-Tracy et al., 2007). Treating human prostate cancer cells with SFN has 
been shown to increase tubulin acetylation and inhibit HDAC6 (Myzak et al., 
2006). Tubacin (HDAC6-specific activity inhibitor) increases tubulin acetylation 
and affects microtubule dynamics (Li et al., 2014). 
EB proteins have an important role in regulating microtubule dynamics; these 
proteins interact with various internal cell structures, such as the cortex, organelles 
and kinetochores, as well as the actin cytoskeleton (Vaughan, 2005, Lansbergen 
and Akhmanova, 2006). EBs can also associate with the microtubule lattice as a 
result of overexpression and could affect its dynamics (Bu and Su, 2001). 
Further studies are required to understand the effect of SFN, in particular its effect 
on microtubule and actin filament organisation and associated proteins, such as EBs 
and HDAC6, and whether such interactions can influence cell migration.  
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4.3 Results 
4.3.1 SFN concentrations greater than 30 µM dramatically 
decrease cell viability in AREP-19 and PANC-1 cells  
The effect of SFN treatment on cell viability was evaluated using an MTT assay. 
This assay is based on the cleavage of the yellow dye MTT to purple formazan 
crystals. This occurs only in living cells, due to dehydrogenase activity in 
mitochondria. Viability was determined by using the MTT assay on SFN-treated 
ARPE-19 and PANC-1 cells with different levels of SFN for 48 hours. Cells were 
seeded in a 96-well plate in triplicate for each condition and left overnight to reach 
confluency. Cells were treated with different levels of SFN 2, 10, 15, 20, 30 and 
40 µM or DMSO, or were left untreated and incubated for 48 hours (Gamet-
Payrastre et al., 2000, Myzak et al., 2006, Jackson et al., 2007, Pledgie-Tracy et al., 
2007, Azarenko et al., 2008, Gibbs et al., 2009, Clarke et al., 2011). Following this, 
the MTT assay protocol was started with the addition of 10 µl of MTT reagent to 
each well, followed by incubation for 4 hours. Crystal dissolving solution (100 µl) 
was added to each well; the cellular homogenate was then measured by recording 
absorbance at 570 nm in a microtiterplate reader, in order to evaluate drug 
cytotoxicity (as described in Chapter II, section 2.3). As shown in Figure 4.1, 30 
µM and 40 µM SFN showed significantly decreased cell viability in ARPE-19 and 
PANC-1 cells after a 48-hour incubation. It can also be observed from the results 
that SFN treatment ranging from 2 to 20 µM had no significant effect on cell 
viability in either cell line, although there was a noticeable decrease in cell number 
and morphology with 20 µM SFN. DMSO at 0.01% concentration was used as a 
vehicle control (the same concentration in which SFN was dissolved) and showed 
no effect on cell viability. 
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These results indicate that treatment with SFN at 30 µM or more significantly 
inhibits cell viability in PANC-1 and ARPE-19 cells. Based on these results, SFN 
at concentrations of up to 15 µM was used for the experiments in this project to 
further investigate cell migration. 
4.3.2 SFN treatment causes distinct morphological changes 
ARPE-19 and PANC-1 cells were seeded to reach subconfluency and grown 
overnight. The following day, they were treated with different concentrations of 
SFN (2, 10 and 15 µM) for 48 hours. Samples were fixed for fluorescent imaging 
while others were used for live time-lapse imaging. Live images of SFN treated 
cells showed a change in morphology, with treated cells appearing larger in area 
compared to DMSO control cells. Furthermore, a decrease was observed in the 
number of cells, along with an accumulation of cells floating in the culture medium, 
with 30 and 40 µM SFN in both cell lines (data not shown). Frames from the Live-
time-lapse imaging were used to analyse cell area. This involved drawing an outline 
of the cell using ImageJ. Statistical analysis was carried out using one-way analysis 
of variance (ANOVA) with Tukey’s multiple comparison test. The drawback of 
this method is that the way of measuring cell area relay on the quality of the images, 
and also on the accurate observation to determine the cell edge. 
In ARPE-19 cells, the data revealed a significant increase in the average area of 
cells treated with 10 and 15 µM, compared to DMSO cells. Untreated and DMSO 
cells exhibited average cell area of 3395 µm2 and 3422 µm2, respectively, compared 
to 4387 µm2 in 10 µM SFN and 5284 µm2 in 15 µM SFN (Figure 4.2, a). Similarly, 
10 µM and 15 µM SFN treated PANC-1 cells revealed a dramatic increase in cell 
area with 4930 µm2 for 10 µM and 6365 µm2 in 15 µM SFN compared to 3540 
µm2 in DMSO treated cells. These changes in cell area following SFN treatment 
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suggest that SFN has an effect on cell adhesion and possibly also cell proliferation, 
causing cell flattening and increased area. 
4.3.3 SFN treatment causes a decrease in the migration 
speed of ARPE-19 cells  
The effect of SFN on random cell migration was analysed in ARPE-19 and PANC-
1 cells using 2, 10 and 15 µM SNF as well as untreated cells and DMSO for 48 
hours. Cells were seeded in a 24-well plate (four wells per condition) for time-lapse 
imaging. The 24-well plates were coated with collagen I or fibronectin with a 
concentration 1 mg/ml before seeding PANC-1 or ARPE-19 cells. It has been 
suggested that collagen 1 is the ECM component suitable for PANC-1 cells (Wang 
et al., 2011), whereas fibronectin was examined in our lab and proved better for 
migration studies  in  ARPE-19. In ARPE-19 cells, images of representative regions 
for DMSO, 2 µM, 10 µM and SFN 15 µM SFN treated cells at t=0 illustrated the 
initial seeding densities for each condition (Figure 4.3 ai, bi, ci, and di). Similarly, 
DMSO, 2 µM, 10 µM and 15 µM SFN treated PANC-1 cells images showed 
representative regions at the initial seeding densities (t=0) (Figure 4.4 ai, bi, ci, and 
di). Separate areas for each condition were imaged live with frames taken every 10 
minutes for a 16-hour period, beginning at the 32-hour SFN treatment. 
For analysis, eight separate positions were examined for each condition with five 
cells from each area and total of 40 cells per condition being analysed. imageJ 
software was utilised to analyse cell movement by using the manual tracking 
module. To allow for the calculation of speed, the position of each analysed cell 
was recorded for each frame in the time course. Where a cell underwent mitosis, 
only one of the resultant daughter cells was followed for the rest of the time-lapse. 
Data for each cell position was combined in the imageJ to produce a line-tracking 
trace, showing the paths taken by every cell analysed. Examples of tracking images 
were illustrated for ARPE-19 cells treated with DMSO (Figure 4.3 aii, Movie S2), 
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2 SFN µM (Figure 4.3 bii, Movie S3), 10 µM SFN (Figure 4.3 cii, Movie S4) and 
15 µM SFN (Figure 4.3 dii, Movie S5). Similarly, examples of tracking images 
were illustrated for PANC-1 cells treated with DMSO (Figure 4.4 aii, Movie S7), 
2 SFN µM (Figure 4.4 bii, Movie S8), 10 µM SFN (Figure 4.4 cii, Movie S9) and 
15 µM SFN (Figure 4.4 dii, Movie S10). The dots represent the position of a cell 
at a particular point in time, whereas the lines represent the path it took over 
previous frames. These combined tracking traces demonstrate the degree of a cell’s 
movement from its original position, and show the direction of the cell movement, 
as coloured lines that represent migrating cell track. 
It was possible to use the position results of cell tracking traces to calculate the total 
distance covered by an individual cell over the time course (16 hours), as well as 
an individual cell’s average velocity. The average velocity result for each analysed 
cell was calculated and presented in a graph to illustrate an overall average velocity 
for each condition. Statistical analysis was performed by using a one-way ANOVA 
with Tukey’s multiple comparison test. This analysis revealed that SFN treatment 
has a significant effect on average speed in ARPE-19 cells treated with SFN 10 and 
15 µM compared to DMSO control cells (Figure 4.5, a). The average velocity of 
ARPE-19 cells for each condition showed that untreated cells moved at an average 
velocity of 0.6328 µm/min and DMSO treated cells with 0.5974 µm/min, while the 
average velocity for 10 and 15 µM SFN treated ARPE-19 cells were 0.4658 
µm/min and 0.2280 µm/min respectively.  
However, SFN treatment showed no significant decrease in PANC-1 average cell 
speed, with 10 and 15 µM SFN treated PANC-1 cells revealing average speeds of 
0.5896 µm/min and 0.5807 µm/min respectively, compared to 0.6052 µm/min in 
DMSO treated cells (Figure 4.6, a). 
Migration software was used to show the destination of individual cells during 
migration, based on the data from cell-tracking traces of migrating cells. Spider 
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graphs for ARPE-19 cells showed greater distance of migration in DMSO and 
2 µM SFN treated cells, compared to treated cells with 10 and 15 µM SFN. At 10 
and 15 µM of SFN, most of the cells were concentrated at the centre; this indicates 
a decrease in distance migrated. Results revealed that DMSO treated cells moved 
around 563 µm and 2 µM SFN treated cells moved around 526, while 10 µM and 
15 µM SFN treated cells moved around 387 µm and 219 µm respectively (Figure 
4.5, b).  
In PANC-1 cells, spider graphs illustrated no significant difference in migrating 
cell distance, with most cells reaching around similar distance. Results showed that 
DMSO treated cells moved around 500 µm, while 2, 10 and 15 µM SFN treated 
PANC-1 cells moved around 524 µm, 598 µm and 591 µm respectively (Figure 
4.5, b).  
 
4.3.4 SFN treatment alters microtubule organisation and 
leads to the formation of distinct bundles 
To investigate the effect of SFN on microtubule organisation, ARPE-19 and 
PANC-1 cells were seeded on coverslips, coated with collagen I, and treated with 
2, 10 and 15 µM SFN and DMSO for 48 hours. Cells were immunolabelled for α-
tubulin. DMSO treated ARPE-19 cells showed a classic radial array of 
microtubules focused in the centre of the cell and the plus-ends spread toward the 
cell periphery with few microtubule bundles, similar to untreated cells (Chapter III, 
figure 3.2). The 2 µM SFN treated cells revealed that microtubules were organised 
in a radial array with few microtubule bundles, and there were no noticeable 
changes in microtubule organisation compared to DMSO treated cells. The 10 and 
15 µM SFN treated ARPE-19 cells showed more microtubule bundles compared to 
DMSO treated cells (Figure 4.7). 
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DMSO treated PANC-1 cells revealed microtubules focused in the centre of the 
cell with a disorganised network elongated towards the cell periphery. This 
organisation is typical in PANC-1 cells and was also observed in untreated cells 
(Chapter III, figure 3.3). The 2 and 10 µM SFN treated PANC-1 cells showed no 
changes in microtubule organisation. However, 15 µM SFN treated cells revealed 
some alterations in microtubule organisation with some cells containing straight 
and bundled microtubules, compared to DMSO treated cells (Figure 4.8).  
 
4.3.5 Actin filaments co-aligned with microtubules in SFN 
treated ARPE-91 cells 
Subconfluent cells were immunolabelled for β-actin or phalloidin to observe any 
changes in the actin filaments relating to the SFN treatment. DMSO treated ARPE-
19 cells revealed actin located at the leading edge of the cell and forming 
lamellipodia with some stress fibres running parallel to long axis of in cell body 
(Figure 4.9, a and 4.10, a).  No obvious changes were observed with 2 µM SFN 
(Figure 4.9, b and 4.10, b). The 10 µM SFN treated ARPE-19 cells revealed actin 
filaments co-aligned with microtubules (Figure 4.9, c,) while phalloidin staining 
showed an increase in stress fibres (Figure 4.10, c). The 15 µM SFN-treated cells 
revealed actin filaments were co-aligned with microtubules with dotted β-actin 
appearance that suggests of breakdown of some actin filaments (Figure 4.9, d). 
Phalloidin staining showed an increased in stress fibres with a decrease of cortical 
actin in 15 µM SFN treated ARPE-19 cells (Figure 4.10, d).   
DMSO treated PANC-1 cells showed β-actin at the periphery with microspikes at 
the front edge. Stress fibres were observed along the cell body with filopodia and 
microspikes at the front of the leading edge (Figure 4.11, and 4.12, a). The 10 µM 
and 15 µM SFN treated PANC-1 cells revealed disorganised actin filaments with a 
Chapter IV: Effects of Sulforaphane on Random Cell Migration. 
121 
   
thin layer of actin at the periphery and some stress fibres in the cell body (Figure 
4.11 and 4.12, c and d). 
4.3.6 EB1 is expressed along the microtubule lattice in SFN 
treated ARPE-19 and PANC-1 cells 
Cells were treated for 48 hours with DMSO or different concentrations of SFN and 
then immunolabelled for microtubules and EB1. DMSO treated ARPE-19 cells 
revealed that EB1 was expressed as classic comets at the microtubule plus-ends 
(Figure 4.13, a). The 2 µM SFN treated ARPE-19 cells showed EB1 comets at the 
plus-ends of microtubules, with no change in its localisation compared to DMSO 
treated cells (Figure 4.13, b). Interestingly, 10 and 15 µM SFN treated ARPE-19 
cells revealed an extensive association between EB1 and microtubules lattice, 
although a distinct accumulation at the plus-end was also evident (Figure 4.13, c, 
d). Western blots were performed to determine the levels of EB1 expression in 
untreated, DMSO- and 2, 10 and 15 µM SFN treated ARPE-19 lysates. No change 
was observed in the levels of EB1 expression in SFN treated cells compared with 
DMSO treated cell (Figure 4.14, a). 
The EB1 comet shape was analysed by measuring the circularity of EB1 
accumulation at the plus-end, using ImageJ software for DMSO and 2 µM SFN 
treated ARPE-19 cells, as well for untreated ARPE-19, as EB1 appeared only at the 
microtubules plus-ends in these conditions. The results indicated there was no 
significant difference in comet circularity among all conditions (Figure 4.14, b). 
Fluorescence intensity analysis was utilised to quantify EB1 lattice association. The 
intensity of EB1 was measured along 2 µm segments at randomly selected regions 
along the lattice located away from the plus-end for cells treated with SFN 10 and 
15 µM or DMSO. Analysis illustrated a significant increase in intensity along the 
microtubule lattice in 10 and 15 µM SFN treated ARPE-19 cells, compared to 
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DMSO treated cells. Significance was assessed by a one-way ANOVA with 
Tukey’s multiple comparison (Figure 4.14, c).  
Similarly, PANC-1 cells were immunolabelled for EB1 and α-tubulin. DMSO and 
2 and 10 µM SFN treated PANC-1 cells revealed that EB1 was localised mainly as 
comets at the plus-ends of microtubules but with some association along the lattice 
around cell centre (Figure 4.15, a and b, and figure 4.16, a). The 15 µM SFN treated 
PANC-1cells revealed a distinct lattice association of EB1 in many microtubules 
(Figure 4.16, b). A western blot was performed to investigate the level of EB1 
expression under these conditions: untreated, DMSO and 2, 10 and 15 µM SFN 
treated PANC-1 cells. Again no marked change was observed in the levels of EB1 
expression in SFN treated cells compared to DMSO treated cells (Figure 4.17, a). 
Furthermore, comet circularity analysis revealed that there was no difference in 
comet circularity between DMSO and 2 or 10 µM SFN treated PANC-1 cells 
(Figure 4.17, b). To analyse EB1 lattice association, fluorescence intensity was 
measured (as previously described) and a significant increase in EB1 intensity 
along the lattice was evident in 15 µM SFN treated PANC-1 cells (Figure 4.17, c). 
EB3 localisation was checked and it was observed that EB3 is sporadically 
expressed in some PANC-1 cells and concentrated around the centrosome and at 
the plus-ends of microtubules or with little expression in other cells (data not 
shown). As expression of EB3 was sporadic, as previously reported for many 
epithelial cell types, EB3 was not investigated any further.   
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4.3.7 EB2 is localised along microtubules and is free in the 
cytoplasm in SFN treated ARPE-19 and PANC-1 cells 
In pancreatic cancer cells, it was shown that EB2 is overexpressed in highly 
invasive cells (Abiatari et al., 2009). ARPE-19 and PANC-1 cells were seeded and 
treated with different concentrations of SFN or DMSO for 48 hours, 
immunolabelled for EB2 and α-tubulin and lysates were taken for western blotting. 
In untreated ARPE-19 and PANC-1 cells, EB2 was localised along the microtubule 
lattice with some at the plus-ends (Chapter III, Figures 3.13 and 3.14). DMSO-
treated ARPE-19 cells showed a typical localisation of EB2 along the lattice with 
some at the plus-ends of microtubules; a similar observation was made in 2 µM 
SFN treated ARPE-19 cells (Figure 4.18, a and b). However, 10 and 15 µM SFN 
treated cells showed more cytoplasmic EB2 with less along the microtubule lattice 
and at the plus-ends (Figure 4.19, a and b). Western blots were performed to 
investigate the level of EB2 expression in 2, 10 and 15 µM SFN treated cells and 
also for untreated and DMSO treated ARPE-19 cells. Results illustrated a slight 
decrease in the upper band in 10 and 15 µM SFN treated cells compared to DMSO 
treated cells, but not compared to the untreated cells (Figure 4.21, a).  
In PANC-1 cells, the DMSO treated cells showed EB2 was localised along the 
microtubules with some free EB2 in cell cytoplasm (Figure 4.20, a). However, 10 
and 15 µM SFN treated cells revealed more cytoplasmic EB2, with some along the 
lattice (Figure 4.20, b & c). Western blot results showed no clear evidence of 
changes in EB2 expression levels in cells treated with 15 µM SFN compared to 
DMSO treated cells. Further investigations are needed to confirm these results 
(Figure 4.21, b). 
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4.3.8 HDAC6 is mainly localised in the cytoplasm in SFN-
treated ARPE-19 and PANC-1 cells 
HDAC6 is mainly localised in the cell cytoplasm. It has been reported to associate 
with microtubule plus-ends and functions as an α-tubulin deacetylase, which plays 
an important role in regulating microtubule dynamics and cell motility (Huo et al., 
2011). Pancreatic cancer cells that overexpress HDAC6 may deacetylate 
microtubules, which promotes cell migration (Li et al., 2014). Importantly, it was 
shown that SFN inhibits HDAC6 activity in human breast cancer cells (Pledgie-
Tracy et al., 2007). Therefore, the effect of SFN on HDAC6 was investigated in 
our study, in order to observe any impact on HDAC6 localisation. ARPE-19 and 
PANC-1 cells were seeded and treated with different concentrations of SFN for 48 
hours. Both cell lines were immunolabelled for HDAC6 and α-tubulin and 
fluorescent images were taken using widefield fluorescence microscopy.  
DMSO and 2 µM SFN treated ARPE-19 cells revealed HDAC6 localised in a 
diffuse puncta throughout the cytoplasm and around the nucleus and cell periphery, 
with some along the microtubule lattice (Figure 4.22, a and b). The 10 and 15 µM 
SFN treated ARPE-19 cells showed little evidence of HDAC6 along the 
microtubule lattice; also it showed diffused puncta in the cytoplasm and around the 
nucleus. The 15 µM SFN treated ARPE-19 cells showed also distinct puncta 
arrangement (Figure 4.23). Interestingly, filament like association is suggested by 
the higher dot-like appearance of HDAC6 in ARPE-19 cells treated with 15 µM 
SFN.   
In PANC-1 cells, HDAC6 was found distributed diffusely with puncta around the 
nucleus and in the cytoplasm, and some lattice association and concentration at 
periphery in DMSO and 2 µM SFN treated cells (Figure 4.24). The 10 and 15 µM 
SFN treated PANC-1 cells revealed no association between HDAC6 and 
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microtubules, and there was also some noticeable accumulation at cell periphery 
(Figure 4.25). 
 
4.3.9 Tubacin treatment has no effect on cell viability in 
ARPE-19 and PANC-1 cells 
Tubacin a small molecule that binds to the deacetylate tubulin domain of HDAC6 
and causes total tubulin acetylation is a specific functional inhibitor of HDAC6 
activity (Haggarty et al., 2003). For example, inhibition of HDAC6 with tubacin in 
human breast cancer cells causes tubulin acetylation and reduces cell movement 
(Saji et al., 2005). SFN had no noticeable effects on ARPE-19 and PANC-1 cells 
(Figure 4.20). A combination of two treatments for cancer prevention and therapy 
has been used in several in vitro and in vivo cell lines. Each agent may have its own 
unique targets, but they also share some common targets. Therefore, SFN used in 
combination with tubacin may provide an advantage over treatment with a single 
agent only, in terms of therapeutic efficacy. 
The effect of tubacin on cell viability was examined using an MTT assay. ARPE-
19 and PANC-1 cell lines were seeded in a 96-well plate in triplicate for each 
condition and incubated overnight (as described in section 4.3.2). Both cell lines 
were treated with 10 µM tubacin for 48 hours; cells were also treated with 
combinations of 10 µM tubacin and 10 µM SFN, and 10 µM tubacin with 15 µM 
SFN, and incubated for 48 hours. The results of the MTT assays showed that there 
were no significant effects on cell viability (Figure 4.26). 
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4.3.10 Inhibition of HDAC6 with tubacin causes cell 
spreading in ARPE-19 and PANC-1 cells 
SFN treatment resulted in increased cell area in ARPE-19 and PANC-1. This was 
statistically confirmed and is illustrated in figure 4.2. Observations on both cell 
lines showed that there were changes in cell morphology relating to the 10 µM 
tubacin treatment as well as the combination of SFN (10 and 15 µM) and 10 µM 
tubacin for 48 hours. 10 µM and 15 µM SFN alone also caused an increase in cell 
area, as previously illustrated (Figure 4.2). Fluorescent images were used to analyse 
the effects of tubacin and the combination of tubacin and SFN on cell area. Analysis 
of the cell area demonstrated that 10 µM tubacin treated ARPE-19 cells showed a 
significant increase in average cell area compared to DMSO treated cells. Similarly, 
cells treated with a combination of 10 µM tubacin and 10 µM SFN showed a 
significant increase in cell area; this was also the case for a combination of 10 µM 
tubacin and 15 µM SFN (Figure 4.27, a). ImageJ software was used to analyse cell 
area for 65 cells per condition. 
The 10 µM tubacin treated PANC-1 cells revealed a significant increase in cell 
area, compared to DMSO treated cells. Moreover, the combinations of 10 µM 
tubacin and 10 µM SFN or 15 µM SFN treated PANC-1 cells revealed a significant 
increase in cell area in both conditions compared to DMSO treated cells, which 
seems to be as a result of tubacin treatment with no further increase with the two 
treatments (Figure 4.27, b). So both separate SFN and tubacin or combined 
treatments resulted in significant increases in cell area. 
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4.3.11 Tubacin induces a marked increase in acetylated 
microtubules in ARPE-19 and PANC-1 cells 
The tubacin inhibitor was used to examine whether inhibition of HDAC6 increases 
the level of tubulin acetylation in the experimental cell lines, ARPE-19 and PANC-
1. Both cell lines were treated with 10 µM tubacin as well as with combinations of 
10 µM tubacin and 10 µM SFN or 10 µM tubacin and 15 µM SFN, and incubated 
for 48 hours. Subsequently, they were stained for acetylated tubulin and α-tubulin 
(total tubulin). In ARPE-91 cells, DMSO treatment showed only that some 
microtubule segments in the central part of the cell were acetylated, whereas 
microtubules at the cell periphery lacked acetylated tubulin (Figure 4.28, a); this 
was also evident in untreated cells (Section 3.3.2, Figure 3.4). In contrast, all 
microtubules in the 10 µM tubacin treated ARPE-19 cells appeared to be acetylated 
(Figure 4.28, b). In 10 µM SFN treated ARPE-19 cells acetylated microtubules 
were concentrated at the central part of the cells except for a few segments near the 
cell periphery. Similarly, 15 µM SFN treated ARPE-19 cells showed acetylated 
microtubules in the central part around the nucleus but with several elongated 
acetylated microtubules reaching the periphery (Figure 4.28, c, d). a combination 
of 10 µM tubacin and 10 µM SFN or 15 µM SFN showed extensive acetylation of 
microtubules throughout the cells (Figure 4.28, e, and f). Western blots of ARPE-
19 cell lysates revealed that 10 µM tubacin and combinations of 10 µM tubacin and 
10 µM SFN or 15 µM SFN caused a marked increase in acetylation. In addition, 
The SFN treatment alone showed a slight increase in acetylated α-tubulin level 
compared to DMSO treatment (Figure 4.30). 
DMSO treated PANC-1 cells showed some acetylated microtubule segments in the 
central part of the cell, with a few acetylated microtubules at the cell periphery 
(Figure 4.29, a); this was also evident in the untreated cells (Figure 3.5). 10 µM 
tubacin treated PANC-1 cells revealed very extensive microtubule acetylation 
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throughout the cells (Figure 4.29, b). 10 µM SFN treated PANC-1 cells showed 
acetylated microtubules in the central part of the cell with some acetylated 
microtubules extending towards the cell periphery. The 15 µM SFN treated cells 
showed acetylated microtubules again concentrated around the central part, but 
with more acetylated microtubules extending towards the periphery (Figure 4.29, 
c, d). Combined treatments of 10 µM tubacin and 10 µM or 15 µM SFN revealed 
extensive acetylated microtubules throughout the cells with some bundle formation 
(Figure 4.29, e, f). Western blots of 10 µM tubacin treated PANC-1 cells showed a 
significant increase in the levels of acetylated tubulin, as well as in combination of 
10 or 15 µM SFN- and 10 µM tubacin treated PANC-1 cells. However, 10 and 
15 µM SFN treated PANC-1 cells  showed no appreciable changes on acetylated 
tubulin levels compared to the DMSO treated cells (Figure 4.30). 
 
4.3.12 A combination of tubacin and SFN causes a 
significant reduction in cell migration speed 
The results of the SFN effect on cell migration demonstrated that 10 and 15 µM 
SFN treatment dramatically reduced the speed of migratory ARPE-19 cells, while 
no significant reduction was observed in PANC-1 cells (Figure 4.6). Since HDAC6 
is highly expressed in pancreatic cancer cells and promotes migration (Li et al., 
2014), a combined effect of HDAC6 inhibitor and SFN treatment may affect 
microtubule dynamics, and as a result, cell migration. Inhibition of HDAC6 activity 
by tubacin was reported to affect cell migration on cancer cells (Tran et al., 2007). 
The effect of a combination of tubacin and SFN on cell migration was therefore 
analysed in ARPE-19 and PANC-1 cells. In the first series of experiments, ARPE-
19 and PANC-1 cells were seeded in a 24-well plate and treated with 10 µM 
tubacin, 10 or 15 µM SFN, and a combination of 10 µM tubacin and 10 µM SFN 
or 15 µM SFN for 48 hours. Cells were imaged at a rate of one frame every 10 
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minutes for 16 hours and 10 cells were analysed from 9 separate positions, to give 
a total of 90 cells for each condition (N=90). Cells were tracked in ImageJ, as 
described before (Section 4.3.3); again, when cells underwent mitosis, just one of 
the daughter cells was tracked to the end of the time-lapse.  
The position data for each cell was utilised to calculate its average speed of cell 
movement. Statistically, a one-way ANOVA with Tukey’s multiple comparison 
test was used to analyse the data. In ARPE-19 cells, it was found that tubacin 
treatment dramatically decreased the cell movement compared to DMSO treated 
cells (Figure 4.31, a, Movie S11). This was also the case for combinations of 10 
and 15 µM SFN and 10 µM tubacin (Figure 4.31, a, Movie S12 and S13). However, 
10 µM tubacin treated PANC-1 cells revealed no marked decrease in cell speed, 
also a combination of 10 µM tubacin and 10 µM SFN showed no reduction in cell 
speed compared to DMSO treated cells (Figure 4.31, b, Movie S14 and S15). 
Importantly, 10 µM tubacin and 15 µM SFN treated PANC-1 cells revealed a 
significant reduction in cell speed compared to DMSO treated cells (Figure 4.31, 
b, Movie S16). 
 
4.3.13 Treatment with tubacin on its own has no effect on 
EB1 localisation and expression in ARPE-19 and PANC-1 
cells 
Our results showed that SFN treatment affects EB1 localisation in ARPE-19 and 
PANC-1 cells. EB1 appeared to associate with the microtubule lattice in 10 and 15 
µM SFN treated ARPE-19 and PANC-1 cells (Figure 4.13 & 4.15). According to 
Zilberman et al. (2009), inhibition of HDAC6 deacetylase activity by tubacin 
affects EB1 appearance at the microtubule ends, with the comet tail appearing 
significantly shorter. We next tested whether tubacin and a combination of SFN 
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and tubacin could affect the localisation of EB1 at microtubule tips. ARPE-19 and 
PANC-1 cells were seeded on coverslips and treated with 10 µM tubacin or a 
combination of 10 µM tubacin and 10 µM SFN or 15 µM SFN for 48 hours. Cells 
were then labelled for EB1 and α-tubulin. 10 µM tubacin treated ARPE-19 cells 
revealed classic comets of EB1 at the plus-ends of the microtubules, similar to 
DMSO-treated cells (Figure 4.32, a and b). A combination of 10 µM tubacin and 
10 µM SFN or 15 µM SFN treated ARPE-19 cells showed extensive association of 
EB1 with the microtubule lattice as also found for 15 µM SFN alone (Figure 4.32 
c and d). Interestingly, there appeared to be a reduction in plus-end comets in 
combined treatments of tubacin and SFN. The western blot of cell lysates revealed 
that 10 µM tubacin treated ARPE-1 cells showed no change in EB1 level compared 
to DMSO treated cells. This was also the case for a combination of 10 µM tubacin 
and 10 µM SFN or 15 µM SFN treated ARPE-19 cells, which showed no effect on 
EB1 expression (Figure 4.33, a). 
EB1 comet circularity was investigated by using ImageJ software. The results 
revealed no significant difference in comet circularity in 10 µM tubacin treated 
ARPE-19 cells compared to DMSO treated cells (Figure 4.33, b). Two-tail unpaired 
t-tests were used to compare the statistical significance of differences between the 
two groups. Fluorescence intensity analysis was utilised to quantify EB1 lattice 
association. This intensity of EB1 was measured along random selected 
microtubules (as described in section 4.3.6). Results revealed a significant increase 
in EB1 association along the microtubules in 10 µM tunacin and 15 µM SFN treated 
ARPE-19 cells, but not with 10 µM tubacin and 10 µM SFN, as compared to 
DMSO treated cells. This was assessed by one-way ANOVA with Tukey’s multiple 
comparison (Figure 4.33, c). 
The 10 µM tubacin treated PANC-1 cells showed that EB1 appeared as comets at 
the plus-ends of microtubules, similar to DMSO treated cells (Figure 4.34, a, b). 
No difference in EB1 comets was observed in 10 µM tubacin and 10 µM SFN 
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treated PANC-1 cells compared to DMSO treated cells, where EB1 was observed 
as comets at the plus-ends (Figure 4.34, c). However, a combination of 10 µM 
tubacin and 15 µM SFN treated PANC-1 cells caused a marked association 
between EB1 and microtubules lattice (Figure 4.34, d), similar to what was 
observed with 15 µM SFN treated PANC-1 cells (Figure 4.16). Western blots 
revealed that 10 µM tubacin treated PANC-1 cells showed no change in EB1 level 
compared to DMSO treated cells; this was the same with the combination of 10 µM 
tubacin and 10 µM SFN or 15 µM SFN treated PANC-1 cells (Figure 4.35, a). 
Analyses of the EB1 comet circularity in 10 µM tubacin and combination of 10 µM 
tubacin and 10 µM SFN treated PANC-1 cells revealed no difference in comet 
shape compared to DMSO treated cells (Figure 4.35, b). The results were assessed 
by one-way ANOVA with Tukey’s multiple comparison. EB1 lattice association 
was analysed by quantifying the fluorescence intensity. A combination of 10 µM 
tubacin and 15 µM SFN treated PANC-1 cells showed a significant increase in EB1 
lattice intensity, compared to DMSO treated cells (Figure 4.25, c). Two-tail 
unpaired t-tests were used to compare the statistical significance of differences 
between the two groups. 
 
4.3.14 Tubacin only treatment has no effect on EB2 
localisation and expression in ARPE-19 and PANC-1 cells 
SFN treatment affected EB2 expression and localisation in ARPE-19 and PANC-1 
cells, with more cytoplasmic EB2 evident in SFN treated cells (Figures 4.19 and 
20). Published data have shown that HDAC6 and EB2 are overexpressed in these 
PANC-1 cells (Abiatari et al., 2009, Li et al., 2014). Experiments were therefore 
performed to assess whether inhibition of HDAC6 by tubacin affects EB2 
expression and localisation on microtubules in ARPE-19 and PANC-1 cells. Both 
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cell lines were seeded and treated with 10 µM tubacin or with a combination of 10 
µM tubacin and 10 µM SFN or 15 µM SFN for 48 hours. Cells were 
immunolabelled for EB2 and α-tubulin and lysates were taken for western blotting. 
10 µM tubacin treated ARPE-19 cells showed EB2 along the microtubule lattice 
and at plus-ends, with some free EB2 in the cytoplasm, similar to DMSO treated 
cells (Figure 36 a and b). The combination of 10 µM tubacin and 10 µM SFN or 15 
µM SFN treated ARPE-19 cells revealed more EB2 in the cytoplasm, with just a 
few along the microtubule lattice (Figure 4.36, c and d).  
The 10 µM tubacin treated PANC-1 cells revealed EB2 along the lattice and at the 
plus-ends of microtubules, with some in the cytoplasm similar to results observed 
in DMSO treated cells (Figure 4.37, a and b). The 10 µM tubacin and 10 µM SFN 
or 15 µM SFN treated PANC-1 cells revealed EB2 localised in the cytoplasm with 
some along the microtubule lattice (Figure 4.37, c and d). Western blots showed no 
changes in the levels of EB2 in all conditions (Figure 4.38). 
 
4.3.15 Tubacin treatment does not lead to co-localisation 
of HDAC6 and microtubules 
It has been reported that inhibition of HDAC6 increases the association between 
microtubules and HDAC6, which enhances microtubule stability. It has been 
suggested that this effect on microtubule dynamics is due to the association 
between microtubules and HDAC6, rather than the increase in acetylation of 
microtubules (Asthana et al., 2013). Experiments were therefore conducted to 
assess whether tubacin could affect HDAC6 association with microtubules in 
ARPE-19 and PANC-1 cells. Cells were seeded on coverslips, then treated with 
10 µM tubacin or with a combination of 10 µM tubacin with 10 µM SFN or 15 µM 
SFN and incubated for 48 hours. Cells were immunolabelled against HDAC6 and 
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α-tubulin. DMSO treated cells revealed HDAC6 free in the cytoplasm and around 
the nucleus, with some along the microtubule lattice (Figure 4.39, a). The 10 µM 
tubacin treated ARPE-19 cells revealed no association between HDAC6 and the 
microtubule lattice, where HDAC6 was arranged in filament-like structure in the 
cytoplasm and around the nucleus (Figure 4.39, b). The combination of 10 µM 
tubacin and 10 µM SFN or 15 µM SFN treated ARPE-19 cells revealed HDAC6 
arranged in filaments-like in the cytoplasm and around the nucleus, with some free 
in the cytoplasm (Figure 4.40, a and c). Again no evidence of co-localisation with 
microtubules. Similar results were observed in the 10 µM and 15 µM SFN treated 
cells (Figure 4.23). 
DMSO treated PANC-1 cells showed HDAC6 diffuse in the cytoplasm and around 
the nucleus with no co-alignment between HDAC6 and microtubules (Figure 4.41, 
a). The 10 µM tubacin treated PANC-1 cells showed no clear association between 
HDAC6 and the microtubules lattice, but HDAC6 was appeared in filaments 
alignment in the cytoplasm and around the cell nucleus (Figure 4.41, b). The 
combinations of 10 µM tubacin and 10 µM SFN or 15 µM SFN treated PANC-1 
cells revealed HDAC6 was mainly arranged in filament-like in the cytoplasm, with 
some concentrated around the nucleus and cell periphery, and there was no co-
alignment between HDAC6 and microtubules lattice (Figure 4.42, a and b). 
The filament-like organisation of HDAC6 observed in tubacin and tubacin and SFN 
treated cells will need further investigation to determing whether HDAC6 is co-
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Table 5: Chapter IV summary. 
Experiments Results 
 MTT assay (Cell 
viability) 
 ≥ 30 µM SFN affects cell viability in ARPE-19 
and PANC-1 cells 
 Morphological 
changes 
 Increase in cell area with 10 and 15 µM SFN both 
cell lines 
 Cell migration (Speed 
and distance)  
 10 and 15 µM SFN cause decrease in migration 
speed in ARPE-19 cells but no effect in PANC-1 
cells. 
 SFN reduced distance in ARPE-19 cells and most 
of treated PANC-1 cells also showed reduced 
distance. 
 SFN and microtubule 
organisation 
 Increased microtubule bundles in ARPE-19 cells 
with 10 and 15 µM SFN. 
 Distinct bundles in PANC-1 cells with 15 µM 
SFN.  
 
 SFN and actin 
ARPE-19:  
 Microtubule and actin co-alignment. 
 Loss of cortical actin with 15 µM SFN. 
PANC-1:  
 Stress fibres in centre increase and dorsal and 





 EB1 lattice association with 10 and 15 µM SFN.  
 No change in comet circularity. 
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SFN and EB1 
 Significant increase in fluorescence intensity along 
lattice. 
PANC-1: 
 Lattice evident in centre of cell in DMSO but also 
in periphery areas with 15 µM SFN. 
 No change in comet circularity. 
 Significant increase in fluorescent intensity along 
lattice with 15 µM SFN. 
 
 
SFN and EB2 
ARPE-19: 
 EB2 lattice association in DMSO and 2 µM SFN. 
 Cytoplasmic with 15 µM SFN. 
PANC-1: 
 Lattice association in DMSO. 




SFN and HDAC6 
ARPE-19: 
 Some along microtubule lattice and in cytoplasm 
in DMSO and 2 µM SFN. 
 Cytoplasmic filament-like with 10 and 15 µM 
SFN. 
PANC-1: 
 Some along microtubule lattice and in cytoplasm 
and at cell membrane in control and 2 µM SFN. 
 Diffuse throughout cytoplasm with 10 and 15 µM 
SFN. 
Tubacin and viability 
 10 µM tubacin (T) and 10 µM T + 10 or 15 µM 
SFN had no significant effect on cell viability. 
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 Tubacin / T+SFN and 
cell area 
 Significant increase in cell area in both cell lines. 
 Tubacin / T + SFN and 
acetylated tubulin 
 Both immunolabelling and Western blots revealed 
marked increase in tubulin acetylation in both cell 






Tubacin / T + SFN and 
cell migration 
ARPE-19: 
 Significant decrease in cell migration speeds for 
all conditions. 
PANC-1: 
 Only significant reduction in migration speed with 
10 µM T + 15 µM SFN. 
 
 
 Tubacin / T + SFN and 
EB1 
 
 No effect on EB1 localisation in both cell lines 
with tubacin alone. 
 T + 10 or 15 µM SFN shows extensive EB1 lattice 
association, confirmed by significant increase in 
fluorescence intensity in ARPE-19 and PANC-1. 
 No change in comet shape. 
Tubacin / T + SFN and 
EB2 
 Tubacin alone has no effect on EB2 localisation, 
but T + SFN T + SFN increases cytoplasmic EB2 
in both cell lines. 
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 Tubacin / T + SFN and 
HDAC6 
 DMSO showed HDAC6 along microtubules and 
in cytoplasm. 
 Tubacin induced cytoplasmic HDAC6 to form 
filament-like structures that did not co-localise 
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4.4 Discussion 
4.4.1 SFN caused an increase in cell area in ARPE-19 and 
PANC-1 cells 
Our data revealed that ARPE-19 and PANC-1 cells treated with 30 µM SFN for 48 
hours dramatically affected cell viability and caused cell death. The 10 and 15 µM 
SFN treated ARPE-19 and PANC-1 cells showed no significant effects on cell 
viability when treated for 48 hours. It is vital to determine the cytotoxic 
concentrations of SFN treatment that affect the viability of the cell lines. It has been 
previously found that the viability of breast cancer cells in vitro has been decreased 
by treating them with 25 µM SFN and incubating them for 48 hours (Jackson et al., 
2007). Additionally, cell viability in human cancer colon cells was reduced by 
treatment with 15 µM SFN, but after incubation for 96 hours (Gamet-Payrastre et 
al., 2000).  
However, SFN treated ARPE-19 and PANC-1 cells showed a significant increase 
in cell area. Fluorescent images were used to analyse cell area and results revealed 
a significant increase in cell area of 10 and 15 µM SFN treated AREP-19 and 
PANC-1 cells. Our results are compatible with other research, where an increase in 
cell area  and decrease in cell migration with inhibition of HDAC6 by tubacin has 
been reported (Tran et al., 2007). These changes in cell area following SFN 
treatment suggest that SFN may have an effect on cell adhesion and possibly also 
cell proliferation, which could lead to affect on cell migration. Cell migration 
requires dynamic microtubules and dynamic focal adhesion (Kaverina et al., 2002), 
so any disturbance in focal adhesions dynamics causes an increase in their area 
which may lead to increase cell area and inhibits cell migration (Lauffenburger and 
Horwitz, 1996, Rodriguez et al., 2003). 
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4.4.2 SFN caused a dramatic decrease in ARPE-19 cell 
migration 
Cell migration was studied for SFN treated ARPE-19 and PANC-1 cells. 
Experiments were performed to examine random cell migration for SFN treated 
ARPE-19 and PANC-1 cells. The 10 µM and 15 µM SFN treated ARPE-19 cells 
revealed a significant reduction in the speed of migrating cells. This is likely due 
to the observed alteration of microtubules, actin organisation and EB1 localisation 
caused by SFN treatment (see section 4.4.3). Moreover, this effect on migration 
speed may result from a change in the balance between dynamic and stable 
microtubules. This is related not only to changes in tubulin acetylation and 
sensitivity to cold treatment but also in changes to EB1 and EB2 microtubule 
localisation. EB1 was extensively associated with the microtubule lattice, with 
more cytoplasmic EB2 in SFN treated ARPE-19 cells. However, the 10 µM and 15 
µM SFN treated PANC-1 cells showed no decrease in the speed of cell migration. 
This unexpected result may be due to EB2 being highly expressed in PANC-1 cells, 
which affects microtubule dynamics and leads to increased cell migration. It has 
been suggested that EB2 enhances microtubule dynamics and induces invasion in 
PANC-1 cells (Abiatari et al., 2009, Goldspink et al., 2013). Moreover, it has been 
reported that HDAC6 is overexpressed in pancreatic cancerous cells, where it leads 
to complete deacetylation of microtubules, regulates the microtubule dynamics and 
influences cell migration (Zhang et al., 2003, Huo et al., 2011, Li et al., 2011, Li et 
al., 2014, Yu et al., 2015). HDAC6 can also associate with end-binding proteins 
such as EB1 and  HDAC6 has been reported to interact with EB1 at the plus-end of 
microtubules to regulate their dynamics and influence cell migration (Li et al., 
2011). All these together suggest that the overexpression of EB2 and HDAC6 in 
PANC-1 cells may prevent SFN from causing a reduction in migration of PANC-1 
cells.   
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4.4.3 SFN altered microtubule and actin organisation and 
resulted in EB1 decorating the microtubule lattice while 
EB2 became cytoplasmic 
SFN treated ARPE-19 and PANC-1 cells revealed a marked increase in the cell 
area. However, only SFN treated ARPE-19 cells showed a decrease in cell 
migration. Our results showed that the microtubules appeared straighter and 
frequently formed bundles in 10 µM and 15 µM SFN treated ARPE-19 cells. 
Bundles of microtubules could also be observed in 15 µM SFN treated PANC-1 
cells. Further work has revealed that actin filaments and microtubules co-aligned 
in SFN treated ARPE-19 cells, where actin filaments co-aligned with microtubule 
bundles. However, this was not the case for SFN treated PANC-1 cells.  
To the best of our knowledge, co-alignment between microtubules and actin 
filaments has not been previously reported as a result in SFN treated cells. Co-
alignment between actin filaments and microtubules was reported in EB2 depleted 
cells where EB1 and ACF7 association along the microtubules lattice enable links 
to actin filaments (Goldspink et al., 2013). Our results suggested a slight reduction 
in EB2 level in SFN treated ARPE-19 cells but not in PANC-1 cells, where it seems 
that there is an increase in EB2 expression with 15µm SFN. Further analysis will 
be needed to confirm these results and possibly using a different loading control as 
SFN may affect actin. In addition, EB2 localisation was affected in SFN treated 
cells. Control ARPE-19 cells showed EB2 localisation in patches along the 
microtubule lattice and at the plus-ends, as previously described (Komarova et al., 
2009). EB2 localisation along the microtubule lattice was affected in ARPE-19 
SFN treated cells, with EB2 found mainly diffuse in the cytoplasm and some along 
the lattice. SFN treated PANC-1 cells seemed to show even more diffuse EB2 in 
the cytoplasm. In a recent publication, it was observed that phosphorylation of  EB2 
can lead to EB2 disassociation from microtubules and release into the cytoplasm 
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(Iimori et al., 2016). This suggests that SFN may induce EB2 phosphorylation and 
this needs to be investigated further. 
EB1 was also relocated from its classic comets at the plus-ends of microtubules to 
associate extensively with the microtubule lattice in SFN treated ARPE-19 and 
PANC-1 cells. This association of EB1 along the microtubule lattice was examined 
by fluorescence intensity analysis and showed a significance association along 
microtubules in 10 µM and 15 µM SFN treated ARPE-19 cells and with 15 µM 
SFN treated PANC-1 cells. However, no change was found in the level of EB1 
expression, as suggested by Western blots results. It has been suggested that EB1 
lattice binding enforces the lateral microtubule protofilament and enhances 
microtubule stability and bundle formation (Sandblad et al., 2006, des Georges et 
al., 2008, Vitre et al., 2008, Zhang et al., 2009). EB1 lattice binding requires this 
stabilisation of microtubules to facilitate its lattice binding; this was observed in 
stable microtubules by Taxol (Jordan et al., 1991, Jordan and Wilson, 2004). 
Increased GTP-tubulin along the microtubule lattice could also facilitate the EB1 
binding lattice; in addition, the reduction of repulsive forces may contribute to this 
association (Dimitrov et al., 2008, Nakata et al., 2011, Buey et al., 2011). Thus, 
EB1 association along the microtubule lattice may increase the stability of 
microtubules, which could lead to reduction in cell migration.  
The results revealed that there is a different response to SFN treatment between 
ARPE-19 and PANC-1 cells. SFN treated ARPE-19 showed a significant decrease 
in cell migration along with marked alternation in microtubules and actin filaments 
organisation. Microtubule bundles co-aligned with actin filaments were observed 
in SFN treated ARPE-19 cells. However, SFN treated PANC-1 cell showed no 
effect on migration or a co-alignment between actin filaments and microtubules; 
however, some microtubules formed bundles in 15 µM SFN treated cells. EB1 was 
extensively associated with microtubules in SFN treated ARPE-19 and PANC-1 
cells. More cytoplasmic EB2 could be observed in SFN treated cells. This suggests 
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that SFN may phosphorylate EB2 and affect its localisation on microtubules (Iimori 
et al., 2016). SFN treated ARPE-19 cells showed a slight reduction in EB2 level, 
but SFN treated PANC-1cells did not show the same reduction in EB2 level. This 
suggests that these differences may occur because PANC-1 cells have highly 
expressed EB2 and HDAC6; this may prevent SFN effects on microtubule 
organisation, and may end with no marked effects on microtubule dynamics and 
stability and thus migration. 
 
4.4.4 SFN treatment caused loss of HDAC6 localisation 
along microtubule lattices in ARPE-19 and PANC-1 cells 
SFN has been shown to inhibit HDACs in a variety of cell types. Our study 
examined whether the localisation of HDAC6 was affected with treatment of SFN 
in ARPE-19 and PANC-1. It has been reported that SFN inhibits global HDAC 
activity in treated breast cancer cells (Pledgie-Tracy et al., 2007). Furthermore, it 
has been shown that inhibition of HDAC6 activity in human breast cancer cells by 
tubastatin A caused a co-localisation between HDAC6 and microtubules (Asthana 
et al., 2013). However, our study revealed loss of HDAC6 association along 
microtubules. Distinct filament-like puncta of HDAC6 were evident with 10 and 
15 µM SFN in ARPE-19 cells. These puncta did not co-localise with microtubules. 
 
4.4.5 Combination treatments of tubacin and SFN 
inhibited PANC-1 cell migration 
A combination of two agents for cancer prevention and therapy has been used in 
various in vitro and in vivo cell lines. Each agent may have its own unique targets, 
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but also share some common targets. Therefore, sulforaphane and tubacin (a 
specific HDAC6 activity inhibitor) were used as a combination treatment in our 
study. This combination may enable suppression of cell migration and improve 
therapeutic efficacy. HDAC6 has been reported to be a microtubule-associated 
protein that deacetylates α-tubulin and regulates microtubule dynamics. It can 
associate with the plus-end of microtubules and form a cap, which facilitates the 
interaction with EB1 and Arp1 (Hubbert et al., 2002, Matsuyama et al., 2002, 
Zhang et al., 2003, Huo et al., 2011, Zilberman et al., 2009). Importantly, HDAC6 
has been reported to be overexpressed in cancerous cells, such as ovarian cancer 
cells, prostate cancer cells and pancreatic cancer cells. Overexpression of HDAC6 
causes complete deacetylation of microtubules and resulted in increased cell 
migration in cancer cells (Hubbert et al., 2002, Yang and Seto, 2008, Huo et al., 
2011, Li et al., 2014). 
We achieved one of our research aims, to decrease the speed of migration in PANC-
1 cells by treating them with a combination of 15 µM SFN and 10 µM tubacin. In 
our experiments, we started by examining whether 10 µM tubacin alone can affect 
the speed of ARPE-19 migration. Data showed that tubacin significantly increased 
cell area and significantly decreased the speed of cell movement in ARPE-19. 
Moreover, 10 µM tubacin caused increased acetylation of microtubules with some 
bundle formation in ARPE-19 cells. This was also shown by Western blotting, with 
a high increase in acetylation tubulin in 10 µM tubacin treated ARPE-19 cells. Our 
results are compatible with other research, where an increase in cell area with 
inhibition of HDAC6 by tubacin has been reported (Tran et al., 2007). Furthermore, 
the total acetylation of microtubules was previously reported as a result of 
inhibition of HDAC6 activity by tubacin with different cells (Haggarty et al., 2003, 
Saji et al., 2005, Tran et al., 2007, Zilberman et al., 2009, Li et al., 2011, Asthana 
et al., 2013), along with a reduction in cell movement (Saji et al., 2005). However, 
while 10 µM tubacin treated PANC-1 cells did not show a marked decrease on cell 
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migration, there was an increase in acetylated microtubules without noticeable 
bundle formation. A combination of 10 µM tubacin and 10 µM SFN or 15µM SFN 
showed a significant decrease in the speed of cell migration in ARPE-19 cells 
(Figure 4.31), as also seen with SFN treatment alone. Importantly, 10 µM tubacin 
and 15 µM SFN treated PANC-1 cells revealed a dramatic reduction in the speed 
of cell migration, with a significant increase in cell area and increase in acetylated 
tubulin along with some bundle formation. It seems that this inhibition in cell 
migration may be due to the effect of SFN on EB1 and EB2 localisation, with EB1 
associating along the microtubule lattice and EB2 appearing to have detached from 
the microtubules. SFN may lead to the phosphorylation of EB2 and this would 
cause loss of association between EB2 and microtubules.  In addition, microtubules 
contribute to the delivery of essential adhesion turnover proteins such as MAP4K4 
and HAX1 which are both interactors of EB2. Therefore, losing EB2 from 
microtubules may affect focal adhesion turnover ending with an increase in cell 
adhesion and thus cell area and consequently inhibiting cell migration. However, 
EB2 is overexpressed in PANC-1 cells so this may prevent SFN effect and some 
EB2 may remain associated with microtubules enabling delivery of MAP4K4 and 
HAX1 to focal adhesions and initiate disassembly. Tubacin inhibits HDAC6 
activity that regulates microtubule dynamics and increases acetylated microtubules. 
A combination of SFN and tubacin is therefore likely to work together 
counteracting the effect of high EB2 and HDAC6 expression leading to suppression 
of cell migration in PANC-1 cells. 
The 10 µM tubacin treated ARPE-19 and PANC-1 cells revealed EB1 as classic 
comets at the plus-end of the microtubules, with no difference in comet area. 
However, it has been reported that inhibition of HDAC6 can affect EB1 association 
with the microtubule plus-ends (Zilberman et al., 2009). A combination of 10 µM 
tubacin and 10 µM SFN or 15 µM SFN treated ARPE-19 cells revealed EB1 
association along the microtubule lattice, and statistical analysis showed a 
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significant association between EB1 and the microtubule lattice. A significant 
association between EB1 and microtubules was observed in SFN alone in ARPE-
19 cells. Meanwhile, a combination of 10 µM tubacin and 15 µM SFN treated 
PANC-1 cells showed an association between EB1 and the microtubule lattice, 
similar to 15 µM SFN treated PANC-1 cells. Thus, it seems that this effect on EB1 
localisation is due to SFN rather than inhibition of HDAC6 activity by tubacin. EB1 
binding along the microtubule lattice has been noticed previously by Goldspink et 
al. (2013) who suggested it is related to an increase in microtubule stability and 
bundling formation. It was also observed in cells depleted of EB2. 
Tubacin alone or a combination of tubacin and SFN-treated ARPE-19 and PANC-
1 cells revealed more free EB2 in the cell cytoplasm with some along the 
microtubule lattice. However, western blots showed no decrease in EB2 level in 
tubacin or the combination of tubacin and SFN treated PANC-1 cells. Loss of EB2 
microtubule association suggests that SFN may phosphorylate EB2 and lead to EB2 
dispersed in the cytoplasm rather than remain localised along the microtubule 
lattices.  This will then enable EB1 to decorate the length of the microtubules, as 
noticed in SFN treated ARPE-19 and PANC-1 cells. It has been reported that 
phosphorylated EB2 reduces its affinity for microtubules and leads to EB2 
detachment from microtubules (Iimori et al., 2016). 
In addition, 10 µM tubacin and a combination of 10 µM tubacin and 10 µM or 15 
µM SFN treated ARPE-19 and PANC-1 cells showed no co-localisation between 
HDAC6 and microtubules, but there was an observation of filament-like 
organisation in tubacin and tubacin and SFN treated cells. The filament-like 
organisation of HDAC6 observed in tubacin and tubacin and SFN treated cells will 
need further investigation to determent whether HDAC6 is co-localising with actin 
of intermediumte filaments. A different observation was made in TAS and 
tubastatin A (HDAC6 inhibitor) treated human breast cancer cells, where HDAC6 
co-aligned with microtubules with suppressed dynamic instability and delayed the 
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depolymerisation of the microtubules (Asthana et al., 2013). Inhibition of HDAC6 
increases the level of acetylated microtubules along with the effect of SFN and 
tubacin on EB2 and EB1 localisation and expression, where it was associated along 
microtubules with more free EB2 in the cytoplasm. This seems due to 
phosphorylation or depletion of EB2 as a result of SFN. All these together may play 
an important role in inhibiting microtubule dynamics or becoming more stable, and 























































































Figure 4.1 SFN ≥ 30µM decreases cell viability in ARPE-19 and PANC-1 
cells
Cell viability was examined with a MTT assay, which is based on the
reduction of yellow tetrazole to purple formazan in living cells. The results
illustrate that 30 and 40µM SFN significantly decreased ARPE-91 and
PANC-1 cell viability. Statistical analysis was compared to DMSO using one-
way ANOVA with Tukey multiple comparison test, [*P<0.01 & **P<0.001].
PANC-1
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Figure 4.2 SFN at 10 and 15µM affects cell size and morphology in ARPE-
19 and PANC-1 cells
Cells were seeded and treated with different concentrations of SFN or DMSO
for 48 h. Selected cells from frames from live imaging recording (a, b), show
morphological changes in treated cells size. Live-images were used to analyse
cell area by using FIJ (Image J) software. c, d) The size of SFN treated cells
significantly increased compared to DMSO. Cell size statistical analysis
determined compared to DMSO, statistical significance assessed by one-way
ANOVA with Tukey’s multiple comparison test, [*P<0.05 & **P<0.001], n=65.
c.
d.







































Figure 4.3 Single cell tracking of ARPE-19 cells
Cells treated with DMSO or different concentrations of SFN (2, 10 and 15 µM)
were seeded into 24 a well plate and imaged by widefield time-lapse microscopy
for 16 h, and frames were taken every 10 minutes. Selective representative fields
of cells at t=0 are shown in ai, bi, ci, di. 10 cells were analysed from each of 20
regions (40 cells total); cells position was tracked at each time point for each cell
to give a trace of position over the time-course and combined to produce the
combined tracking trace illustrated (aii, bii, cii, dii), with the different coloured lines
representing individual cell track. All scale bars =100µm.







































Figure 4.4 Single cell tracking of PANC-1 cells
Cells treated with DMSO or different concentrations of SFN (2, 10 and 15 µM)
were seeded into 24 a well plate and imaged by widefield time-lapse microscopy
for 16 h, and frames were taken every 10 minutes. Selective representative fields
of cells at t=0 are shown in ai, bi, ci, di. 10 cells were analysed from each of 20
regions (40 cells total); cells position was tracked at each time point for each cell
to give a trace of position over the time-course and combined to produce the
combined tracking trace illustrated (aii, bii, cii, dii), with coloured lines
representing individual cell track. All scale bars =100µm.
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Figure 4.5 SFN causes decreased speed and spread of random migration in
ARPE-19 cells
Cells were treated with SFN for 48 h. Cells were seeded sparsely into 24 well plate
and imaged by widefield time lapse microscopy for a 16 h period beginning 32 h post
initial treated, with frames taken every 10 minutes. 40 cells for each treatment were
analysed. The position of each cell was tracked in FIJI (ImageJ) software for each
time-point across the time-course. a) From these data, the average velocity for each
cell across the time was calculated and plotted. Analysis by one-way ANOVA with
Tukey’s multiple comparison test shows a significant decrease in cell velocity with SFN
10 and 15 µM compared to DMSO [P<0.001]. b) Spider graph show the distance of
individual cells during migration and reveal a decrease in spread with both 10 and
15µM SFN. SFN treated cells travel short distance compared to DMSO treated cells.
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Figure 4.6 SFN did not affect the speed and spread of random migration in PANC-1
cells
Cells were treated with SFN for 48 h. Cells were seeded sparsely into 24 well plate and
imaged by widefield time lapse microscopy for a 16 h period beginning 32 h post initial
treated, with frames taken every 10 minutes. 40 cells for each treatment were analysed.
The position of each cell was tracked in FIJI (ImageJ) software for each time-point across
the time-course. a) From these data, the average velocity for each cell across the time-
period was calculated and plotted. Analysis by one-way ANOVA with Tukey’s multiple
comparison test showed no significant decrease in cell velocity with SFN 10 and 15 µM
compared to DMSO [P<0.001]. b) Spider graph show the distance of individual cells
migration and show no marked differences in spread with few cells appear travel more in
15µM SFN. Generally, SFN and DMSO treated cells travel similar distance.
b.




















































Figure 4.7 SFN affects microtubule organisation in ARPE-19 cells
Cells were treated with different concentrations of SFN and DMSO for 48 h.
Cells were immnolabelled for a-tubulin (green, invert) and DAPI (blue). DMSO
and 2µM SFN treated cells show a classic radial array of microtubules
focused on the centre of the cell. 10µM and 15µM SFN treated cells show
more microtubule bundles formation (arrows). Scale bars = 10µm.
α-tubulin





















Figure 4.8 SFN affects microtubule organisation in PANC-1 cells
Cells were treated with different concentrations of SFN and DMSO for 48 h.
Cells were then immnolabelled for a-tubulin (green, invert) and DAPI (blue).
DMSO treated cell shows disorganised microtubules focused in the centre
of the cell and elongated towards cell periphery. 2µM and 10µM SFN
treated cells reveal similar microtubule pattern to DMSO treated cell.
However, 15µM SFN treated cell reveals some cells forming straight and
bundled microtubules (arrows). Scale bars = 10µm.

























Figure 4.9 SFN causes actin filaments disorganisation and co-alignment with
microtubules in ARPE-19 cells
Cells were immunolabelled for microtubules (α-tubulin; red) and actin (β-actin, green,
invert). a) DMSO treated cell shows actin located at cell edges and forming
lamellipodium with some actin filaments running parallel to long axis of in cell body,
and (b) 2µM SFN treated cell shows similar organisation. 10µM SFN treated cell
reveals actin filaments are co-aligned with microtubules (enlarged boxed). 15µM
SFN treated shows actin filaments are accumulated and co-aligned with
microtubules. The dotted appearance of β-actin suggests of breakdown actin
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Figure 4.10 Stress fibres organisation in SFN treated ARPE-19 cells
Cells were immunolabelled for microtubules (α-tubulin; purple) and actin filaments
(phalloidin, green, invert). a) DMSO treated cell shows stress fibres running parallel
in the cell centre and actin at periphery, and 2µM SFN treated cell shows similar
organisation (b). c) 10µM SFN treated cell reveals an increase of stress fibres
(enlarged boxed). d) 15µM SFN treated cell shows an increase of stress fibres but
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Figure 4.11 Effects of SFN on actin organisation in PANC-1 cells
Cells were immunolabelled for microtubules (α-tubulin; red) and actin (β-actin, green,
invert). a) DMSO treated cell shows actin filaments at the cell periphery with
microspike at the front of the cell (boxed region, arrow). b) 2µM SFN treated cell
shows actin filaments at the cell periphery. c) 10µM and 15µM treated cell reveals
disorganised actin filaments with some accumulated actin in cell with some reduction
of cortical actin (boxed region, arrow). Scale bars = 10µm.




























Figure 4.12 Stress fibre organisation in SFN treated PANC-1 cells
Cells were immunolabelled for microtubules (α-tubulin; red) and stained for actin
filaments (Phalloidin, green, invert). a, b) DMSO and 2µM SFN treated cells reveal
actin fibres close to periphery with filopodia and microspikes at the very front of the
leading (boxed region). c, d) 10µM and 15µM treated cells show some stress fibres in
the cell body with some decrease in microspikes at the front edge (arrows, boxed
region). Scale bars = 10µm.























Figure 4.13 EB1 localisation in SFN treated ARPE-19 cells
Cells were immunolabelled for EB1 (red, inverted) and α-tubulin (green), and
images were taken with Widefield fluorescence microscopy. a and b) DMSO
and SFN 2µM treated cells show EB1 as classic comets at microtubule plus-
ends. 10 and 15µM SFN treated cells reveal an extensive association
between EB1 and microtubules, with EB1 binding along the microtubules
lattice and with a distinct accumulation at the plus-ends (boxed region) (c and
d). Scale bars = 10µm.


















































Figure 4.14 EB1 expression and comet analysis in SFN treated ARPE-19
Cells were treated with different concentrations of SFN for 48 h. a) Western
blot result shows no change in the levels of EB1 in all concentrations. b) The
analysis of EB1 comets shape shows no significant difference in EB1 comets
circularity between the 2µM SFN AND DMSO treated cells. c) Fluorescence
intensity analysis was used to quantify EB1 lattice association. The analysis of
EB1 lattice association for 10 and 15µM SNF treated cells shows a dramatic
increase in EB1 intensity along the microtubule lattice compared to DMSO
treated cells. Significance was assessed by one-way ANOVA with Tukey’s



























Figure 4.15 EB1 localisation in SFN treated PANC-1 cells
Cells were immunolabelled for EB1 (red, inverted) and α-tubulin (green). a)
The fluorescence image for DMSO treated cell shows EB1 as classic
comets at microtubules plus-ends with some lattice association in the
centre of the cell. b) 2µM treated cell reveals EB1 accumulated at the plus-
ends of microtubules as comets (boxed region). Scale bars = 10µm.
b.










Figure 4.16 EB1 localisation in SFN treated PANC-1 cells
Cells were immunolabelled for EB1 (red, inverted) and α-tubulin (green). a)
10µM SFN treated cell shows EB1 as comets at microtubules plus-ends
(boxed region). b) 15µM SFN treated cell reveals an extensive association


















































Figure 4.17 EB1 expression and comet analysis in PANC-1 cells
Cells were treated with different concentrations of SFN for 48 h. a) Western
blot result suggests no change in the level of EB1 expression in all
conditions. b) The analysis of EB1 comets shape reveals no significant
difference in EB1 comets circularity between all conditions, (one-way
ANOVA with Tukey’s multiple comparisons test). c) Fluorescence intensity
analysis was used to quantify EB1 lattice association. The analysis of EB1
lattice association for 15µM SNF treated cells show a significant increase in
intensity along the microtubule lattice compared to DMSO treated cells.
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Figure 4.18 EB2 localisation in SFN treated ARPE-19 cells
Widefield fluorescent images of cells immunolabelled for α-tubulin (red) and
EB2 (green, inverted). a) DMSO treated cell shows location of EB2 along the
lattice with some at the plus-ends of microtubules, with few free in the
cytoplasm (arrow, boxed region). b) 2µM SFN treated cell reveals EB2




α-tubulin  EB2 EB2a.
Chapter IV: Effects of Sulforaphane on random cell Migration
ARPE-19
α-tubulin  EB2b. EB2
Figure 4.19 EB2 localisation in SFN treated ARPE-19 cells
Cells were immunolabelled for α-tubulin (red) and EB2 (green, inverted). a and
b)10µM and 15µM SFN treated cells reveal more cytoplasmic EB2 (arrows)
























Figure 4.20 EB2 localisation in SFN treated PANC-1 cells
Cells were immunolabelled for α-tubulin (red) and EB2 (green, inverted) and
treated with SFN and DMSO for 48 h. a) DMSO treated cell shows EB2
associated along the microtubules lattice with some at the cytoplasm (boxed
region , arrows).10 and 15µM SFN treated cells reveal more free EB2 in the
cytoplasm (arrows) with some along the lattice (boxed region and arrows) (b &
c). Scale bars= 10µm.
α-tubulin EB2 EB2 α-tubulin  EB2
b.
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Figure 4.21 EB2 expression in SFN treated ARPE-19 and PANC-1 cells
Western blot were used to investigate the level of EB2 expression in SFN
treated cells. a) Western blot result shows a slight decrease in upper band
of 10 and 15µM SFN compare to DMSO treated cells. b) In contract,
western blot for PANC-1 cells reveals slight increased in the level of EB2
expression in SFN treated cells compared to DMSO treated cells.
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Figure 4.22 HDAC6 localisation in SFN treated ARPE-19 cells
Cells were immunolabelled for α-tubulin (green) and HDAC6 (red, invert).
a) DMSO treated cell reveals HDAC6 free in the cytoplasm (arrow) and
around the nucleus with some along the microtubule lattice. b) 2µM SFN
treated cell shows HDAC6 mainly in the cytoplasm (arrow) with some along
lattice (boxed region). All scale bars = 10µm.
HDAC6
α-tubulin HDAC6 HDAC6 α-tubulin HDAC6
SFN 10µM
ARPE-19
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Figure 4.23 HDAC6 localisation in SFN treated ARPE-19 cells
Cells were immunolabelled for α-tubulin (green) and HDAC6 (red, invert).
a) 10µM SFN treated cell reveals HDAC6 mainly in the cytoplasm and
around the nucleus with no much evidence of association along the
microtubules lattice (boxed region). b) 15µM SFN treated cell shows some
filament-like of HDAC6 in the cytoplasm (arrow) and free in the cytoplasm,
with no much evidence of association along the microtubules lattice. All scale
bars = 10µm.




Figure 4.24 HDAC6 localisation in SFN treated PANC-1 cells
Cells immunolabelled for α-tubulin (green) and HDAC6 (red, invert). a)
DMSO treated cell reveals HDAC6 mainly diffused in the cytoplasm and
around the nucleus also some association along the microtubules and the
periphery (arrows). Similar observation is found in 2µM SFN treated cell,
where HDAC6 is free in the cytoplasm and around the nucleus, with no











Figure 4.25 HDAC6 localisation in SFN treated PANC-1 cells
Cells were immunolabelled for α-tubulin (green) and HDAC6 (red, invert).
The 10 and 15µM SFN treated cells show no association between
HDAC6 and microtubules lattice. However, there is some marked
accumulation in cell periphery (arrow) and around the nucleus and free in
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Figure 4.26 Tubacin at 10µM and combination of tubacin and 10µM or 15µM 
SFN has no significant effect on cell viability in ARPE-19 and PANC-1 cells
Cell viability was examined by MTT assay, which based on the reduction of
yellow tetrazole to purple formazan in living cells. The results reveal no Effects
on cell viability in 10µM tubacin and a combination with 10µM tubacin and 10µM
or 15µM treated ARPE-19 cells (a). 10µM tubacin and combinations of 10µM
tubacin and 10µM or 15µM treated PANC-1 cells show no Effects on the cell
viability compared to DMSO treated cells and untreated (b). Statistical analysis
















































































































Figure 4.27 Relative size of ARPE-19 and PANC-1 cells in the absence of
active HDAC6
Cells were treated with 10µM tubacin or combination of 10µM tubacin and 10µM
or 15µM SFN and incubated for 48 h. Cell area were measured by using image
J. Results of both cell lines show that, inhibition HDAC6 by tubacin causes a
significant increase in cell area compare to DMSO cell. The combination of
tubacin and SFN shows also a significant increase in cell area, as well as with
SFN treatment alone. Statistical analysis using one-way ANOVA with Tukey’s
multiple comparison test, [P<0.00], n=65.
ARPE-19 PANC-1
T vs 10µM SFN P<0.001 P<0.001
T vs 15µM SFN P<0.001 P<0.05
T vs 10µM T + 10µM SFN P>0.05 P<0.001
T vs 10µM T + 15µM SFN P>0.05 P>0.05
ARPE-19
Chapter IV: Effects of Sulforaphane on random cell Migration
174
acetylated DAPI  α-tubulin 
acetylated
DAPI  α-tubulin 
acetylated    
DMSO SFN 10µM
SFN 10 + Tubacin 10µM
Tubacin 10µMSFN 15µM







Figure 4.28 The Effects of tubacin on microtubule acetylation in ARPE-19
Cells were stained for acetylated α-tubulin (green, inverted) and α-tubulin (red)
DAPI (blue). a) In DMSO treated cell, acetylated α-tubulin is mostly
incorporated into scattered microtubule segments. b) In 10µM tubacin treated
cell, all microtubules appear acetylated. c) 10µM SFN treated cell shows
acetylated microtubules at the central of the cell with some segments near cell
periphery. d) 15µM SFN treated cell shows more long segments of acetylated
microtubules in the cell body. The combination of tubacin and SFN treatment
show all microtubules are acetylated (e-f). Scale bars = 10µm.
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Figure 4.29 The Effects of tubacin om microtubule acetylation in PANC-1
Cells were labelled for acetylated α-tubulin (green, inverted) and α-tubulin (red)
DAPI (blue). a) DMSO treated cell shows small segments of acetylated α-
tubulin along microtubules. b) 10µM tubacin, treated cell shows that all
microtubules consist of acetylated α-tubulin. c) 10µM SFN treated cell shows
acetylated microtubules at the centre of the cell with some segments near cell
periphery. b) 15µM SFN treated cell shows longer segments of acetylated
microtubules. A combination of tubacin and SFN treatment produces




Figure 4.30 The Effects of tubacin and a combination of tubacin and
SFN on microtubule acetylation in ARPE-19 and PANC-1 cells
Western blot of lysates was used for untreated, DMSO, tubacin, SFN (10
&15µM), and combination of 10µM tubacin and SFN (10 &15µM). a)
ARPE-19 cells show high level of acetylated α-tubulin in 10µM tubucin and
in a combination of tubacin and SFN treated cells. The 10 and 15µM SFN
treated ARPE-19 cells show a slight reduction in acetylation levels
compared to DMSO. b) The 10µM tubacin and a combination of 10µM
tubacin and 10µM or 15µM SFN treated PANC-1 cells reveal an increase
in the level of expression of acetylated tubulin compared to DMSO treated
cells.
Acetylated tubulin50 kDa 
55 kDa Actin
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Figure 4.31 A combination of tubacin and SFN causes a reduction in
speed of cell migration in ARPE-19 and PANC-1 cells
Cells were treated with tubacin & SFN for 48 h. Cells imaged by widefield time-
lapse microscopy for a 16 h period beginning 32 h post initial treatment, with
frames taken every 10 minutes. a) The 10µM tubacin, SFN (10 and 15µM), and
combinations of 10µM tubcain and 10 or 15µM SFN treated ARPE-19 cells
show a significant decrease in the average velocity compared to DMSO treated
cells. b) The 10µM tubacin, SFN (10 and 15µM), and combinations of 10µM
tubcain and 10µM SFN treated PANC-1 cells reveal no significant decrease in
the average velocity compared to DMSO treated cells. The combination of
tubacin and 15µM SFN shows a significant reduction in the average cell
velocity compared to DMSO treated cells. Significance was assessed by one-
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Figure 4.32 EB1 localisation in tubacin and combinations of tubacin and 
SFN treated ARPE-19 cells
Cells were immunolabelled for microtubules (α-tubulin; green) and EB1 (red,
invert). a) EB1 appears as classic comets at plus-ends of microtubules in DMSO
treated cells. b) The 10 µM tubacin treated cell shows EB1 at the plus-ends of
microtubules as comets (boxed region). A combination of tubacin and SFN
treated cells reveals an extensive association between EB1 and microtubules























Figure 4.33 EB1 expression and comet analysis in tubacin and in
combinations of tubacin and SFN treated ARPE-19 cells
Cells were treated with tubacin and SFN for 48 h. a) Western blot reveals
no effect on the levels of EB1 expression in all conditions. b) The analysis
of EB1 comet shape shows no significant difference in EB1 comets
circularity between DMSO and 10µM tubacin treated cells. c) Fluorescence
intensity analysis was used to quantify EB1 lattice association in DMSO,
10µM tubacin and a combination 10µM tubacin and 10 or 15µM SFN.
Results show a significant increase in EB1 intensity in 10µM tubacin and
15µM SFN treated cells compared to DMSO treated cells. One-way ANOVA
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Figure 4.34 EB1 localisation in tubacin treated PANC-1 cells
Cells were immunolabelled for microtubules (α-tubulin; green) and EB1 (red, invert).
a) In DMSO treated cells, EB1 appears as classic comets at plus-ends of
microtubules. b) The 10 µM tubacin treated cell shows EB1 at plus-end of
microtubules (boxed region), as well in tubacin &10µM SFN (c). d) A combination of
10µM tubacin and 15µM SFN treated cell reveals EB1 associated extensively along
microtubules lattice (boxed region). Scale bars=10µm.












































Figure 4.35 EB1 expression and comets analysis in tubacin and in
combinations of tubacin and SFN treated PANC-1 cells
Cells were treated with tubacin and SFN for 48 h. a) Western blot reveals no
marked Effects on the levels of EB1 in all conditions. b) The analysis of EB1
comets shape shows no significant difference in EB1 comet circularity
between all conditions. c) Fluorescence intensity analysis was used to
quantify EB1 lattice association in DMSO treated cells and a combination
10µM tubacin and 15µM SFN. Results show a significant increase in
intensity compared to DMSO treated cells, P<0.01. One-way ANOVA with
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Figure 4.36 EB2 localisation in tubacin treated ARPE-19 cells
Cells were immunolabelled for α-tubulin (green) and EB2 (red, invert). a) DMSO
treated cell shows EB2 along microtubules lattice (arrow) and at the cytoplasm
(boxed region). b) 10µM tubacin treated cell shows some EB2 along the lattice and
at the cytoplasm (arrows and boxed region). 10µM tubacin and 10µM or 15µM SFN
treated cells reveal EB2 mainly in the cytoplasm with few EB2 along the lattice
(arrows) (c and d) (boxed region). All scale bars = 10µm.
PANC-1
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Figure 4.37 EB2 localisation in tubacin treated PANC-1 cells
Cells were immunolabelled for α-tubulin (green) and EB2 (red, invert). a) DMSO
treated cell shows EB2 along microtubules lattice and at the cytoplasm (arrows and
boxed region). b) 10µM tubacin treated cell shows EB2 along the lattice and with
some in the cytoplasm (arrows and boxed region). 10µM tubacin and 10µM or
15µM SFN treated cells reveal EB2 mainly in the cytoplasm with few EB2 along the
lattice (c and d) (arrows and boxed region). All scale bars = 10µm.





Figure 4.38 EB2 expression in tubacin treated PANC-1 cells
Western blots of PANC-1 lysates for 10µM tubacin and 10µM tubacin
and 10µM or 15µM SFN. Result shows no changes on the level of
EB2 expression in a combination of 10µM tubacin and 10µM or
15µM SFN treated cells, and also in 10 or 15µM SFN treated cells
compared to DMSO treated cells.
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Figure 4.39 HDAC6 localisation in tubacin treated ARPE-19 cells
Cells were immunolabelled for α-tubulin (green) and HDAC6 (red,
invert). a) DMSO treated cell shows HDAC6 localised in the cytoplasm
(arrow) with some along microtubules lattice (arrow) and around the
nucleus. b) 10µM tubacin treated cell shows no co-localisation between
HDAC6 and microtubules, with HDAC6 arranged in filaments-like
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Figure 4.40 HDAC6 localisation in tubacin treated ARPE-19 cells
Cells were immunolabelled for α-tubulin (green) and HDAC6 (red,
invert). 10µM tubacin and 10µM or 15µM SFN treated cells reveal
HDAC6 arranged in filament-like structure in the cytoplasm (arrows)
and around the nucleus but with no co-localisation with microtubules
(arrows and boxed region) (a & b). All scale bars = 10µm.
α-tubulin  HDAC6 HDAC6
α-tubulin  HDAC6 HDAC6
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Figure 4.41 HDAC6 localisation in tubacin treated PANC-1 cells
Cells were immunolabelled for α-tubulin (green) and HDAC6 (red,
invert). a) DMSO treated cell shows diffuse HDAC6 in the cytoplasm
(arrow) and around the nucleus with no co-localisation between HDAC6
and microtubules (boxed region). 10µM tubacin treated cell reveals no
co-localisation between HDAC6 and microtubules with most of HDAC6 in
the cytoplasm (arrows and boxed region). All scale bars = 10µm.
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Figure 4.42 HDAC6 localisation in tubacin treated PANC-1 cells
Cells were immunolabelled for α-tubulin (green) and HDAC6 (red, invert).
10 µM tubacin with 10 µM or 15 µM SFN treated cells reveal HDAC6
was mainly dispersed in the cytoplasm with some concentrated around
the nucleus and cell periphery. There is no co-localisation between
HDAC6 and microtubules (boxed region). All scale bars = 10µm.
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5.1 Overview 
The purpose of this chapter is to investigate microtubule dynamics and stability in 
SFN-treated cells and to determine whether treatment can affect focal adhesion 
dynamics and turnover. This chapter starts by introducing what is already known 
about the effect of SFN on microtubule dynamics and focal adhesion dynamics in 
cancer cells. Then, start presents the effect of SFN on acetylation and 
detyrosination, microtubule stability and cold treatment. In addition, this chapter 
shows the effect of SFN on microtubule dynamics and focal adhesion turnover. 
Finally, the chapter ends with a summary and discussion of the results. 
 
5.2 Introduction 
The dynamic instability of microtubules enables cells to rapidly reorganise the 
microtubule cytoskeleton into various cellular patterns that suit particular 
functions, such as cell polarisation, cell division and migration (Mitchison and 
Kirschner, 1984, Gelfand and Bershadsky, 1991, Howard and Hyman, 2003, 
Hawkins et al., 2010). This instability is an essential behaviour of microtubule 
subunits, which are heterodimers of α/β-tubulin, and is regulated by a multitude of 
microtubule-associated proteins. Some of these proteins accumulate at the growing 
end of microtubules, while others bind along the microtubule lattice (Valiron et al., 
2001, Heald and Nogales, 2002, Burbank and Mitchison, 2006, Nogales and Wang, 
2006). For example, plus-end-tracking proteins, such as EB1, APC, CLIP 170, 
CLASP, and dynactin complex, play important roles in regulating microtubule 
dynamics (Akhmanova et al., 2001, Akhmanova and Hoogenraad, 2005, Patel et 
al., 2012, Akhmanova and Steinmetz, 2015, Nehlig et al., 2017). These +TIPs can 
also influence microtubule interaction with other cellular structures, such as actin, 
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and focal adhesions (Kaverina et al., 2002, Mimori-Kiyosue et al., 2005, Chhabra 
and Higgs, 2007). 
The post-translation modification of tubulin is an important mechanism via which 
microtubule dynamics are controlled. It allows microtubules to assume distinct 
properties and roles within the overall network (Verhey and Gaertig, 2007, 
Garnham and Roll‐Mecak, 2012, Yu et al., 2015). Generally, there are two distinct 
populations among undifferentiated cells during interphase: the majority are 
tyrosinated, and a small and distinct subset are detyrosinated (Gundersen et al., 
1984). Tyrosinated microtubules are mostly dynamic, while detyrosination has 
been linked to stable long-lived microtubules and is used as a marker for 
microtubule stability. The removal of tyrosine (Glu-Tur) from the C-terminal of α-
tubulin occurs on the outer surface of the microtubules (Gundersen et al., 1984, 
Webster et al., 1987, Bulinski and Gundersen, 1991). Acetylation is another type 
of tubulin modification, which occurs on lysine 40, located in the luminal face of 
the microtubule (L'Hernault and Rosenbaum, 1985, Bulinski and Gundersen, 1991, 
Janke and Bulinski, 2012). The exact effects of tubulin acetylation are still not fully 
understood, but it most commonly associated with stable microtubules. Acetylation 
is reversible, and there are two types of microtubule deacetylase, HDAC6 (Hubbert 
et al., 2002) and SIRT2, which can function independently (North et al., 2003). 
Tubulin undergoes modifications when polymerised into microtubules, and the 
reversible reaction occurs mainly in depolymerised microtubule subunits 
(Westermann and Weber, 2003). Therefore, several types of post-translational 
tubulin modifications accumulate in stable (long-lived) microtubules (Hammond et 
al., 2008). It was further shown that tyrosine residues in tubulin play a vital role in 
recruiting certain proteins to the plus-end of microtubules, such as CLIP-170 and 
p150Glued, which are known to help regulate microtubule dynamics. Therefore, 
detyrosination affects microtubule behaviour by altering the affinity of 
microtubules to specific proteins that regulate their dynamics and stability 
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(Akhmanova et al., 2001, Akhmanova and Hoogenraad, 2005). Similarly, the 
acetylation of tubulin has been utilised to identify stable microtubules because it 
leads to reduced microtubule dynamics (Piperno et al., 1987, Webster and Borisy, 
1989). Moreover, it has been reported that acetylation can affect the binding of 
microtubules to certain motor proteins, such as kinesin-1 (Reed et al., 2006, 
Dompierre et al., 2007, Janke and Bulinski, 2011, Garnham and Roll‐Mecak, 
2012). At the same time, other studies have shown that the acetylation of tubulin 
does not affect microtubule dynamics (Haggarty et al., 2003, Palazzo et al., 2003, 
Zhang et al., 2008, Asthana et al., 2013). In neurones, it has been suggested that 
acetyltransferase and the acetyltransferase complex can acetylate tubulin (Creppe 
et al., 2009). It is not clear whether this is the case in ARPE-19 and PANC-1. 
Meanwhile, the molecules that facilitate the reverse reaction, deacetylation, which 
include HDAC6 and SIRT2 (class III NAD-dependent histone deacetylase), have 
been identified in several studies (Hubbert et al., 2002, Matsuyama et al., 2002, 
North et al., 2003, Zhang et al., 2003). 
One of the main questions in this project is whether SFN can inhibit microtubule 
dynamics and increase stability. It has been suggested that SFN can suppress 
microtubule dynamic instability and decrease turnover in various cancer cells, such 
as human breast cancer cells, affecting individual growth and shrinkage rates 
(Azarenko et al., 2008). However, prior dynamic instability analysis was only based 
on four microtubules (Azarenko et al., 2008). Additionally, SFN treatment leads to 
changes in post-translational tubulin modifications, including increased tubulin 
acetylation. Concentrations ≥15 µM SFN promotes acetylated tubulin in human 
breast cancer and prostate cancer cells.  Meanwhile, concentrations ≥ 50 µM SFN 
in human breast cancer cells showed completely depolymerised microtubules 
(Azarenko et al., 2008, Gibbs et al., 2009, Clarke et al., 2011). Interestingly, a 
recent study by Dickinson (2014) showed that 15 µM SFN decreased the level of 
Chapter V: Sulforaphane treatment and Microtubule Dynamics and Stability 
193 
        
acetylated tubulin; this was observed in vitro in SFN-treated human skin 
keratinocytes (HaCaT) after 48 hours of incubation (Dickinson et al., 2015). 
Cell migration is a vital process for wound healing, developmental morphogenesis 
and tumour metastasis. This process requires the combined activities of the 
cytoskeleton, cell membrane and extracellular matrix (ECM) (Lauffenburger and 
Horwitz, 1996, Rodriguez et al., 2003). Focal adhesions are organelles that play an 
important role in cell migration. Focal adhesion disassembly requires dynamic 
microtubules, where microtubules have been observed at peripheral focal adhesions 
and contribute to promote adhesion disassembly (Kaverina et al., 2002). Focal 
adhesion site enlarged when microtubules were disassembled by nocodazole, 
which means that dynamic microtubules are crucial for focal adhesion disassembly 
(Kaverina et al., 2002, Krylyshkina et al., 2002). Additionally, it has been shown 
that ACF7 regulates focal adhesion dynamics, with the absence of ACF7 leading 
to stabilised actin filaments and a focal adhesion network, and preventing the 
targeting of microtubules along actin filaments reaching to focal adhesion sites (Wu 
et al., 2008). Recent studies have shown that dynamic microtubules can increase 
focal adhesion turnover by delivering proteins that are essential for disassembly. 
This occurs via the interaction of kinase kinase kinase kinase 4 (MAP4K4, 
disassembly protein) and EB2. The knockout of MAP4K4 stabilises focal adhesion 
and impairs cell movement (Yue et al., 2014). 
One important aspect of the phenotype observed following SFN treatment in 
ARPE-19 cells was the apparent reorganisation of microtubules into bundles that 
were co-aligned with actin filaments (Chapter 4). The appearance of microtubules 
bundles in cells is indicative of stabilised microtubules, suggesting that SFN may 
be involved in influencing the stability of the microtubule population. Stable 
microtubules have been correlated with an accumulation of post-translational 
tubulin modifications, such as acetylation and detyrosination. It has been shown 
that SFN treatment alters post-translational tubulin modifications, increasing 
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tubulin acetylation and stable microtubules. This was also observed in breast cancer 
and prostate cancer cells (Azarenko et al., 2008, Clarke et al., 2011). Therefore, it 
is important to analyse acetylation and detyrosination level and expression in SFN 
treated ARPE-19 and PANC-1 cells. 
Another essential change noted in cells treated with SFN was a significant increase 
in cell area with a dramatic decrease in ARPE-19 cell migration (Chapter 4). 
Successful cell migration requires a balance between stable and dynamic 
microtubules and dynamic focal adhesion, with dynamic microtubules contributing 
to the regulation of focal adhesion dynamics and turnover (Kaverina et al., 2002). 
Thus, any decrease in microtubule dynamics leads to a change in the state of focal 
adhesion turnover, which leads to reduced cell migration and increases cell area. It 
is therefore important to study focal adhesion dynamics and turnover in SFN treated 
cells and determine whether SFN induced changes in microtubules have dramatic 
effects on cell migration and whether the increase in the area of cells treated with 
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5.3 Results 
5.3.1 SFN treated ARPE-19 but not PANC-1 cells express 
more acetylated microtubules 
ARPE-19 and PANC-1 cells were grown on glass coverslips and treated with 10 or 
15 µM SFN for 48 hours, with DMSO being used as a control, and then fixed with 
-20o C methanol for five minutes. Cells were then immunolabelled for acetylated 
tubulin and α-tubulin. DMSO and SFN treated ARPE-19 cells expressed acetylated 
tubulin. The DMSO treated ARPE-19 cells revealed few acetylated microtubules 
around the centre of the cell, with only small acetylated segments along these 
microtubules, which was similar to the results for the untreated ARPE-19 cells 
(Figure 5.1). However, the 10 µM and 15 µM SFN treated ARPE-19 cells showed 
prominent acetylation along the length of other curly microtubules extending from 
the centre of the cell towards the cell periphery, where curly microtubules are 
commonly observed with acetylated microtubules. Distinct bundles of acetylated 
microtubules were also evident in the 15 µM SFN treated ARPE-19 cells (Figure 
5.1). The amount of acetylated tubulin as a percentage of total tubulin in ARPE-19 
cells was accessed following SFN treatment was analysed using ImageJ. Ten 
immunolabeled cells for acetylated tubulin and α-tubulin were used for this analysis 
(as described in 2.10). The 10 µM and 15 µM SFN treated ARPE-19 cells revealed 
a significant increase in the total area of acetylated microtubules as compared to 
DMSO treated cells (Figure 5.2, a). Western blot suggested that there was a slight 
increase in the level of acetylated tubulin expression in 10 µM and 15 µM SFN 
treated ARPE-19 cells compared to DMSO treated cells (Figure 5.2, b). 
This marked increased in acetylated microtubules suggests an increase in 
microtubule stability. This was tested in SFN treated ARPE-19 cells via cold 
treatment. The incubation of cells on ice causes depolymerisation of microtubules 
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with only stable microtubules being resistant to the cold and remaining 
polymerised. The incubation of DMSO treated cells on ice for 15 minutes showed 
that most of microtubules had depolymerised. In contrast, 10 µM SFN treated 
ARPE-19 cells revealed a marked number of stable microtubules, and 15 µM SFN 
treated ARPE-19 cells showed a further increase in number of stable microtubules. 
These remaining microtubules were resistant to cold and thus more stable (Figure 
5.3). 
In PANC-1 cells, acetylated tubulin was also observed in DMSO and SFN treated 
cells. DMSO treated cells showed a few acetylated microtubules concentrated in 
the cell centre and along small subsections of the microtubules. The 10 µM and 15 
µM SFN treated PANC-1 cells had prominent acetylated microtubules around the 
cell centre and long acetylated segments along the microtubules (Figure 5.4). 
Analysis of the acetylated tubulin area revealed no significant increase in the 
percentage of total area of acetylated microtubule in 10 µM and 15 µM SFN treated 
PANC-1 cells, compared to DMSO treated cells (Figure 5.5, a). Western blots 
suggested that there was no change in the levels of acetylated tubulin in 10 µM and 
15 µM SFN treated PANC-1 cells, compared with DMSO treated cells (Figure 5.5, 
c). The cold treatment experiment suggested that untreated and DMSO treated 
PANC-1 cells had some stable microtubules (Figure 5.6). The 10 µM and 15 µM 
SFN treated PANC-1 cells underwent little change. Networks of stable 
microtubules could be observed around the nucleus and in the cytoplasm, 
suggesting no marked increase in microtubule stability in SFN treated PANC-1 
cells (Figure 5.6).  
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5.3.2 SFN treated ARPE-19 but not PANC-1 cells reveal 
an increase in detyrosinated tubulin 
To assess whether the expression of detyrosinated tubulin was affected by SFN 
treatment, ARPE-19 and PANC-1 cells were seeded on glass coverslips, incubated 
overnight and then treated with 10 µM or 15 µM SFN and incubated for 48 hours. 
SFN and DMSO treated ARPE-19 and PANC-1 cells were fixed and 
immunolabelled for tyrosinated and detyrosinated tubulin. DMSO treated ARPE-
19 cells had mostly tyrosinated microtubules, along with few detyrosinated 
microtubules. These few detyrosinated microtubules were concentrated in the cell 
centre and a few small segments along the microtubules (Figure 5.7). Similar 
observations were made in 10 µM SFN treated ARPE-19 cells. However, 15 µM 
SFN treated ARPE-19 cells revealed extensive detyrosinated bundles of 
microtubules that were composed of straight detyrosinated microtubules that 
exbended from the cell centre toward the periphery (Figure 5.7). 
DMSO treated and 10 µM and 15 µM SFN treated PANC-1 cells showed minimal 
expression of detyrosinated tubulin. This suggests that SFN does not increase 
expression of detyrosinated tubulin in PANC-1 cells (Figure 5.8). 
 
5.3.3 SFN treatment affects microtubule dynamics in 
ARPE-19 cells 
To assess the effect of SFN treatment on microtubule dynamics, GFP-CLIP-170 
comet dynamics were analysed in SFN treated ARPE-19 and PANC-1 cells. Cells 
were grown in glass-bottomed dishes and incubated overnight. Cells were then 
treated with 10 and 15 µM SFN and incubated for 48 hours. For each concentration, 
cells expressing GFP-CLIP-170 were imaged using live time-lapse fluorescence 
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microscopy for three minutes, with frames taken every three seconds, yielding 60 
frames in total. GFP-CLIP-170 comets were followed using the automated tracking 
software U-Track, originally packaged as plusTipTracker (Applegate et al., 2011). 
All post-tracking analysis was conducted using MATLAB, as described in chapter 
4.13. Importantly, it must be noted that stable microtubules cannot be identified via 
this method. GFP-CLIP-170 may cause an increase in microtubule rescue.  
U-Track analysis of GFP-CLIP-170 comets over a three-minute period, every three 
seconds, showed GFP-CLIP-170 comets with lines presenting different phases, 
growing (red), shrinking (yellow) and pausing (blue) (Figure 5.9, Movie S17, S18 
and S19). CLIP-170 tracking images suggested that SFN may affect microtubules 
length. Analysis of GFP-CLIP-170 comets in the ARPE-19 cells treated with 10 
µM and 15 µM SFN revealed a significant decrease in the average comet’s speed. 
The DMSO treated ARPE-19 cells revealed an average CLIP-170 comet speed of 
14.6 µm min-1. In contrast, the 10 µM and 15 µM SFN treated ARPE-19 cells 
showed average CLIP-170 comet speeds of 9.9 µm min-1 and 9.05 µm min-1, 
respectively (Figure 5.10, a). Furthermore, analysis of mean growth length of 
microtubules in DMSO and SFN treated ARPE-19 cells showed that 10 µM and 15 
µM SFN treated cells had significantly decreased CLIP-170 growth lengths 
compared to DMSO treated cells (Figure 5.10, b, Movies S20, S21 and S22). 
The microtubule dynamics in PANC-1 cells were analysed in the same way as those 
in ARPE-19 cells. U-Track analysis of GFP-CLIP-170 comets over three-minutes 
period with growing (red), shrinking (yellow) and pausing (blue) (Figure 5.11). The 
10 µM and 15 µM SFN treated PANC-1 cells revealed no significant difference in 
comet speed compared to DMSO treated cells (Figure 5.12, a). Moreover, 10 µM 
and 15 µM SFN treated PANC-1 cells showed no changes in the comet growth 
length compared to DMSO treated cells (Figure 5.12).  
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The results revealed that SFN treatment decrease significantly microtubule 
dynamics in AREP-19, however, no significant reduction was observed in SFN 
treated PANC-1 cells. 
 
5.3.4 SFN treatment increases focal adhesion area AREP-
19 cells 
To assess whether SFN treatment affects focal adhesion area and turnover, ARPE-
19 and PANC-1 cells were seeded on glass coverslips and incubated overnight. 
These cells were then treated with 10 µM and 15 µM SFN, incubated for 48 hours 
and immunolabelled for focal adhesion kinase (FAK) and microtubules. DMSO 
treated ARPE-19 cells revealed focal adhesions at the cell edge, along with some 
focal adhesions in the cell body. Treatments with 10 µM and 15 µM SFN in ARPE-
19 cells showed more FAK in the centre of the cell, along with some adhesions at 
the cell periphery (Figure 5.13).  
In contrast, DMSO treated PANC-1 cells showed focal adhesions at the cell 
periphery, along with some FAK staining that was diffuse in the cytoplasm. The 10 
µM and 15 µM SFN treated PANC-1 cells revealed more dispersed FAK (Figure 
14). 
Focal adhesion images were analysed using imageJ software. AREP-19 and 
PANC-1 cells were grown on glass coverslips, treated with SFN for 48 hours, then 
with GFP-paxillin construct for four hours and fixed. The adhesion areas in the 
AREP-19 and PANC-1 cells were assessed. GFP-paxillin images revealed focal 
adhesions at the cell periphery and in cell body in DMSO and SFN treated ARPE-
19 cells (Figure 5.15, a), while they localised mainly at the cell periphery in DMSO 
and SFN treated PANC-1 cells (Figure 5.16, a). The surface area of the cell 
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including all focal adhesions were quantified. To obtain the percentage of focal 
adhesion area in the cells, the total focal adhesion area was divided by the total area 
of the cell. The mean focal adhesions area was also analysed in the cells.  
The results illustrated that 15µM SFN treated ARPE-19 cells had a significant 
increase in the percentage of total adhesion area of focal adhesion compared to the 
DMSO treated cells (Figure 5.15, b). In contrast, the 10 µM and 15 µM SFN treated 
PANC-1 cells showed no significant increase in total focal adhesion area or in the 
average area of focal adhesion compared to the DMSO treated cells (Figure 5.16, 
b and c). 
 
5.3.5 SFN treatment and focal adhesion dynamics in 
ARPE-19 and PANC-1 cells 
To investigate whether SFN treatment has an effect on focal adhesion turnover, 
ARPE-19 and PANC-1 cells were grown in glass-bottom dishes and incubated 
overnight. The following day, these cells were treated with 10 µM or 15 µM SFN 
and incubated for 48 hours. The ARPE-19 and PANC-1 cells were then transfected 
with GFP-paxillin, incubated for four hours, given fresh medium and then 
incubated for a total of 48 hours. Adhesion dynamics was then analysed in live in 
ARPE-19 and PANC-1 cells expressing GFP-paxillin using FRAP (fluorescence 
recovery after photobleaching). Confocal microscopy (Zeiss LSM510 META 
scanning confocal microscope) was used for the live imaging in ARPE-19 and 
PANC-1 cells expressing GFP-paxillin, every three-seconds over a three-minute 
period (as described in Material and Methods, 2.8.3). The fluorescence mean 
recovery after FRAP was measured with time needed to return to the full recovery 
(as described in Material and Methods, 2.14). As illustrated in Figure 5.17 and 5.18 
for DMSO and SFN treated ARPE-19 and PANC-1 cells, where focal adhesions 
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underwent to FRAP over three-minutes (Figure 5.17 and 5.18, Movies S23, S24, 
S25, S26, S27 and S28). 
The results showed no significant difference in the percentage of the mean recovery 
between DMSO and SFN treated AREP-19 cells (Figure 5.19, a). DMSO treated 
cells showed that the percentage of mean recovery reached about 58% within 33 
Meanwhile, 10 and 15 µM SFN treated cells revealed that the percentage of mean 
recovery reached about 53% and 58% within 36 and 42 respectively (Figure 5.19, 
b). However, none of the three conditions of treated cells showed a fully recovery 
after photobleaching.  
The 10 and 15 µM SFN treated PANC-1 cells revealed a significant increase in the 
percentage of the mean fluorescence GFP-paxillin recovery compared to DMSO 
cells (Figure 5.20, a). The results revealed that DMSO treated PANC-1 cells 
reached the percentage of the mean recovery around 50% within 42, while 10 and 
15 µM SFN treated cells reached the percentage the mean recovery of 59% and 
68% within 30 and one respectively. Increasingly, 10 and 15 µM SFN treated 
PANC-1 cells reached 46% and 40% within 10 seconds compared to DMSO treated 
cells, which reached the percentage of the mean recovery of 29% within 10 seconds 
(Figure 5.20, b). These FRAP studies suggested that there is no significant change 
in the focal adhesion dynamics in SFN treated ARPE-19 cells. However, there is a 
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SFN and acetylated tubulin 
ARPE-19: 
 Significant increase in the total area of 
acetylated microtubules 
 Western blot showed an increase in 
acetylated tubulin. 
 Cold treatment suggested marked increase in 
microtubule stability 
PANC-1: 
 No significant increase in the total area of 
acetylated microtubule 
 Western blot revealed no increase in 
acetylated tubulin. 
 Cold treatment suggested no marked increase 




SFN and microtubule 
dynamics 
ARPE-19: 
 CLIP-170 comet analysis revealed a 
significant decrease in the average comet 
speed and in the length growth of MTs in 
SFN treated cells. 
PANC-1: 
 No significant decrease in the average of 
comets speed or in the growth length of MTs 
in SFN treated cells. 
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SFN and focal adhesion 
ARPE-19: 
 Focal adhesion analysis showed a significant 
increase in the percentage of total focal 
adhesion area and in the average area in SFN 
treated cells. 
PANC-1: 
 Focal adhesion analysis revealed no 
significant increase in the average of total 
focal adhesion area or in the area of focal 




SFN and focal adhesion 
dynamics 
ARPE-19: 
 FRAP analyses showed no significant effect 
on focal adhesion recovery between DMSO 
and SFN treated ARPE-19 cells, with no 
marked difference in recovery time. 
PANC-1: 
 FRAP analyses showed a significant increase 
in the mean of focal adhesion recovery in 
SFN treated cells, and SFN treated cell 
showed to recover faster compared to DNSO. 
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5.4 Discussion 
5.4.1 SFN increases acetylated and detyrosinated 
microtubules and inhibits microtubule dynamics in 
ARPE-19 but not in PANC-1 cells 
The analysis of acetylated microtubules revealed that SFN treated ARPE-19 cells 
expressed more acetylated tubulin. This was also suggested by analysing the 
acetylated microtubule area in SFN treated ARPE-19 cells, which it revealed a 
significant increase in acetylated area. Coupled with this, the microtubule bundles 
that formed in SFN treated ARPE-19 cells expressed more detyrosinated 
microtubules, which suggests stable microtubules. Further results demonstrated 
that cold treatment caused total depolymerisation of microtubules in DMSO treated 
ARPE-19 cells, whereas in SFN treated cells, several stable microtubules remained 
intact despite the cold treatment. Importantly, the CLIP-170 comet dynamic results 
showed a dramatic decrease in comet speed and growth length in SFN treated 
AREP-19 cells, which suggest that SFN may inhibit microtubule dynamics. These 
results are in line with those of other studies in which SFN treatment has been 
shown to suppress microtubule dynamics and growth rate, for example, in human 
breast cancer cells (Azarenko et al., 2008). However, here we base the microtubule 
dynamics analysis on a global read from entire cells and not just a few peripheral 
microtubules by Azarenko et al (2008). Moreover, SFN treatment has been shown 
to affect on microtubule post-translational modifications. Specifically, it caused an 
increase in acetylated microtubules and thus more stable microtubules in human 
breast cancer and prostate cancer cells (Azarenko et al., 2008, Gibbs et al., 2009, 
Clarke et al., 2011). 
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SFN treated PANC-1 cells revealed no marked changes in acetylation level and 
expression. This was also suggested by analysing acetylated area in SFN treated 
PANC-1 cells, where no significant increase in acetylated area was evident. Cold 
treatment results indicated similar stable microtubules can be observed in SFN and 
DMSO treated cells. It is likely that any acetylation induced by SFN in PANC-1 
cells is counteracted by the high expression of HDAC6. The analysis of 
microtubule dynamics in SFN treated PANC-1 cells revealed they remained largely 
unchanged, with no significant alteration in comet speed or growth length of 
microtubules. These results are in line with our observations regarding cell 
migration, which revealed that SFN treated PANC-1 cells showed no significant 
difference in cell migration, which requires dynamic microtubules, as compared to 
DMSO treated cells.  
To summarise, the overall capability of SFN to affect microtubule dynamics 
appears to be related to an increase in acetylated microtubules and thus microtubule 
stability (Piperno et al., 1987, Webster and Borisy, 1989). Furthermore, it has been 
shown that acetylated tubulin can influence the ability of motor proteins to 
associate with microtubules (Janke and Bulinski, 2011, Garnham and Roll‐Mecak, 
2012), which may affect cellular functions such as focal adhesion turnover and cell 
migration. In PANC-1 cells, SFN had a different effect, with no increase in 
acetylated microtubules being seen in treated cells and there thus being no effect 
on microtubule dynamics. Our suggestion is that this may be due to EB2 and 
HDAC6 being highly expressed in the PANC-1 cell line (Abiatari et al., 2009, Li 
et al., 2014), with the EB family being essential regulators of microtubule dynamics 
(Komarova et al., 2009). Moreover, depleting EB2 causes more stable microtubules 
and decreased microtubule dynamics (Goldspink et al., 2013), and HDAC6 
deacetylates microtubules and increases microtubule dynamics (Li et al., 2011). All 
these together may prevent or minimise SFN effects on microtubule dynamics and 
stability in PANC-1 cells. 
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5.4.2 SFN treatment leads to increased focal adhesion area 
in ARPE-19 but not in PANC-1 cells 
Microtubules are involved in two essential stages of cell motility, the first stage 
being the reorientation of cellular organelles towards the direction of movement 
(Gundersen and Bulinski, 1988) and the second stage being the regulation of focal 
adhesion dynamics and turnover (Kaverina et al., 1999). According to our results, 
one important observation made regarding SFN treated ARPE-19 and PANC-1 
cells was a distinct increase in cell area (Chapter 4.3.2). Such an increase in cell 
size is likely to be related to focal adhesions, resulting in a decrease in cell 
migration (Lauffenburger and Horwitz, 1996, Rodriguez et al., 2003). It was 
critical, therefore, to investigate whether there was any evidence of effecting focal 
adhesions turnover in SFN treated cells. Focal adhesion areas was significantly 
increased in SFN treated ARPE-19 cells but not in PANC-1 cells. Focal adhesion 
dynamics are related to microtubule dynamics. Specifically, less dynamic 
microtubules can affect focal adhesion dynamics and turnover. As previously 
indicated, SFN treated ARPE-19 cells showed an increase in microtubule stability, 
which may affect focal adhesion states. Acetylated microtubules may cause an 
increase in transport of essential proteins to maintain their focal adhesion dynamics. 
It has been suggested that EB2 contributes to focal adhesion turnover by associating 
with essential proteins, such as HAX1 (HCLS1-asociated protein X-1) and 
MAP4K4, and knockdown of MAP4K4 results in focal adhesion stability (Yue et 
al., 2014, Liu et al., 2015). Thus, the reduced association between EB2 and the 
microtubule lattice in SFN treated cells may affect focal adhesion. 
Overall, microtubule dynamics play a critical role in focal adhesion dynamics, and 
we suggest that SFN inhibits microtubule dynamics, which then may affect focal 
adhesion dynamics. Therefore, this may be one of the mechanisms via which SFN 
affects cell migration. 
Chapter V: Sulforaphane treatment and Microtubule Dynamics and Stability 
207 
        
 
5.4.3 SFN treatment did not inhibit focal adhesion 
turnover 
As we have previously shown that SFN treatment leads to an increase in total focal 
adhesion area in ARPE-19 cells and further investigations were performed 
regarding focal adhesion turnover. Focal adhesion turnover requires dynamic 
microtubules to ensure full and successful. Unexpectedly, our results showed no 
significant effect on the percentage of the mean focal adhesion recovery in SFN 
treated ARPE-19 cells compared to DMSO treated cells. However, SFN treated 
PANC-1 cells showed an increase in the percentage of the mean focal adhesion 
recovery. It seems that the focal adhesions in the SFN treated cells did not fully 
disassemble, with more focal adhesions being observed in the cell body. The reason 
for dynamics and turnover not being affected could be that SFN may affect GFP-
paxillin expression in treated cells, which showed no full recovery of fluorescence 
after photobleaching in FRAP experiments.   
To summarise, the overall ability of SFN to affect focal adhesion dynamics and 
turnover and how it may contribute to the overall cell migration process are not 






Figure 5.1 SFN treated ARPE-19 cells express acetylated tubulin along 
microtubules
Cells were Immunolabelled for microtubules (α-tubulin; red) and acetylated
tubulin (green, invert) and DNA with DAPI. DMSO treated cell shows some
acetylated microtubules mainly around the centre of the cell. 10 and 15µM
SFN treated cells reveal extensive acetylation of curly microtubules that
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Figure 5.2 SFN  increases acetylated microtubules in ARPE-19 cells
a) Images highlighting the areas of acetylated tubulin (white) compared to
total α-tubulin area (green). b) Analysis of acetylated microtubule using
ImageJ shows that 10 and 15µM SFN significantly increased the
acetylated microtubule area compared to DMSO treated cells, N=20
[*P<0.05 & **P,0.001]. Scale bars=10µm. c) Western blots suggests a
slight increase in acetylation levels in 10 and 15µM SFN treated ARP-19










Figure 5.3 SFN stabilises microtubules against cold in ARPE-19 cells
Cells were treated with SFN (10 and 15µM) for 48 h. Cells were then
incubated on ice for 15 mins, and fixed and immunolabelled for α-tubulin
(inverted). Untreated cell shows that all microtubules have de depolymerised.
DMSO treated cell reveals a few remaining microtubules (arrow). 10 and 15
µm SFN cells show an increase in remaining microtubules, suggesting an
increase in stability in SFN treated cells (arrowed). Scale bars=10µm.
PANC-1
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Figure 5.4 SFN treated PANC-1 cells express acetylated tubulin
Cells were Immunolabelled for microtubules (α-tubulin; red) and
acetylated tubulin (green, invert). DMSO treated cell shows acetylated
microtubules localised at the centre of the cell with some extending to
periphery. 10 and 15µM SFN treated cells reveal acetylated
microtubules around the centre of the cell with more microtubules
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Figure 5.5 SFN treated PANC-1 cells shows no significant increase in acetylated 
microtubules expression 
a) Images highlighting the areas of acetylated tubulin (white) compared to total α-
tubulin area (green). b) Analyses of acetylated microtubule using ImageJ indicates that
10 and 15µM SFN treatment for 48 h results in no significant increase in acetylated
microtubules area, compared to DMSO treated cells, N=20. Scale bars=10µm. b)
Western blot suggests there is no change in acetylated tubulin levels in SFN treated
cells compared to DMSO treated cells.
PANC-1








Figure 5.6 SFN treated PANC-1 cells shows no marked increase in
stable microtubules against cold treatment
Cells were treated with 10 and 15µM SFN for 48h and then incubated on ice for 15
mins and immunolabelled for α-tubulin (inverted). Untreated and DMSO treated
cells show a few stable microtubules (inset, arrows). 10 µM and 15 µM SFN treated
cells reveal networks of stable microtubules around the nucleus and in the
cytoplasm (inset, arrows), suggesting no marked increase in stability in SFN treated
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Figure 5.7 SFN treated ARPE-19 cells express detyrosinated tubulin in 
microtubule bundles
Cells Immunolabelled for tyrosinated tubulin (red) and detyrosinated tubulin
(green, invert). DMSO treated cell reveals that most of microtubules were
tyrosinated with some detyrosinated microtubules at the centre of the cell and
along small segments. 10µM SFN treated cell shows a few detyrosinated
microtubules similar to DMSO treated cell. 15µM treated cell reveals extensive
detyrosinated microtubules bundles elongated from the centre of the cell to the
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Figure 5.8 Detyrosinated tubulin is not expressed in PANC-1 cells
Cells were immunolabelled for tyrosinated tubulin (red) and
detyrosinated tubulin (green, invert). DMSO and SFN treated cells
reveal minimal expression of detyrosinated tubulin. Scale bars=10µm.
ARPE-19
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Figure 5.9 Microtubule dynamical tracking of ARPE-19 cells
Cells were imaged using live fluorescence microscopy for three minutes, and frames
were taken every three seconds.
GFP-CLIP-170 comes in DMSO and 10 and 15µM SFN treated cells were live imaged
and analysed using the automated tracking software U-Track. MATLAB was used to
conduct all post-tracking analysis for microtubule dynamics, where coloured lines are
presenting microtubules phases (red lines presents growing microtubules). DMSO
treated cells show long dynamic microtubules. SFN treated cells reveals short
















Figure 5.10 SFN treatment leads to decrease CLIP-170 comet
velocity and growth events in ARPE-19 cells
GFP-CLIP-170 comets in DMSO and SFN treated cells were analysed to
assess microtubule dynamics. a) 10 and 15µM SFN treated cells reveal a
significant decrease in the mean comet speed compared to DMSO treated
cells. b) the growth length of microtubules is significantly decreased in 10
and 15µM SFN treated cells compared to DMSO treated cells. Statistical
significance assessed by one-way ANOVA with Tukey’s multiple
comparison test, [*P<0.05], n=7.
PANC-1
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Figure 5.11 Microtubule dynamical tracking of PANC-1 cells
Cells were imaged using live time-lapse fluorescence microscopy for three minutes,
and frames were taken every three seconds.
GFP-CLIP-170 comes in DMSO and 10 and 15µM SFN treated cells were live time-
lapse imaged and analysed using the automated tracking software U-Track. MATLAB
was used to conduct all post-tracking analysis for microtubule dynamics, where
coloured lines are present microtubules behaviour (red lines presents growing
microtubules). DMSO and SFN treated cells show no marked different in microtubules
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GFP-CLIP-170 comet speed
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Figure 5.12 SFN treatment does not affect microtubule dynamics in
PANC-1 cells
GFP-CLIP-170 comes in control and SFN treated cells was analysed to
determined microtubules dynamics. a) 10 and 15µM SFN treated cells
show no significant effect on the mean of comet speed compared to DMSO
treated cells. b) the mean length of microtubules reveals no significant
decrease in 10 and15µM SFN treated cells compared to DMSO treated
cells. Statistical significance assessed by one-way ANOVA with Tukey’s


















Figure 5.13 SFN treatment leads to spread more focal adhesion in
ARPE-19 cells
Cells were immunelabelled for focal adhesion (FAK, red, invert) and
microtubule (green). DMSO treated cell shows most of focal adhesions
localised at cell periphery. In SFN treated cells, focal adhesion is mainly at
cell periphery with some more in cell body in particular in 15µM SFN treated
cells. Scale bars=10µm.



















Figure 5.14 SFN treatment and focal adhesion localisation in PANC-
1 cells
Cells were immunelabelled for focal adhesion (FAK, red) and microtubule
(green). DMSO treated cell shows focal adhesions at cell periphery. In
SFN treated cells, focal adhesion is mainly at cell periphery with some
appear accumulated the periphery of 15µM SFN treated cells, suggesting
no noticeable change in SFN treated cells. Scale bars=10µm.
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Figure 5.15 SFN treatment leads to increase adhesion area and size in
ARPE-19 cells
a) GFP-Paxillin construct was added to cells, then live images were taken
for quantitative analysis. b) 15µM SFN reveal a significant increase in focal
adhesion area compared to DMSO treated cells. Statistical significance
assessed by one-way ANOVA with Tukey’s multiple comparison test,





































































Figure 5.16 SFN treatment shows no effect on adhesion area or size in
PANC-1 cell
a) GFP-Paxillin construct was added to cells, then live images were taken for
quantitative analysis. b) 10 and 15µM treated SFN cells show no significant
increase in adhesion area compared to DMSO treated cells. c) 10 and 15µM
treated SFN cells reveal also no significant increase in the size of focal
adhesions compared to DMSO treated cells. Statistical significance assessed
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Figure 5.17 FRAP of GFP-paxillin at focal adhesion in ARPE-19 cells
Cells were treated with SFN and with GFP-paxillin construct. Live-confocal
microscopy was used and selected focal adhesions were subjected to
FRAP. Images from a time-lapse recording showing recovery of GFP-
paxillin at the focal adhesion following photobleaching in DMSO and 10
and15µM SFN treated cells over three minutes (arrows).
ARPE-19
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Figure 5.18 FRAP of GFP-paxillin at focal adhesion in PANC-1 cells
Cells were treated with SFN and with GFP-paxillin construct. Live-
confocal microscopy was used and selected focal adhesions were
subjected to FRAP. Images from a time-lapse recording showing
recovery of GFP-paxillin at the focal adhesion following photobleaching
in DMSO and 10 and µM SFN treated cells over three minutes (arrows).
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Figure 5.19 FRAP analyses of GFP-paxillin in ARPE-19 cells
Cells were treated with SFN for 48 h and with GFP-paxillin construct. Live-
confocal microscopy was used and selected focal adhesions were subjected
to FRAP. a) FRAP analyses illustrated there is no significant different in the
percentage of the mean recovery between DMSO and 10 and 15µM SFN
treated cells. b) FRAP results showed the fluorescence intensity during
recovery following photobleaching of the DMSO (black) and 10µM (green)
and 15µM (purple) SFN treated cells during experiment time, with no
marked difference in the GFP-paxillin intensity during recovery following
photobleaching, n=10.
PANC-1
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Figure 5.20 FRAP analyses of GFP-paxillin in PANC-1 cells
Cells were treated with SFN for 48 h and with GFP-paxillin construct. Live-
confocal microscopy was used and selected focal adhesions were subjected to
FRAP. a) FRAP analyses illustrates a significant increase in the percentage of
the mean recovery in10 and 15µM SFN treated cells compared to DMSO. b)
FRAP results showed the fluorescence intensity during recovery time following
photobleaching of the DMSO (black) and 10 (green) and 15µM (purple) SFN
treated cells during experiment time, with marked recovery at 10µM and 15µM










Chapter VI: General 
Discussion 




The microtubule cytoskeleton is one of the main targets for cancer research due to 
its dynamic instability, which allows microtubules to undergo the vital 
rearrangements required for various functions such as cell polarisation, division 
and migration. Microtubules along with other cytoskeletal elements play important 
roles in cell movement, generating distinct polarity and tracks for vesicle transport 
to the leading edge. They are also able to contribute to force production which is 
needed for movement. Dynamic instability allows the microtubules to explore the 
cytoplasm and make contact with cellular structures such as kinetochores or the cell 
cortex and regulate focal adhesion dynamics (Mitchison and Kirschner, 1984, 
Galjart and Perez, 2003, Howard and Hyman, 2003, Galjart, 2010, Li et al., 2011). 
Microtubule dynamics is tightly regulated by different groups of proteins, in 
particular the +TIP family of proteins. This family includes the EB family of 
proteins as well as HDAC6. EBs have an essential role in regulating microtubule 
dynamics, since they can interact with various other +TIPS as well as internal cell 
structures such as the cortex, organelles and the actin cytoskeleton (Vaughan, 2005, 
Lansbergen and Akhmanova, 2006). EBs can also associate along the microtubule 
lattice as a result of overexpression, which may affect the microtubule dynamics 
(Bu and Su, 2001, Goldspink et al., 2013). HDAC6 can associate with microtubule 
plus-ends and contribute to the regulation of microtubule dynamics. In addition, 
HDAC6 can promote and regulate cell motility, with overexpression of HDAC6 
enhancing cell motility, while inhibition of its activity may impair cell movement 
(Pledgie-Tracy et al., 2007, Aldana-Masangkay and Sakamoto, 2010, Li et al., 
2011, Li et al., 2014).  
Due to these wide networks of microtubule-related proteins and their varying 
behaviour, it is interesting to investigate whether SFN could affect microtubule 




organisation and dynamics in migrating epithelial cells both normal and cancerous, 
as well as its impact on EBs and HDAC6. 
SFN is a promising potential cancer agent that is effective in different types of 
cancers, such as human prostate, colon and breast cancer (Jackson and Singletary, 
2004, Gibbs et al., 2009, Clarke et al., 2011). SFN has been reported to affect 
microtubule behaviour, cell migration and mitosis. It has been reported that SFN 
reduces cell migration in ovarian cancer cells, but only in cytotoxic concentrations 
(Bryant et al., 2010). SFN also causes alterations in post-translational microtubule 
modifications and increases tubulin acetylation. This has been linked with stable 
microtubules, as reported in human breast and prostate cancer cells (Azarenko et 
al., 2008, Gibbs et al., 2009, Clarke et al., 2011).  
There is thus a great desire to understand these actions, since they will likely lead 
to further development of effective drugs, especially for an aggressive cancer type 
such as pancreatic cancer, with patients expecting to survive for only five years 
after diagnosis. Pancreatic cancer, one of the most common diseases, is the most 
complicated epithelial cancers to treat since it is strongly resistant to current cancer 
treatment (Bardeesy and DePinho, 2002, Wang et al., 2011). 
This project aimed to assess whether SFN will increase microtubule stability and 
decrease dynamics and whether SFN could induce a reduction in the speed of 
pancreatic cancer cell migration and normal epithelial cells. In addition, the project 
investigated whether SFN could affect the organisation of microtubules and actin 
filaments, as well as the localisation and expression of EBs and HDAC6. More 
generally, it also attempted to increase our knowledge of the effects of SFN 
treatment on cytoskeleton organisation and cell migration in cancer cells, thereby 
providing a better understanding of this process.  




6.1.1 Research findings 
The key findings of this project include the following: 
1. SFN treatment dramatically reduced cell migration velocity in normal 
(ARPE-19) epithelial cells but not in PANC-1 cells (Chapter VI). 
 
2. SFN treatment supressed microtubule dynamics (Chapter V), and caused a 
distinct phenotype with co-alignment between microtubules and actin 
filaments and EB1 relocated along the microtubule lattice resulting in the 
formation of microtubule bundles. These observations are in keeping with 
EB2 being cytoplasmic and thus allowing EB1 lattice association and 
microtubule bundle formation (Chapter IV). 
 
3. SFN and tubacin together significantly reduced cell velocity of migration 
in pancreatic (Panc-1) cancer cells. Interestingly, no association between 
HDAC6 and microtubules was evident as previously reported (Hubbert et 
al., 2002) (Chapter IV). 
 
4. SFN leads to an increase in focal adhesion size and area, with a significant 
increase in acetylated and detyrosinated microtubules and a marked 
increase in stable microtubules in normal (ARPE-19) epithelial cells. 
However, PANC-1 cells showed no increase in acetylated microtubules and 
stability, and also no different in focal adhesion size and area (Chapter V). 




6.2 General discussion 
SFN treatment showed a significant inhibition on cell migration in ARPE-19 
epithelial cells but not in PANC-1 (pancreatic cancer cells) (Chapter IV). This 
significant reduction in cell migration in SFN treated ARPE-19 is likely to be due 
to the changes in the organisation of microtubules and actin filaments, as well as 
changes in the localisation of EB1 and EB2, where this may effect microtubules 
dynamics. SFN treated ARPE-19 cells showed alterations in the balance between 
dynamic and stable microtubules, with more acetylated and detyrosinated 
microtubules following SFN treatment. SFN has been reported to cause an increase 
in acetylation of microtubules in human breast and prostate cancer cells to result in 
decreased microtubule dynamics (Azarenko et al., 2008, Gibbs et al., 2009, Clarke 
et al., 2011). Tubulin acetylation and detyrosination are also known to be linked to 
stable microtubules (Kalebic et al., 2013, Sirajuddin et al., 2014, Yu et al., 2015). 
Our results also revealed, for the first time, co-alignment between microtubules and 
actin filaments as a result of SFN treatment, along with the formation of 
microtubule bundles (Chapter IV). This co-alignment has been reported in EB2-
depleting cells with EB1 and ACF7 association along the microtubule lattice, which 
enables links to actin filaments (Goldspink et al., 2013).  
Interestingly, SFN treatment leads to EB1 binding along the microtubule lattice and 
EB2 dispersal to the cytoplasm rather than along the lattice. The association 
between EB1 and the microtubule lattice suggests that EB1 lattice binding could 
enforce the lateral binding between microtubules protofilament, which may 
promote microtubule stability and also cause microtubule bundle formation 
(Sandblad et al., 2006, Vitre et al., 2008, Zhang et al., 2009, Goldspink et al., 2013). 




SFN may indirectly cause phosphorylation of EB2 but future studies will be needed 
to confirm this. Studies have indicated that phosphorylation of EB2 by Aurora B or 
CDK1 on entry into mitosis leads to a decrease in the affinity of EB2 for 
microtubules and leads to EB2 release into the cytoplasm and this has been shown 
to be vital for normal mitosis progression (Iimori et al., 2016, Nehlig et al., 2017). 
SFN may thus induce EB2 phosphorylation at any stage of the cell cycle and lead 
to EB2 detachment from the microtubules lattice. A consequence of this could be 
that EB1 binds along the microtubule lattice. EB2 normally associates with the 
microtubule lattice and can bind and deliver MAP4K4 and HAX1 to focal 
adhesions, where MAP4K4 and HAX1 active IQSEC1 and Arf6 leading to focal 
adhesion turnover which is required for cell migration. Knockdown of EB2 has 
been shown to lead to focal adhesion stability and inhibit cell migration, as a result 
of undelivered MAP4K4 and HAX1 to focal adhesion and decrease focal adhesion 
turnover (Yue et al., 2014, Liu et al., 2015). EB2 has also been shown to be 
phosphorylated by CK2 causing a decrease in endothelial cell adhesion (Stenner et 
al., 2013). It is therefore possible that EB2 phosphorylation and detachment from 
the microtubule lattice could have a similar effect to EB2 depletion, with EB1 and 
ACF7 associating along the microtubule lattice and interacting with actin filaments 
causing their co-alignment (Goldspink et al., 2013). Further investigation of this 
would be very interesting.   
In addition, SFN caused formation of microtubule bundles and an increase in 
ARPE-19 cell area. These results are compatible with other studies, where 
inhibition of HDAC6 in mouse embryonic fibroblast cells leads to increased 
adhesion area and decreased turnover with marked increase in cell area resulting in 
suppression of cell migration (Tran et al., 2007). These results suggest that all these 




affects may play vital roles in the ARPE-19 cell migration mechanisms and reduce 
the speed of the cell migration. 
Interestingly, SFN treated PANC-1 cells at concentration up to 15 M did not show 
an effect on speed of cell migration or marked changes in microtubule organisation. 
However, EB1 was associated along the microtubule lattice and EB2 was found in 
the cytoplasm and along the microtubule lattice. These unexpected results may be 
due to the fact that EB2 and HDAC6 are highly expressed in PANC-1 cells, which 
may enhance microtubule dynamics and may lead to increased cell migration. EB2 
is overexpressed and  involved in the invasion in  pancreatic cancer and HDAC6 
causes complete deacetylation of microtubules and associates with EB1 and CLIP-
170 at the plus-end to regulate microtubule dynamics that  leads to increased cell 
migration (Hubbert et al., 2002, Matsuyama et al., 2002, Zhang et al., 2003, 
Abiatari et al., 2009, Zilberman et al., 2009, Clarke et al., 2011, Huo et al., 2011, 
Li et al., 2014, Ding et al., 2014, Ran et al., 2015). 
The combination of the two treatments (SFN and tubacin) with distinct targets was 
used to achieve significant results. The combination of SFN and tubacin 
significantly decreased PANC-1 cancer cell migration (Chapter IV). To the best of 
our knowledge, this is the first time it has been reported that a combination of 
tubacin (a specific HDAC6 inhibitor) and SFN results in a dramatic reduction in 
the speed of pancreatic cancer cell migration, where tubacin or SFN alone did not 
affect PANC-1 cell migration. However, SFN showed an effect on EB1 and EB2 
localisation, with extensive association between EB1 and microtubule lattice and 
with marked increase in cytoplasmic EB2. Interestingly, no effect on microtubule 
dynamics in PANC1 cells was observed although this should be investigated 
further. However, EB2 is overexpressed in PANC-1 cells and this may prevent SFN 
from causing total detachment of EB2 from the microtubule lattice and thus allow 




some MAP4K4 delivery to focal adhesions. Additionally, HDAC6 is also 
overexpressed in PANC1 cells and it seems that SFN alone cannot counteract the 
activity of HDAC6. Tubacin was used to inhibit HDAC6 and in ARPE-19 cells 
10µM tubacin caused a marked increase in cell area and a significant decrease in 
cell migration. However, tubacin alone was not sufficient to induce a decrease in 
cell migration in PANC-1 cells but a combination of tubacin and SFN led to 
reduced migration. This suggests that SFN and tubacin may work together affecting 
the localisation of the EBs and the activity of HDAC6 and combined they lead to a 
significant reduction in cell migration in PANC-1 cells. 
We answered one of our research questions, namely, whether SFN treatment affects 
microtubule dynamics and stability in both normal and cancerous epithelial cells. 
Our results suggested that SFN inhibits microtubule growth in normal epithelial 
cells, as indicated by GFP-CLIP-170 dynamic analyses, with a significant reduction 
in average comet speed and growth length in SFN treated AREP-19 cells. However, 
SFN treated PANC-1 cells did not display a marked effect on microtubule growth 
length or speed. It has been reported that SFN supresses microtubule dynamics, 
with a significant reduction in microtubule growth rate in human breast cancer 
cells; however, only four microtubules were used to analyse microtubule dynamics, 
which is insufficient to deference significance (Azarenko et al., 2008). In addition, 
we found that the average area of acetylated microtubules increased dramatically 
in SFN treated ARPE-19 cells but not in PANC-1 cells. This was also suggested by 
cold treatment, where more stable microtubules were observed in SFN treated 
ARPE-19 cells. However, in PANC-1 cells, cold treatment resulted in the presence 
of stable microtubules without SFN treatment and no increase in stable 
microtubules in SFN treated PANC-1 cells compared to DMSO treated cells. 
Moreover, analysis of the average area of acetylated microtubules in SFN treated 




PANC-1 cells revealed no significant increase in the area of acetylated 
microtubules. The results showed that SFN did not affect PANC-1 cell migration 
and this could be due to there is no marked decrease in microtubule dynamics in 
SFN treated PANC-1 cells. Western blot also suggested that there was an increase 
in the level of acetylated tubulin expression in SFN treated ARPE-19 cells but not 
in SFN treated PANC-1 cells. 
The focal adhesion results revealed that the global focal adhesion area and 
individual size were significantly increased in the SFN treated ARPE-19 cells. 
Whereas, SFN treated PANC-1 cells showed no changes in focal adhesion global 
area or individual size. The focal adhesion recovery from FRAP results showed 
SFN had no effect on focal adhesion turnover in ARPE-19, but it increased focal 
adhesion dynamics in SFN treated PANC-1 cells. In general, further investigation 
is needed here to better understand the effect of SFN on focal adhesion dynamics 
and turnover. 
To summarise, SFN treatment showed significant effects on microtubules and actin 
filaments organisation with marked co-alignment between actin filaments and 
bundle microtubules. It can suggested that this co-alignment is due to association 
between EB1 and ACF7, but this will need further investigation. EB2 could be 
phosphorylated by SFN treatment, as phosphorylation leads to EB2 detachment 
from the microtubules lattice and decreases focal adhesion turnover by affectting 
focal adhesion proteins (MAP4K4 and HAX1) delivery via EB2 (as been discussed 
early) (Yue et al., 2014, Liu et al., 2015). In addition, detachment of EB2 from 
microtubule may enhance more EB1 association along the lattice with marked 
microtubule bundles. This is similar to depleted EB2 effects with extensive 
association between EB1 and ACF7 (Goldspink et al., 2013). It seems that all these 




results together lead to effect the mechanisms of migration and inhibit cell 
migration. 
A suggested model of the possible mechanism of the effect of SFN on cell 
migration is shown in Figure 6.1. It is known that dynamic microtubules are guided 
to focal adhesions along actin filaments and cross-linking proteins, such as ACF7 
(Kaverina et al., 1999, Wu et al., 2008). Microtubules can act as a track for the 
delivery of proteins that are essential for focal adhesion disassembly, with 
disassembly of focal adhesions being critical for cell movement. MAP4K4 is a 
focal adhesion regulator that associates indirectly with microtubules by binding to 
EB2, and its depletion leads to focal adhesion stabilisation and inhibition of 
migration. Microtubules can therefore deliver MAP4K4 to focal adhesions through 
binding to EB2. At the focal adhesion, MAP4K4 activates Arf6 via IQSEC1 and 
initiate focal adhesion disassembly (Yue et al., 2014, Liu et al., 2015). We propose 
that SFN may lead to the phosphorylation of EB2 causing EB2 to disassociate from 
microtubules. Cytoplasmic EB2 may in addition sequester MAP4K4/HAX1 and 
prevent the delivery of MAP4K4/HAX1 to focal adhesions. This would lead to a 
decrease in focal adhesion disassembly and turnover leading to suppression of cell 
migration. 
Generation of a specific EB2 inhibitor may thus be of potential interest in the 
treatment of certain cancers in a similar way to HDAC6 inhibitors which have 
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Figure 6.1 Model for SFN effects on cell migration 
A working model for a possible mechanism by which SFN may effect cell migration. a)
Dynamic microtubules target focal adhesions being guided along actin filaments by EB1/ACF7.
This enables delivery of key disassembly components along microtubules to focal adhesions.
MAP4K4 and HAX1 interact with EB2 and are delivered to focal adhesion. At the focal
adhesion MAP4K4 activates IQSEC1 which activates Arf6 leading to integrin internalisation
and focal adhesion disassembly. b) SFN may lead to phosphorylation of EB2 causing
disassociation from microtubules. Cytoplasmic EB2 sequester MAP4K4/HAX1 and prevents
their delivery to the focal adhesions, decreasing focal adhesion turnover and thus also cell
migration. Detachment of EB2 from the microtubule lattice enable EB1 lattice association.






































6.3 Future work 
There remains several areas for future study, such as investigating whether SFN 
causes phosphorylation of EB2 and disassociation from the microtubules. This may 
provide a better understanding of the role of EB2 and the influence of SFN on 
microtubules and its interaction with other proteins. Furthermore, the co-alignment 
of actin filaments with microtubules as a result of SFN treatment must be 
investigated further, as to whether it is related to association with other proteins, 
such as ACF7 and EB1. It has been shown that ACF7 can bind to microtubules, 
EB1 and actin filaments (Goldspink et al., 2013). In depleted EB2 cells, EB1 was 
observed to bind along the microtubule lattice, recruiting ACF7 and facilitating 
microtubule bundle formation with co-alignment with actin filaments (Alves-Silva 
et al., 2012, Goldspink et al., 2013). The possible effects of SFN on ACF7 related 
to actin filaments and microtubules could also be investigated. This may provide a 
better understanding of the cell migration mechanism. In addition, HDAC6 and its 
association with EB1 may be interesting to study, as well as the possible association 
between HDAC6 and actin filaments or intermediate filaments with SFN treatment. 
In addition, microtubule bundle formation and microtubule and actin filament co-
alignment needs further investigation by using transmission electron microscope 
(TEM). 
Furthermore, SFN affects on focal adhesion turnover require additional 
investigation. Study has shown that the inhibition of HDAC6 leads to increase the 
focal adhesion area and inhibits focal adhesion turnover (Tran et al., 2007). Thus, 
it would be interesting to examine whether the combination of tubacin and SFN at 
low concentrations has the same effect on focal adhesion in cancerous epithelial 
cells. It would perhaps be most interesting, however, to investigate microtubule 




dynamics in normal and cancer epithelial cells given both of these treatments, 
including whether this could affect protein delivery via microtubules. Other studies 
have revealed that dynamic microtubules and EB2 contribute to the delivery of 
essential focal adhesion disassembly proteins, such as MAP4K4 and HAX1 (Yue 
et al., 2014, Liu et al., 2015). Thus, SFN may affect the delivery of proteins that 
are essential for focal adhesion dynamics via its effect on EB2 localisation. This 
represents one possible mechanism by which SFN may affect focal adhesion 
dynamics. In addition, further investigation is needed to determine the effect of 
SFN in 3D model systems to observe whether it has similar effects on cell migration 

















































Appendix A: Reagents and Solutions 
 
Western Blotting Solutions 
Protein Lysis Buffer 
In ddH2O: 
50mM  HEPES   pH 7.5  
50mM             NaCl  
1%   Triton X-100  
1mM   EDTA  




125mM  Tris-HCI at   pH 6.8 
2%                  SDS (Sodium dodecyl sulphate) 
0.02%            Bromophenol Blue 








Lower Gel Buffer (6%) (In final volume 250mls ddH2O) 
200mls ddH2O 
45.375 g Tris (1.5M)   pH 6.8 
1 g  SDS (0.4% w/v) 
 
 
Upper Gel Buffer (In final volume 250mls ddH2O) 
200 mls ddH2O 
15.125 g Tris (500Mm)  pH 6.8 
1 g  SDS (0.4% w/v) 
 
6% Lower Resolving Gel  
Per gel (12ml total volume):  
1.8ml 40% Acrylamide (Sigma, Poole, Dorset)  
3ml  Lower Gel Buffer  
7.2ml  ddH2O  
72μl 10% Ammonium persulphate (Sigma, Poole, Dorset) 
14μl  TEMED (N,N,N’,N’Xtetramethylethylenediamine) 







8% Lower Resolving Gel 
Per gel (12ml total volume): 
2.4ml 40% Acrylamide 
3ml  Lower Gel Buffer 
6.6ml  ddH2O 
72μl 10% Ammonium persulphate 
14μl  TEMED 
 
 
5% Upper Stacking Gel 
Per gel (8ml total volume): 
1ml 40% Acrylamide 
2ml  Upper Gel Buffer 
5ml   ddH2O 
72μl 10%  Ammonium persulphate 
14μl   TEMED 
 
10x SDS Running Buffer 
In a final volume of 5l ddH20: 
151g  Tris (250mM) 
720g  Glycine (1.9M) 





Transfer Buffer  
In a final volume of 1l: 
800ml  ddH2O 
2.9g  Glycine (39mM)  
5.8g  Tris (48mM)   adjusted to pH 8.3 
0.375g  SDS (0.0375% w/v) 




In a final volume of 200ml PBS: 




100mM Tris   adjusted topH8.5 with Hydrochloric acid 
 
ECL Solution A 
In 10ml Tris-HCL, pH 8.5: 
45μl       Coumaric acid (91mM stock solution: 0.15g in 10ml DMSO) 
(Sigma, Poole, Dorset) 




(Sigma, Poole, Dorset) 
 
ECL Solution B 
In 10ml Tris-HCL, pH 8.5:  










Movie S1: Cell tracking in sub-confluent untreated ARPE-19 cells 
Time-lapse movie of untreated ARPE-19 cells, where 10 cells were taken from 
eight different locations. For each cell, position was tracked from each frame for a 
16-hour time-lapse experiment with images taken every 10-minutes using a x10 
objective, and movies replayed at 10 frames per second. Position data for all cells 
were then combined, and ImageJ was used to prepare the traces. 
 
Movie S2: Cell tracking in sub-confluent DMSO treated ARPE-19 cells 
Time-lapse movie of DMSO treated cells, where 10 cells were taken from eight 
different locations. For each cell, position was tracked from each frame for a 16-
hour time-lapse experiment with images taken every 10-minutes using a x10 
objective, and movies replayed at 10 frames per second. Position data for all cells 
were then combined, and ImageJ was used to prepare the traces. Cells appeared to 
move generally similar to those in untreated cells. 
 
Movie S3: Cell tracking in sub-confluent 2 µM SFN treated ARPE-19 cells 
Time-lapse movie of 2 µM SFN treated cells, where 10 cells were taken from eight 
different locations. For each cell, position was tracked from each frame for a 16-
hour time-lapse experiment with images taken every 10-minutes using a x10 
objective, and movies replayed at 10 frames per second. Position data for all cells 
were then combined, and ImageJ was used to prepare the traces. Movie revealed 








Movie S4: Cell tracking in sub-confluent 10 µM SFN treated ARPE-19 cells 
Time-lapse movie of 10 µM SFN treated cells, where 10 cells were taken from 
eight different locations. For each cell, position was tracked from each frame for a 
16-hour time-lapse experiment with images taken every 10-minutes using a x10 
objective, and movies replayed at 10 frames per second. Position data for all cells 
were then combined, and ImageJ was used to prepare the traces. Movie revealed a 
decrease in the speed of 10 µM SFN treated cells compared to DMSO cells.  
 
Movie S5: Cell tracking in sub-confluent 15 µM SFN treated ARPE-19 cells 
Time-lapse movie of 15 µM SFN treated cells, where 10 cells were taken from 
eight different locations. For each cell, position was tracked from each frame for a 
16-hour time-lapse experiment with images taken every 10-minutes using a x10 
objective, and movies replayed at 10 frames per second. Position data for all cells 
were then combined, and ImageJ was used to prepare the traces. Movie revealed a 
decrease in the speed of 15 µM SFN treated cells compared to DMSO cells. 
 
Movie S6: Cell tracking in sub-confluent untreated PANC-1 cells 
Time-lapse movie of untreated cells, where 10 cells were taken from eight different 
locations. For each cell, position was tracked from each frame for a 16-hour time-
lapse experiment with images taken every 10-minutes using a x10 objective, and 
movies replayed at 10 frames per second. Position data for all cells were then 
combined, and ImageJ was used to prepare the traces. 
 
Movie S7: Cell tracking in sub-confluent DMSO treated PANC-1 cells 
Time-lapse movie of DMSO treated cells, where 10 cells were taken from eight 
different locations. For each cell, position was tracked from each frame for a 16-
hour time-lapse experiment with images taken every 10-minutes using a x10 
objective, and movies replayed at 10 frames per second. Position data for all cells 
were then combined, and ImageJ was used to prepare the traces. Cells appeared to 






Movie S8: Cell tracking in sub-confluent 2 µM SFN treated PANC-1 cells 
Time-lapse movie of 2 µM SFN treated cells, where 10 cells were taken from eight 
different locations. For each cell, position was tracked from each frame for a 16-
hour time-lapse experiment with images taken every 10-minutes using a x10 
objective, and movies replayed at 10 frames per second. Position data for all cells 
were then combined, and ImageJ was used to prepare the traces. Movie revealed 
no marked decrease in the speed of 2 µM SFN treated cells compared to DMSO 
cells. 
 
Movie S9: Cell tracking in sub-confluent 10 µM SFN treated PANC-1 cells 
Time-lapse movie of 10 µM SFN treated cells, where 10 cells were taken from 
eight different locations. For each cell, position was tracked from each frame for a 
16-hour time-lapse experiment with images taken every 10-minutes using a x10 
objective, and movies replayed at 10 frames per second. Position data for all cells 
were then combined, and ImageJ was used to prepare the traces. Movie revealed 
no marked decrease in the speed of 10 µM SFN treated cells compared to DMSO 
cells. 
 
Movie S10: Cell tracking in sub-confluent 15 µM SFN treated PANC-1 cells 
Time-lapse movie of 15 µM SFN treated cells, where 10 cells were taken from 
eight different locations. For each cell, position was tracked from each frame for a 
16-hour time-lapse experiment with images taken every 10-minutes using a x10 
objective, and movies replayed at 10 frames per second. Position data for all cells 
were then combined, and ImageJ was used to prepare the traces. Movie revealed 










Movie S11: Cell tracking in sub-confluent 10 µM tubacin treated ARPE-19 
cells 
Time-lapse movie of 10 µM tubacin treated cells, where 10 cells were taken from 
eight different locations. For each cell, position was tracked from each frame for a 
16-hour time-lapse experiment with images taken every 10-minutes using a x10 
objective, and movies replayed at 10 frames per second. Position data for all cells 
were then combined, and ImageJ was used to prepare the traces. Movie revealed a 
marked decrease in the speed of 10 µM tubacin treated cells compared to DMSO 
cells. 
 
Movie S12: Cell tracking in sub-confluent 10 µM tubacin and 10 µM SFN 
treated ARPE-19 cells 
Time-lapse movie of 10 µM tubacin and 10 µM SFN treated cells, where 10 cells 
were taken from eight different locations. For each cell, position was tracked from 
each frame for a 16-hour time-lapse experiment with images taken every 10-
minutes using a x10 objective, and movies replayed at 10 frames per second. 
Position data for all cells were then combined, and ImageJ was used to prepare the 
traces. Movie revealed a marked decrease in the speed of 10 µM tubacin and 10 
µM SFN treated cells compared to DMSO cells. 
 
Movie S13: Cell tracking in sub-confluent 10 µM tubacin and 15 µM SFN 
treated ARPE-19 cells 
Time-lapse movie of 10 µM tubacin and 15 µM SFN treated cells, where 10 cells 
were taken from eight different locations. For each cell, position was tracked from 
each frame for a 16-hour time-lapse experiment with images taken every 10-
minutes using a x10 objective, and movies replayed at 10 frames per second. 
Position data for all cells were then combined, and ImageJ was used to prepare the 
traces. Movie revealed a marked decrease in the speed of 10 µM tubacin and 15 







Movie S14: Cell tracking in sub-confluent 10 µM tubacin treated PANC-1 cells 
Time-lapse movie of 10 µM tubacin treated cells, where 10 cells were taken from 
eight different locations. For each cell, position was tracked from each frame for a 
16-hour time-lapse experiment with images taken every 10-minutes using a x10 
objective, and movies replayed at 10 frames per second. Position data for all cells 
were then combined, and ImageJ was used to prepare the traces. Movie revealed 
no marked decrease in the speed of 10 µM tubacin treated cells compared to DMSO 
cells. 
 
Movie S15: Cell tracking in sub-confluent 10 µM tubacin and 10 µM SFN 
treated PANC-1 cells 
Time-lapse movie of 10 µM tubacin and 10 µM SFN treated cells, where 10 cells 
were taken from eight different locations. For each cell, position was tracked from 
each frame for a 16-hour time-lapse experiment with images taken every 10-
minutes using a x10 objective, and movies replayed at 10 frames per second. 
Position data for all cells were then combined, and ImageJ was used to prepare the 
traces. Movie revealed no marked decrease in the speed of 10 µM tubacin and 10 
µM SFN treated cells compared to DMSO cells. 
 
Movie S16: Cell tracking in sub-confluent 10 µM tubacin and 15 µM SFN 
treated PANC-1 cells 
Time-lapse movie of 10 µM tubacin and 15 µM SFN treated cells, where 10 cells 
were taken from eight different locations. For each cell, position was tracked from 
each frame for a 16-hour time-lapse experiment with images taken every 10-
minutes using a x10 objective, and movies replayed at 10 frames per second. 
Position data for all cells were then combined, and ImageJ was used to prepare the 
traces. Movie revealed no marked decrease in the speed of 10 µM tubacin and 15 










Movie S17: DMSO treated ARPE-19 GFP-CLIP-170 dynamics 
Time-lapse of DMSO treated cell transiently expressing GFP-CLIP-170. Images 
were taken every three-seconds over three-minute period (60 frames in total) and 
replayed at 5 frames per second. The movie shows U-Track analysis of GFP-CLIP-
170 comets over images period with growing (red), shrinking (yellow) and pausing 
(blue) microtubule highlighted. 
 
Movie S18: 10 µM SFN treated ARPE-19 GFP-CLIP-170 dynamics 
Time-lapse of 10 µM SFN treated cell transiently expressing GFP-CLIP-170. 
Images were taken every three-seconds over three-minute period (60 frames in 
total) and replayed at 5 frames per second. The movie shows U-Track analysis of 
GFP-CLIP-170 comets over images period with growing (red), shrinking (yellow) 
and pausing (blue) microtubule highlighted. 
 
Movie S19: 15 µM SFN treated ARPE-19 GFP-CLIP-170 dynamics 
Time-lapse of 15 µM SFN treated cell transiently expressing GFP-CLIP-170. 
Images were taken every three-seconds over three-minute period (60 frames in 
total) and replayed at 5 frames per second. The movie shows U-Track analysis of 
GFP-CLIP-170 comets over images period with growing (red), shrinking (yellow) 
and pausing (blue) microtubule highlighted. 
 
Movie S20: DMSO SFN treated PANC-1 GFP-CLIP-170 dynamics 
Time-lapse of DMSO treated cell transiently expressing GFP-CLIP-170. Images 
were taken every three-seconds over three-minute period (60 frames in total) and 
replayed at 5 frames per second. The movie shows U-Track analysis of GFP-CLIP-
170 comets over images period with growing (red), shrinking (yellow) and pausing 








Movie S21: 10 µM SFN treated PANC-1 GFP-CLIP-170 dynamics 
Time-lapse of 10 µM SFN treated cell transiently expressing GFP-CLIP-170. 
Images were taken every three-seconds over three-minute period (60 frames in 
total) and replayed at 5 frames per second. The movie shows U-Track analysis of 
GFP-CLIP-170 comets over images period with growing (red), shrinking (yellow) 
and pausing (blue) microtubule highlighted. 
 
Movie S22: 15 µM SFN treated ARPE-19 GFP-CLIP-170 dynamics 
Time-lapse of 15 µM SFN treated cell transiently expressing GFP-CLIP-170. 
Images were taken every three-seconds over three-minute period (60 frames in 
total) and replayed at 5 frames per second. The movie shows U-Track analysis of 
GFP-CLIP-170 comets over images period with growing (red), shrinking (yellow) 
and pausing (blue) microtubule highlighted. 
 
Movie S23: DMSO treated ARPE-19 GFP-paxillan recovery after FRAP 
Time-lapse of DMSO treated cell transiently expressing GFP-paxillan. Selected 
focal adhesion was subjected to FRAP (fluorescence recovery after photo-
bleaching). Images were taken every three-seconds over three-minute period (60 
frames in total) and replayed at 5 frames per second. The movie shows selected 
focal adhesion that subjected to FRAP and its recovery over 3 minutes period. 
 
Movie S24: 10 µM SFN treated ARPE-19 GFP-paxillan recovery after FRAP 
Time-lapse of 10 µM SFN treated cell transiently expressing GFP-paxillan. 
Selected focal adhesion was subjected to FRAP (fluorescence recovery after photo-
bleaching). Images were taken every three-seconds over three-minute period (60 
frames in total) and replayed at 5 frames per second. The movie shows selected 









Movie S25: 15 µM SFN treated ARPE-19 GFP-paxillan recovery after FRAP 
Time-lapse of 15 µM SFN treated cell transiently expressing GFP-paxillan. 
Selected focal adhesion was subjected to FRAP (fluorescence recovery after photo-
bleaching). Images were taken every three-seconds over three-minute period (60 
frames in total) and replayed at 5 frames per second. The movie shows selected 
focal adhesion that subjected to FRAP and its recovery over 3 minutes period. 
 
Movie S26: DMSO treated PANC-1 GFP-paxillan recovery after FRAP 
Time-lapse of DMSO treated cell transiently expressing GFP-paxillan. Selected 
focal adhesion was subjected to FRAP (fluorescence recovery after photo-
bleaching). Images were taken every three-seconds over three-minute period (60 
frames in total) and replayed at 5 frames per second. The movie shows selected 
focal adhesion that subjected to FRAP and its recovery over 3 minutes period. 
 
 
Movie S27: 10 µM SFN treated PANC-1 GFP-paxillan recovery after FRAP 
Time-lapse of 10 µM SFN treated cell transiently expressing GFP-paxillan. 
Selected focal adhesion was subjected to FRAP (fluorescence recovery after photo-
bleaching). Images were taken every three-seconds over three-minute period (60 
frames in total) and replayed at 5 frames per second. The movie shows selected 
focal adhesion that subjected to FRAP and its recovery over 3 minutes period. 
 
Movie S28: 15 µM SFN treated PANC-1 GFP-paxillan recovery after FRAP 
Time-lapse of 15 µM SFN treated cell transiently expressing GFP-paxillan. 
Selected focal adhesion was subjected to FRAP (fluorescence recovery after photo-
bleaching). Images were taken every three-seconds over three-minute period (60 
frames in total) and replayed at 5 frames per second. The movie shows selected 
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